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Introduction
During the last fifteen years there has been increasing 
awareness that the renin-angiotensin-aldosterone hormonal 
system affects sodium and potassium balance and blood pres­
sure homeostasis (1-4). The system appears to function 
as follows: renin is released from the kidney under situat­
ions in which its perfusion pressure is compromised, such 
as sodium depletion, hemorrhage, or a fall in mean arterial 
pressure (5). Renin, released into the circulation, hydrol­
yses plasma renin substrate (angiotensinogen) to yield 
a decapeptide, angiotensin I (Figure 1). Plasma angiotensin 
I is then rapidly hydrolysed by converting enzyme to angio­
tensin II primarily during passage through the lungs.
Neither renin nor angiotensin I has any well documented 
physiological effect. Angiotensin II however' has at least 
two major physiological actions. As the most powerful 
vasoconstrictor substance known, it constricts arteriolar 
smooth muscle thus increasing arterial pressure, while 
at the same time it is a potent stimulus for aldosterone 
biosynthesis. Aldosterone is the second effector hormone 
of the system. Its adrenal secretion is governed by two 
major stimuli, the plasma levels of potassium and angiotensin
II. Aldosterone, in turn, increases renal potassium excretion 
and promotes renal sodium conservation (Figure 1),
From this brief outline, it can be appreciated that 
the renin-angiotensin-aldosterone system reacts to changes 
in sodium and potassium balance or blood pressure, and 
these three parameters in turn affect the hormonal system.
— 4 —
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Introduction
The present work was begun in a setting in which the 
gross physiology of the three hormones had been worked out, 
but the role and interactions of the system in the minute 
by minute maintenance of sodium and potassium balance and 
blood pressure was still in question. Further elucidation 
of the nuances of the hormonal interactions required, first 
of all, refinement of the methods for measurement of the 
hormones. Accordingly, methods are presented which were 
developed or improved upon for measurement of plasma renin 
activity (6-8), plasma renin substrate (6) and urinary (9-11) 
and plasma aldosterone (12). These methods are simpler, more 
accurate and more sensitive than those previously utilized, 
providing the advantage that subnormal values can be de­
tected with confidence, thus allowing investigation of the 
system over a wide spectrum of activity (13, 14).
Angiotensin II is the effector hormone of the renin limb 
of the hormonal system. Thus its blood level would be ex­
pected to be the most meaningful indicator of changes in 
physiological activity of the system. However, although 
methods for measurement of angiotensin II were available they 
were not sufficiently sensitive to detect with confidence 
low levels of the hormone. Accordingly, plasma renin 
"activity" measurements were utilized instead since all evi­
dence suggests that angiotensin I generation closely reflects 
angiotensin II levels, there being no evidence that convert­
ing enzyme activity is ever rate limiting.
Since the production rate of angiotensin in plasma is
— 6—
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dependent on both plasma renin and substrate concentrations, 
studies were carried out to determine if a change in renin■ 
secretion is the dynamic component which maintains the rate 
of generation of angiotensin at an appropriate level. First, 
the importance of changes in plasma renin substrate on the 
measurement was examined (6,15,16). Then the characteristics 
of metabolic clearance rate of renin were evaluated over a 
wide range of plasma renin levels, allowing a more precise 
evaluation of the relationship of renal renin secretion to 
peripheral renin measurements (16) .
Although it has been generally accepted that renin and 
aldosterone are important for regulation of sodium excretion 
at low and normal sodium intakes, the role of the hormonal 
system in regulating salt balance at high levels of sodium 
intake has not been clarified. To study this question, normal 
subjects were evaluated during sodium loading (11,17). Daily 
measurement of renin and aldosterone revealed that the two 
hormones continue to have a regulating influence on urine 
sodium excretion, even at high sodium intakes (18),
The hormonal responses to extreme changes in sodium and
potassium balance were studied in parallel in normal man and
in rats, A new coordinate of the renin-angiotensin-aldosterone
system was exposed when it was demonstrated that.changes in
potassium balance directly affect renin secretion (19,20).
Sodium depletion has been shown to induce moderate potassium
retention. The influence of this increase in potassium balance
on the relationship of renin to aldosterone during sodium
-7-
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depletion was studied in normal man (17,18). It was found 
that both plasma renin activity (i.e., angiotensin II) and 
potassium are important trophic stimuli for aldosterone secre­
tion during sodium deprivation in normal subjects with the 
subtly positive potassium balance working to attenuate the 
rise in renin secretion.
Aldosterone promotes both renal sodium retention and 
potassium excretion. On the face of it these two simultaneous 
actions would be expected to produce wide and inappropriate 
fluctuations in the balance of one of the two ions in defend­
ing changes in dietary intake of the other. However, it will 
be demonstrated that when aldosterone secretory changes are 
considered together with concurrent changes in intrarenal 
physical forces such as glomerular filtration rate, and 
proximal tubule sodium reabsorption, a system can be proposed 
which accounts for the simultaneous appropriate regulation 
of both ions (18),
A question that has intrigued many investigators who 
study the factors involved in maintenance of sodium balance, 
is whether another hormone exists which promotes sodium 
elimination (i.e. a natriuretic hormone). This possibility 
was suggested initially by a study by de Wardener and co­
workers (21) who demonstrated that urine sodium excretion 
could be regulated appropriately under conditions in which 
glomerular filtration and aldosterone were unchanged or in­
appropriate. To investigate the existence of a natriuretic 
hormone, extraction, concentration and purification proce-,
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dures were developed for the fractionation of urine and plasma 
on the basis of molecular weight and a new biological assay 
was elaborated for detection and quantitation of natriuretic 
extracts (22) . We found a natriuretic substance in urine 
and plasma which appears to have physiological relevance since 
it could be detected in urine and plasma from salt-loaded - 
subjects but not in extracts derived from subjects who were 
sodium deprived. Evidence suggests that the substance may 
participate in regulation of sodium reabsorption in a distal 
portion of the nephron, beyond the distal tubular potassium 
secretory site (22-24).
The renin-angiotensin-aldosterone hormonal system is also 
involved in blood pressure homeostasis. Variations in pressor 
sensitivity to angiotensin II are known to occur with changes 
in sodium balance. To investigate the physiological basis for 
these differences, angiotensin II antibodies were injected 
into rats on three different sodium intakes. It was possible 
to characterise specific angiotensin vascular receptors which 
exhibit significant variation in their affinity for angioten­
sin depending on the state of salt balance (25).
The interdependence of sodium balance and angiotensin II 
in the maintenance of arterial pressure was also studied in 
experimental and human renovascular hypertension. When we 
blocked angiotensin II activity in two different experimental 
models of renovascular hypertension, blood pressure fell only 
in the two-kidney model in which plasma renin activity was 
elevated (26). Other investigators of our group then demon-
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strated that when arterial filling was reduced in the non- 
responsive model by sodium depletion, blood pressure fell 
in this model too in response to angiotensin II blockade 
(27). We conclude that, depending on the availability 
of sodium, experimental renal hypertension may be maintained 
by either excess renin (angiotensin II) or alternatively 
by inappropriately excessive arterial filling (sodium).
A new approach to analysis, understanding and identifi­
cation of curable forms of human renovascular hypertension 
emerged when these studies of animal models were analysed in 
conjunction with another study of renal vein renin measure­
ments in patients with essential hypertension. Clinical 
counterparts of the two different animal models of renovascu­
lar hypertension appear to exist in man. It will be demon­
strated in the final section of this memoir that the two 
forms can be distinguished on the basis of peripheral and 
renal vein renin measurements alone (16,28). Since only the 
renin dependent form can be cured by unilateral renal surgery, 
this new understanding is important for evaluation of patients 
with renovascular hypertension.
Altogether, therefore, this memoir is concerned with the 
renin-angiotensin-aldosterone hormonal system, the methods for 
measurement of its components, the interpretation of these 
measurements in physiological and pathological settings, and 
an evaluation of the relative importance of the systems in the 
overall maintenance of sodium and potassium balance, and blood 
pressure homeostasis.
—10 —
PART I: .
METHODOLOGY OF RENIN, ALDOSTERONE AND NATRIURETIC HORMONE
I, Measurement of the Components of the Renin System
. -1 '
Renin was discovered in 1898 by two medical Studehts, 
Robert Tigerstedt and Per Bergman, who noted an increase in 
the blood pressure of anesthetized rabbits when saline ex­
tracts of kidney were injected (29). These observations 
remained in dispute until 1938, when three groups confirmed 
this earlier finding (30-32). Meanwhile, other studies 
had implicated the kidney in the hypertensive process (33) 
and in 19 34 Goldblatt produced chronic experimental hyperten­
sion for the first time by placing a clip around the renal 
artery of a uninephrectomized dog (34).
In 1939, Page (35) and Braun-Menendez and coworkers 
(36) reported that renin was not by itself a pressor sub­
stance but acted in plasma as an enzyme to release a pressor 
peptide. Angiotensin is released from a circulating plasma 
globulin (37-39) and.has been shown by Peart and also Skeggs 
and coworkers to be present in plasma in two forms, a decapep­
tide and an octapeptide (40-43). Skeggs and colleagues in 1956 
(44) isolated a converting enzyme from horse plasma which 
splits the decapeptide angiotensin I to angiotensin II.
These workers were able to identify angiotensin II and the 
dipeptide, histidyl-leucine as products of reaction.
Measurement of the components of the renin system was 
not a simple task. Circulating levels of angiotensin are so 
minute that, in the early assays, excessive amounts of blood 
had to be collected (45,46). However, in 1953 Helmer
-14-
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and Judson (47) developed a bioassay method for measuring 
plasma renin which utilized the fact that renin reacts with . 
plasma renin substrate to generate angiotensin. By incubat­
ing the plasma for a fixed period of time, prior to bioassay, 
sufficient angiotensin was generated to enable detection and ■ 
quantitation in a small volume of plasma.
Most methods which have been developed for measurement 
of plasma renin are based on this principle and differ mainly, 
in techniques used for increasing sensitivity of the.assay 
and for inactivation of angiotensinases which destroy the 
angiotensin formed during incubation. , The first method to be 
developed which successfully eliminated the angiotensinase 
problem, and thus could be used to accurately measure plasma 
renin, was developed by Lever and coworkers (48). In this 
method addition of exogenous substrate helped to increase the 
sensitivity of the measurement since substrate concentration 
in plasma is normally rate limiting. Angiotensinases were 
separated chemically from renin. Other techniques for angio­
tensinase inhibition include adsorption of the formed angio­
tensin onto a resin (45) , dialysis (49-51), inactivation 
by heat at pH 4.5 (51,52) and addition of inhibitors (6,7, 
49,50,53-57).
The use of plasma renin rather than angiotensin II 
measurements in assessing the physiological role of the renin 
system has introduced some complications. Since the plasma 
concentration of renin substrate is normally rate limiting, the 
capacity of plasma to generate angiotensin is a function of both
-15“
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renin and substrate concentrations. Thus methods for measure­
ment of plasma renin differ in whether they measure plasma 
renin concentration or plasma renin activity. In the first 
approach, a fixed amount of renin substrate (angiotensinogen) 
is added to the incubation medium so that the measurement 
reflects only differences in enzyme concentration (51,52,55,58). 
However, when plasma renin activity is measured, endogenous . 
plasma angiotensinogen is utilized as the substrate in the 
incubation step and the measurement reflects the net capacity 
of plasma to generate angiotensin (6,45,49,51,53,54,56,57).
Thus the measurement is a reflection of a first order 
reaction between the enzyme and its substrate and for this 
reason is referred to as plasma renin activity, and not plasma 
renin concentration.
Plasma renin substrate is measured by its capacity to 
generate angiotensin I during incubation in the presence of 
an excess of renin (6,50,53,59). In addition, the capacity 
of plasma to generate angiotensin can be evaluated by 
measuring the response of plasma to addition of a fixed 
amount of endogeneous renin (6, 49). This latter measure­
ment allows analysis of the effects of activators and inhibi­
tors on the renin reaction.
At first a rat bioassay was used to quantitate the angio­
tensin generated during the incubation step (6,45,49-51,53,58, 
60). More recently, with the development of radioimmunoassay 
techniques by Yalow and Berson (61), the rat pressor bioassay 
has been replaced by a more sensitive, radioimmunoassay of formed
-16-
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angiotensin I (6,52,54-57).
In this section, the methods developed in our laboratory 
for measurement of plasma renin activity, renin substrate and 
the reactivity of plasma to renin will be presented in detail. 
They comprise a basic incubation step during which angioten­
sin I is generated followed by quantitation of the angioten­
sin by radioimmunoassay.
Incubation Steps :
(a) Plasma renin activity : (Table 1, Figure 2)
Since renin is measured by its capacity to form angio­
tensin I during a fixed incubation time, generation of angio­
tensin I prior to incubation must be inhibited. For this 
reason the plasma is chilled immediately after collection. In 
addition, conversion of angiotensin I to angiotensin II or to 
break-down products must be inhibited. Three factors operate 
to destroy angiotensin I: converting enzyme, angiotensinases
and bacteria (Figure 2). These must all be inhibited during 
the incubation step.
EDTA, added during collection of blood, acts as anti­
coagulant. In addition, the concentration used as anti­
coagulant (0.003M) also inhibits converting enzyme (44) and, 
to some extent, angiotensinases during the incubation proce­
dure (49). DFP (diisopropylfluorophosphate), added to plasma, 
inhibits remaining angiotensinases (4 9) and addition of neo­
mycin sulphate helps to retard bacterial growth (6).
Prior to incubation, the plasma is adjusted to the pH
-17-
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FIGURE 2
PLASMA RENIN ACTIVITY MEASUREMENT: INCUBATION OF PLASMA 
FOR GENERATION OF ANGIUTEWSIN 1
RENIN
RENIN SUBSTRATE
pN 5.7, 37°C, 3 HRS(OR IShrs)
EDTA + DFP + N e o m y c i n
^ ANGIOTENSIN I
ANGIOTENSINASES
EDTA DFP 
N e o m y c i n
Ba c t e r i a l  G r o w t h
B r e a k d o w n
Products
C o n v e r t i n g
E n z y m e
EDTA
A n g i o t e n s i n  II
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TABLE 1
INCUBATION FOR GENERATION OF ANGIOTENSIN I 
(20 or more samples can be incubated as one batch)
2 ml plasma containing .003M EDTA 
Combine 25 ul 10% neomycin sulphate ,
2 drops (40 u l)  DFP (1/20 d i lu t io n  in  isopropyl a lcohol)?
Adjust pH to 5.7 w ith IN, 0.5N, o r G.IN HCl
Divide in to  3 portions
Incubate fo r  3 or 18 hours at 37^0 
Freeze
Radioimmunoassay one o f  the portions (the other 2 are fo r  repeats, i f  necessary)
*  Blood co llec ted  in to potassium EDTA vacutainers 
* *  Acceptable range 5.6 - 5.7
* * *  Entire  incubation step is  repeated fo r  18 hours
i f  PRA is less than 1 ng/m l/hr. Samples are incubated overn ight
t  Tox ic ! Wear disposable gloves
—19“
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TABLE 2
INCUBATION FOR RENIN SUBSTRATE 
20 ul plasma
400 ul human renin: 0.034 GU/ml in  0.1 M phosphate
b u ffe r ,  pH 5.7, containing 0.003 M EDTA and 200 
mg/100 ml neomycin
One drop DFP (1:20 d i lu t io n )
Incubate 1 hour a t 37^0
Freeze
Assay 10 and 20 ul a t  1:10 d i lu t io n
INCUBATION FOR SUBSTRATE REACTIVITY
0.9 ml plasma containing 0.003 M EDTA
0.1 ml human renin 0.0085 GU/ml in 0.1 M phosphate
b u ffe r ,  pH 5.7
One drop DFP
Incubate 2 hours a t 37^C
Freeze
Assay 10 and 20 ul a t  1:20 d i lu t io n
Renin: Incubation
optimum, 5.7, with hydrochloric acid. This step increases 
by two-fold the rate of angiotensin generation as compared 
with pH 7.4, and it also potentiates the actions of EDTA 
and DFP to inhibit angiotensinase and converting enzyme 
activities. Incubation is carried out for three hours at 
37°C in a shaker water bath. However, if the rate of angio­
tensin generation is found to be less than 1 ng/ml/hour, the 
incubation step is repeated for 18 hours (8).
(b) Plasma renin substrate : (Table 2).
Plasma renin substrate is measured by its capacity to 
yield angiotensin I in the presence of excess renin. Highly 
purified human renin is added to plasma containing EDTA, DPP 
and neomycin, in amounts sufficient to exhaust the substrate 
during a one hour incubation. The generated angiotensin is 
then quantitated by radioimmunoassay. Plasma renin sub­
strate is reported as ng angiotensin I generated per ml 
plasma.
(c) Substrate reactivity : (Table 2)
This index describes the capacity of a given plasma to 
generate angiotensin in response to addition of a fixed 
amount of highly purified human renin and can be used to de­
tect inhibitors and activators in plasma, or changes in renin 
activity due to changes in plasma renin substrate (6,49,62). .
The added renin is sufficient to generate about 5 0 ng angiotensin 
I per ml plasma per hour of incubation assuming normal levels of 
renin substrate. In the calculation of substrate reactivity
endogenous plasma renin activity is subtracted so that only
- 21-
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the angiotensin I generated in response to the added renin is 
reported.
Quantification of Angiotensin ^ ^  Radioinimunoassay:
1) Principles of radioimmunoassay (63) : The angiotensin
I generated during the incubation step is quantitated by 
utilizing (a) its affinity for highly specific antibodies and
(b) competition between radioactive and unlabelled angioten­
sin I for binding sites on the antibodies (Figure 3) (63).
The angiotensin to be quantitated is added to a mixture of 
radioactive angiotensin and antibody in Tris buffer. The 
proportions of these two components are such that half of the 
radioactive angiotensin is bound to antibody and the other 
half remains free. The extent to which radioactive angioten­
sin I is displaced from the antibody by the unknown sample 
is a measure of the amount of angiotensin in the sample. The 
angiotensin I content of the unknown sample is determined 
precisely by comparing it to the displacement caused by addi­
tion of known amounts of unlabelled angiotensin I.
In practice, a mixture of antibody and labelled angio­
tensin is added to a series of tubes containing known amounts 
of angiotensin or unknown samples. After 18 hours the bound 
angiotensin is separated from the free by adsorption of the 
free angiotensin onto dextran coated charcoal. After cen­
trifugation the bound angiotensin is decanted and counted in 
a gamma spectrometer, while the free (charcoal plug) is dis­
carded. From the counts bound the amount of angiotensin in
— 22—
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FIGURE 3
PRINCIPLES OF RADIOIMMUNOASSAY
LABELED 
ANGIOTENSIN I 
(f r e e )
SPECIFIC 
■ ANTIBODY
^  LABELED ANGIOTENSIN 1/ 
”  ANTIBODY COMPLEX • 
(b o u n d )
UNLABELED 
ANGIOTENSIN I
,IN KNO WN s t a n d a r d ; 
,S O L U T I O N S  OR * 
.UNKNOWN S A M P L E S  -
UNLABELED 
ANGIOTENSIN I/ANTIBODY 
COMPLEX .
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the unknown sample can be calculated (6,8).
2) Radioimmunoassay of angiotensin A flow-sheet of
the radioimmunoassay is presented in Table 3, 0.IM Tris
buffer, pH 7.5, is used throughout the procedure. Protein 
is added to the buffer to inhibit adsorption of angiotensin 
onto glassware and plastic and to increase the stability of 
the diluted antibody. Considerable adsorption to plastic 
has been observed when the protein concentration is reduced 
below 0.4%. . Neomycin and phenylmecuric acetate are added to 
retard bacterial growth.
A unique feature of this particular radioimmunoassay 
is the prior mixing of radioactive angiotensin with anti­
body. This simplifies the procedure considerably and re­
duces inaccuracies caused by multiple pipettings. ■
Prior to radioimmunoassay the samples are diluted in 
Tris buffer if the renin value is expected to be above the 
normal range. However, for most samples no pre-dilution 
is necessary. 10 tubes in duplicate are included in the 
standard curve. Different amounts of angiotensin I are added
to seven pairs of tubes. Tubes are also included in duplicate
125for measurement of the total counts, the binding of I 
angiotensin in the absence of antibody to proteins in the buf­
fer solution (non-specific binding) and the binding of radio­
active angiotensin to antibody in the absence of unlabelled 
angiotensin I.
Tubes are prepared in duplicate for about 2 0 plasma 
samples and for 2 standard plasma samples. The
-24-
Renin: RIA . • ; . ^ ill.
w  . - I * ,
TABLE 3 . . '
RADIOIMMUNOASSAY
1, Dilution of Samples
If the expected value for PRA is high, the samples should be diluted prior to 
radioimmunoassay, or if in a previous radioimmunoassay, the values fell out­
side the standard curve, they should be repeated after appropriate dilution.
The samples can be diluted 1:2, 1:5, 1:25, 1:100, depending on the expected 
value. All dilutions are carried out on the chilled samples using tris buffer.
2. Radioinimunoassay -
(a) Standard Curve:
Tube # A I Standard Volume A I
ng/ml ng
T,2 1 10 .010
3,4 1 20 .020
5,6 4 10 .040
7,8 4 20 .080
9,10 15 10 ,150
11,12 15 20 .300
13,14 20 20 .400
15,16 total counts, no charcoal (T)
17,18 non-specific binding; no antibody
19,20 no added angiotensin (8 )
(b) Unknown Samples:
10 and 20 ul of each unknown sample and of 2 standard plasma samples are 
added to small test tubes.
(c) Addition of ^^^I Angiotensin I/Antibody Mixture:
i. 2 ml mixture are added to each tube from (a) and (b) except ^17,18
11. 2 ml mixture without antibody are added to tubes #17,18
iii. Mix well
iv. Place in refrigerator for 18 hours (overnight)
3. Addition of Charcoal
(a) Place rack of tubes in ice bath
(b) Add 0.5 ml chilled tris buffer to tubes #15,16
(c) Add 0.5 ml chilled charcoal mixture to all other tubes
4. Centri fugation
Centrifuge 20 minutes at 2000 rpm. All tubes should be centrifuged together 
as one batch.
5. Counting
Decant supernatant into appropriately labeled test tubes.
Count'for 10 minutes each with background subtract.
6. Calculations '
Calculate standard curve 
Plot standard curve (Figure 4 )
Calculate standard plasma samples and derive ng from standard curve 
If error is less than 20% calculate unknowns
If duplicates of unknowns vary by less than 15%, answer is acceptable
-25-
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latter are included for quality control purposes, 10 and 
20 ul of each sample are assayed. 2 ml of the radioactive 
angiotensin/antibody mixture is added to all tubes except 
17 and 18 (Table 3). 2 ml of mixture without antibody is
added to tubes 17 and 18 for measurement of non-specific 
binding.
After 18 hours at 4 for equilibration of angiotensin 
with antibody, the angiotensin bound to antibody is sepa­
rated from the free by adsorption of free angiotensin onto 
dextran-coated charcoal. Because of the tendency of the 
charcoal to slowly adsorb small amounts of bound angioten­
sin (64) the duplicates of the standard curve are divided 
so that charcoal is added to one half at the beginning and 
to the other half at the end of the series. After centri­
fugation the supernatant from each tube is counted.
Plasma renin activity is calculated as illustrated in 
Tables 3 and 4. The relationship of bound to free angio­
tensin I is calculated first, using a modified logit plot 
(Figure 4) (65). The counts bound in the standard tubes 
are divided by the mean counts bound in tubes 19 and 2 0 to 
which no unlabelled angiotensin was added (B/Bq ).
1-B/Bq
is then calculated and plotted against the amount of angio­
tensin I for each tube of the standard curve. When log/log 
paper is used a straight line relationship is achieved.
The amount of angiotensin in unknown samples is derived 
from the standard curve and then plasma renin activity is 
is calculated taking into account (a) the volume of plasma
-26-
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TABLE 4
Sample
Counts
bound
T bT' B/% (=V)
anglo chem RIA ng AI
ng DF DF / m l T W r
PRA
error ng AI 
mean % - ^ml/h'r
Standard Curve
1 12789 .96 24.0 .010
2 12995 .98 48.0 .010
3 12262 .92 11.5 . .020
4 12238 . 92 11.5 .020
5 1144B .86 6,1 .040
6 11328 .85 5.7 .040
7 9579 .72 2.57 .080
B 9785 . .74 2.85 .080
9 7549 ,57 1.33 .150
10 7660 *57 1.33 .150
11 5547 .42 0.72 .300
12 5411 ■ .41 0.69 .300
13 4718 .35 0.54 .400
14 4888 .37 0.59 .400
15 149
16 163 1% non specific bind:
17 • 24314
10 24739 total counts
19{BJ 13162
■ 20 13462 54% binding
\
Standard
Sample
d
Plasma
Counts
bound
-JbT
Samples
B/B,
B/B„
(»Y)
anglo
ng
chem
DF
RIA
DF
ng AX 
/ml/3hr mean
error
%
PRA 
ng AI 
/mi/hr
Xt30f’
X(60)
11841 
■ 10574
.89
.79
8.1
3-76
,029{"3%) 
.060( 0%)
— '
. . - ■
* p.
Z(150) 
Z (300)
8020
5710
.60
.43
1.50
0.75
,139{-7%) 
.270 (-10%)
Unk nown Samples
379
379*
10153
8289
.76
.62
3.2
1.6
.070
.135
1,06 100
50
7.4
7.2 •
7.3 13 2.4
380
380*
10854
9315
.82
.70
4.6
2.3
.050
.095
1.06 100
50
5.3 
5.0 -
5.2 2% 1.7
381
381*
12250
11510
.92
.86
11.5
6,1
.021 . 
.038
1.08 100
50 1:1
2.2 5% 0,7*
384
384*
8420
6337
.63
.48
1.7
0.92
.130
.240
1.06 100
50
13.8
12.7
13.3 4% 4.4
*Repeat incubation for 18 hours,
Chem DP = dilution factor due to addition of DPP, neomycin and acid for pH adjustment, 
RIA DF = dilution factor for volume of plasma added to radioimmuncassay and if plasma 
diluted before radioimmunoassay* *
* ^ Numbers in parenthesis = mean pg value for standard plasma samples.
was
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FIGURE 4
ANGIOTENSIN I  STANDARD CURVE
5 0
5.0B/B
0 , 5 0
10 2 0  4 0  8 0  150 3 0 0  4 0 0
pg A N G I O T E N S I N  I
Picograms of angiotensin I added to each, tube of the 
standard curve plotted on log/log paper against a function 
of the change in the counts bound caused by addition of 
unlabelled angiotensin II.
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assayed (10 or 20 ul), (b) dilution of plasma due to
addition of DPP, neomycin and acid to adjust the pH,
(c) dilution of incubated plasma prior to radioimmunoassay,
(if any) and (d) incubation time (3 or 18 hours). Plasma 
renin activity is expressed as ng angiotensin I generated 
per ml per hour.
3) Problems encountered in the radioimmunoassay :
Radioimmunoassay involves many steps and when variability
occurs it can be ascribed to many different problems. Addition
of charcoal for separation of bound from free is often a source
for error. The charcoal should be stirred vigorously and every
effort should be made to add it as quickly and consistently as
possible. A useful guide to detection and identification of
changes in the radioimmunoassay is the non-specific binding
(Table4ftubes 15 and 16) (66). If the duplicates of these
tubes vary, erratic addition of charcoal may be the cause.
When changing to a new batch of charcoal the non-specific bind-\
ing may differ. Different batches of charcoal often have 
different activity and the optimum amount should be calculated 
for each batch. If too much is added^ adsorption of antibody- 
bound angiotensin will increase to unacceptable levels.
If the non-specific binding gradually and consistently 
increases with each set —  it should be 2-3% of the total 
counts -- this is a sign that the radioactive angiotensin 
is deteriorating and fresh label should be acquired.
Another guide to adequacy of radioactive angiotensin I 
is the variability of the standards at the extremes of the
-29-
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standard curve. As the label ages the sensitivity of the 
standard curve decreases and the lowest point often fails to 
fall on the straight line (Figure 4). Also if the antibody 
binds considerably greater or less than 50% of the iodinated 
angiotensin the points at the extremes of the standard curve 
may not fall on the straight line. Only that portion of the 
standard curve which falls on the straight line should be 
used in the assay. Samples which fall outside of this range 
should be repeated.
Because angiotensin II is not stable when stored in 
dilute solution, the standards used in the radioimmunoassay 
are prepared fresh daily from concentrated solutions (6). To 
eliminate this as a potential source of error two standard plasma 
samples are run with each set. If these do not fall within a 
predetermined range the set is discarded and repeated.
Validation of Method :
A. Incubation :
1. pH Optimum:
The pH optimum for human renin with plasma renin sub­
strate was found to be between pH 5.5 and 6.5 (Figure 5) (7,8) 
confirming previous reports (49,56,67,68). The rate of 
angiotensin generation fell steeply below pH 5.5 and declined 
less steeply above 6.5. At pH 7.4, the rate of angiotensin 
generation was almost half that found at the pH optimum. In . 
addition, the pH of plasma did not remain stable during
-30-
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FIGURE-S-
PLASMA RENIN ACTIVITY pH OPTIMUM
6.0
5.0
4.0
P R A
ng A l / m l  /hr 3.0
2.0 
1.0
HH Mean ^
/
4.5 5.0 5.5
1_
Range during 
incubation
JL
6.0 6.5
pH
JL
7.0 7.5 8.0 8.5 9.0
pH optimum of human renin with human renin 
substrate. The same sample was incubated at different pH 
levels for 3 hours with EDTA, DFP and neomycin. Arrows 
represent the change in pH during incubation. The pH 
remains quite stable below pH 6.0 but can increase by 
almost 1 pH unit during incubation at alkaline pH,
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incubation above pH 6,0 and in some samples it drifted high 
enough to almost stop the reaction (7,68). In this study 
buffers were not used to adjust the pH on the assumption that 
the endogenous plasma buffers would hold the pH constant.
This had previously been confirmed for pH 5,7. The gradual 
increase in pH during incubation in samples adjusted to above 
pH 6,0 may have been due to slow elimination of carbon dioxide 
from plasma. The lack of change in pH below 6.0 may have been 
caused by prior elimination of CO2 during addition.of acid to 
adjust the pH.
The. use of the pH optimum for incubation precludes 
the need for addition of strong buffer to hold the pH con­
stant and leads to a two-fold increase in the rate of 
angiotensin generation. In addition, if perchance the pH 
does change slightly during incubation, the rate of gener­
ation of angiotensin will not vary since the flat portion 
of the pH optimum curve is exploited.
2. ■ EDTA, DFP and Neomycin as Protective Agents :
The effectiveness of EDTA as both a converting enzyme and 
an angiotensinase■inhibitor is well documented (44,49).
The action of EDTA to inhibit converting enzyme may 
be more effective at pH 5.7 than at alkaline pH (57) because 
the pH optimum for converting enzyme is around 7.4 (50) and 
its action at pH 5.7 may be somewhat retarded. DFP does not 
inhibit converting enzyme (68), but it has been shown to be 
an effective angiotensinase inhibitor, especially at acid pH 
(69) .
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To evaluate its importance, DPP was omitted from the 
incubation medium in 15 plasma samples (7)(Table 5).
After 3 hours incubation with DFP 23.6 ng/ml angiotensin I 
was found and this fell to 11.4 ng/ml (48%) when DFP was 
omitted. The activity of low renin samples, incubated, for 
18 hours, fell from 15.8 to 1.3 (8%) when DFP was omitted.
The potency of DPP as an angiotensinase inhibitor was 
also evaluated at pH 7.4. During 18 hours incubation, the 
activity of low renin samples increased from 2.63 to 5.88 
ng/ml (22 4%)when DPP was added to the incubation medium. 
However, the effect of addition of DFP to the incubation 
medium was less apparent during a 3 hour incubation period 
(Table 5). The data suggested that angiotensinase blockade 
by DFP was incomplete during 18 hours' incubation at pH 7.4, 
since the renin value was only 37% of that found at pH 5,7, 
whereas for the 3 hour incubation the renin value was 46% 
of that found at pH 5.7.
BAL(dimercaprol) and 8-hydroxyquino1ine have also been 
recommended as protective agents during incubation at pH 7.4 
(57). In our studies they were found to be less effective 
than DFP both at pH 5.7 and 7.4 (7) (Table 5). During 3 
hours incubation at pH 5.7, 12.9 ng/ml were found compared 
to 23.6 ng/ml with DFP. During 18 hours incubation at pH 
7.4, 3.0 ng/ml were found compared with 5.88 ng/ml with DFP.
Addition of neomycin to the incubation medium has been 
shown by us to increase net production of angiotensin (6).
In another study in which neomycin was omitted and the water
-33-
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TABLE 5
COMPARISON OF THE EFFECT OF DFP OR BAL AND 8-HYDROXYQUINOLINE 
ON INCUBATION FOR GENERATION OF ANGIOTENSIN I
pH 5.7 pH 7.4
DFP BAL None' . DFP BAL None ' ■ . •
etc etc
. 3 hour incubation: normal and high renin samples (N=10)
Angiotensin I*(ng/ml)23.6 12.9 11.4 10.9 10.2 10.3
(6.8) (3.6) (2.9) (3.0) (3.0) (2.7)
%AI found at
pH 5.7 with DFP . 55% 48% 46% 43% 44%
18 hour incubationt low renin samples (N~5) 
Angiotensin I*(ng/ml)15.8 2.8 1.3 5.9 3.0 2.6
(2.1) (0.9) (0.6) (1.4) (0.5) (0.7)
%AI found at ’
pH 5.7 with DFP 18% 8% 37% 19% 17%
* Angiotensin I generated during incubation. The 3 hour incubation ' 
was carried out using different samples from those used in the 18 hour 
incubation. Figures in parenthesis represent the standard error 
of the mean.
— 34"
Renin: Validation: Incubation
bath was not shaken during incubation, the amount of angioten­
sin I found was reduced by 42% (7).
Several publications have presented evidence that BAL 
and 8-hydroxyquinoline together with EDTA are effective in 
completely inhibiting converting enzyme and angiotensinase 
activities (57,68,70,71). The discrepancy between 
those observations and our own are based on three differences 
in design of the studies: In our studies (1) the incubation
time is prolonged (2) dilution of plasma is kept to a minimum 
and (3) pH 5.7 is used for incubation. Since EDTA is effec­
tive in completely inhibiting converting enzyme activity, the 
discrepancies appear to be related to differences in effec­
tiveness of inhibition of angiotensinases.
Incubation time: Plasma angiotensinases are slow acting
(68). In the studies in which neither DFP or BAL and 8- 
hydroxyquinoline were added, destruction of angiotensin I 
during 18 hours incubation was fractionally greater than dur­
ing 3 hours incubation (7). This may be due to the slow rate 
of destruction of formed angiotensin and because during pro­
longed incubations larger amounts of angiotensin are generated. 
Thus, studies which utilize a short incubation time are less 
likely to peveal the limited effectiveness of protective agents
Dilution of plasma prior to incubation reduces the concen­
tration of angiotensinases in the medium and thus reduces their 
activity. The amount of angiotensin found after one hour incu­
bation of 3-fold diluted plasma was not increased by addition 
of DFP and was only slightly increased during 3 hours incuba-
-35-
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FIGURE 6
DILUTION OF plasma;
An Effective Angiotensin Inhibitor 
During Short Incubations
PLASMA
RENIN
ACTIVITY
ng/ml /hr
6.0 r
5.0
4.0
3.0
2.0 
1.0
DFP
0
undiluted
plasma
NO DFP
DFP ^ samples 
diluted 
NO DFP 3 fold
1
0 1 2 3
INCUBATION TIME (hr)
When plasma was incubated after three-fold 
dilution with maleate buffer, pH 5.7, addition of DPP 
to th;e incubation medium did not enhance the amount of 
angiotensin measured after one hour of incubation. 
However, a more prolonged period of incubation, or 
incubation of undiluted plasma, required the presence 
of DFP for complete angiotensinase inhibition.
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tion (Figure 6) (7), suggesting that angiotensinase activity
was minimal. However, addition of DFP markedly increased the 
amount of angiotensin found after incubation of undiluted 
plasma. Therefore, a more prolonged period of incubation, or 
incubation of undiluted plasma requires the presence of DFP 
for complete angiotensinase inhibition.
pH of incubation : The angiotensinase inhibited by DFP
has greatest activity at acid pH (49,69) so that incubations 
in alkaline media would be expected to exhibit less angio­
tensinase activity.
Therefore, by incubating diluted plasma at alkaline pH 
for a short incubation time, other protective agents will 
appear to be as effective as the ones we.have chosen. None­
theless, maximum generation of angiotensin is very important 
in detecting accurately low renin samples. Since complete 
inhibition of angiotensinase and converting enzyme activity. 
for 18 hours can only be accomplished when the incubation 
is carried out at pH 5.7 in the presence of EDTA, DFP and 
neomycin, we have chosen to use this combination routinely. 
In addition, stability of pH is ascertained without addition 
of strong buffers and without dilution of, plasma (7).
3. Linearity in the Rate of Angiotensin Generation :
The effectiveness of EDTA, DFP and neomycin as protective 
agents is confirmed in studies in which samples were incu­
bated for both 3 and 18 hours (8). Samples with low plasma 
renin activity were used in this study to minimize an effect 
of substrate utilization on the rate of angiotensin genera-
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FIGURE 7
COMPARISON OF 3 AND 18 HOUR INCUBATIONS 
SAMPLES WITH LOW PLASMA RENIN ACTIVITY
8 hr
PRA ng A l/m l/hr  
18HR!NCUBAT10N
0.8
0.6
0.4
0.2
0.2 0.4 0.6 0.8 1.4 1.6
PRA ng A l /m l /h r  
3 HR INCUBATION
No difference was found in the hourly rate 
of angiotensin generation when samples were incubated for 
three or eighteen hours*
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tion. 26 different plasmas were incubated for both 3 
and 18 hours and the hourly rates of angiotensin generation 
were compared (Figure 7). There was a direct relationship 
between the two measurements over the entire range of activ­
ity and the best fit was a line of slope 0.9 and intercept 
0.07r demonstrating an equal rate of angiotensin generation 
for the two time periods, The ratio of the 18 hour rate of 
angiotensin generation to the 3 hour rate was 1,04. The 
correlation coefficient of 0.9 85 was very high, which empha­
sizes the accuracy of the two measurements, even at low 
levels of plasma renin activity.
B, Radioimmunoassay :
Adequacy of the renin assay is determined in part by the 
sensitivity and specificity of the antibody used in the radio­
immunoassay step. Unlike most other radioimmunoassay proce­
dures, such as the angiotensin II assay, sensitivity of the 
radioimmunoassay system need not be a problem because the 
amount of angiotensin generated can be increased by prolonging 
the incubation time until there is sufficient to be measured 
accurately. Few methods take advantage of this great poten­
tial. Thus, even though our radioimmunoassay step has a sen­
sitivity similar to other methods, we can detect much lower 
levels by prolonging the time of incubation to 18 hours and 
optimizing the conditions of the incubation step (7),
(1) Blank subtraction : The ability to prolong the incu­
bation time also eliminates a problem inherent to radio-
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immunoassay. Most antibodies to angiotensin I cross-react 
with non-specific substances in plasma (72) . Since renin 
activity is expressed as the rate of angiotensin generation, 
if angiotensin or other immuno-reactive substances are pres­
ent in unincubated plasma the value will be falsely high 
unless the blank is subtracted. By prolonging the incuba­
tion time it is possible to generate so much angiotensin 
that the amount present in unincubated plasma can be ignored 
(8,66). Thus, in the method just described, no blank sub­
traction is included so that the number of samples for assay 
is reduced by half.
(2) Volume of plasma added to radioimmunoassay :
Many methods recommend addition of 50 ul or more of plasma 
to 1 ml of radioimmunoassay mixture (57,68,70). In our 
method a maximum volume of 20 ul is added to 2 ml of radio­
active angiotensin/antibody mixture. This small volume of 
plasma was chosen because when it was increased to 50 ul 
the values for plasma renin activity fell significantly.
Thus mean values for plasma renin activity for 10 samples 
fell from 0.68 ng/ml/hr. (10 ul sample) to 0,50 ng/ml/hr.
(50 ul sample)(p < .01).
In our original radioimmunoassay method (6), instead 
of reincubatihg plasmas with low renin activity for 18 
hours, 50 and 100 ul of the 3 hour incubated samples were 
assayed in a special radioimmunoassay in which charcoal 
extracted pooled plasma was added to each tube so that the 
volume of plasma in each tube was 0,1 ml (5% plasma) (6,7).
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This addition of plasma to each tube, including the 
standard curve, eliminated the necessity of subtracting a 
blank from each result, and interference caused by addition 
of a large volume of plasma only to the unknown samples was 
eliminated. However, this approach was replaced by the 
longer incubation when we demonstrated that the 18 hour 
incubation afforded greater reproducibility (7).
C. Relationship of Bioassay to Radioimmunoassay :
When bioassay of angiotensin was replaced by radioimmu­
noassay, it was found that samples measured by radioimmuno­
assay were consistently 2.2 times higher than those measured 
by rat pressor bioassay (Figure 8)(6), Studies were car­
ried out to identify the source of the discrepancy.
Two changes were introduced when the assay was switched 
For radioimmunoassay the incubation time for generation of 
angiotensin I was reduced for most samples from 18 to 3 
hours. Secondly, the reference standard was changed from 
angiotensin II (bioassay) to angiotensin I. Angiotensin II 
had been used as reference standard in the bioassay because 
it had been assumed that angiotensin II was the final pro­
duct in the incubation. However, in the presence 
of EDTA, conversion of angiotensin I to angiotensin II 
is inhibited (44). Angiotensin I can be measured by rat 
pressor bioassay only because it is converted to angioten- . 
sin II by the rat ^ s own converting enzyme. When the potency 
of angiotensin I was compared with angiotensin II in the
— 41—
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FIGURE 8
P L A S M A  RENIN A C T IV IT Y
Corretoffon of Bioossay (Angjo IT  std) 
and Radioimmunoassay (Angio Is td )
BIOASSAY
PRA
n g / m l / h r
6.0
5.0
4 .0
3 .0
2.0 
1.0
Incubation Time! 
Bio = 24hrs  
RlA= 3hrs
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- ® @ 0 8#  «
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Measurement of plasma renin activity by radio­
immunoassay resulted in values 2.2 times higher than those 
measured by bioassay. The correlation of the two values was 
high (r = 0.91) over a wide range of plasma renin measurements. 
The difference in values could be ascribed to the inappropriate 
use of angiotensin II instead of angiotensin I as reference 
standard in the bioassay and substrate utilization during 
the more prolonged incubation time used for the bioassay.
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rat assay it was found that, on a weight basis, it had only 
50% of the activity. This observation was supported by a 
study in which the bioassay was compared with the radioimmuno­
assay using angiotensin I as reference standard in both assays. 
In this comparison study the values differed by only 20%.
Thus the incorrect use of angiotensin II as reference stan­
dard in the bioassay had resulted in falsely low estimates 
of plasma renin activity. This also led to falsely low esti­
mates of plasma renin substrate (6,73).
The 20% difference in the results by radioimmunoassay 
and bioassay in the preceding experiment may be explained by 
substrate utilization during incubation. In that experiment 
samples assayed by radioimmunoassay were incubated for 3 
hours whereas those assayed by bioassay had been incubated 
for 18 hours. As illustrated in Figure 9, the rate of angio­
tensin generation is dependent on substrate concentration at 
levels which span the physiological range (6), A gradual reduc­
tion in substrate concentration during the 18 hour incubation 
utilized for bioassay may have gradually but significantly 
lowered the rate of generation during the incubation, espe­
cially in samples with high plasma renin activity. This 
possibility was supported by the observation that the ratio 
of assays of samples incubated for the same time period (18 
hours) but assayed against different reference standards, 
was 1.9 in contrast to the ratio of 2.2 which was found when 
different incubation times and reference standards were used.
Using a correction factor of 2.2 for measurements of
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-   . FIGURE 9
R E L A T IO N S H IP  BETWEEN RENIN SUBSTRATE AND S U B S TR A TE  R E A C T IV IT Y
19 Normal Subjects
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Direct relationship between plasma renin 
substrate concentration and the amount of angiotensin 
generated in response to addition of a fixed amount of 
human renin (substrate reactivity) in 19 normal subjects.
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plasma renin activity and one of 2.0 for the measurement of 
renin substrate concentration, data derived from bioassay 
and radioimmunoassay become completely interchangeable. The 
reasons for the discrepancies in the data have been accounted 
for by differences in the reference standard and substrate 
utilization during the incubation for plasma renin activity.
When plasma renin activity is related to the concurrent 
24-hour urine sodium excretion in normal man a hyperbolic 
relationship is found (Figure 10). Using a corrective fac­
tor of 2.2, data from bioassay and radioimmunoassay are 
superimposable over the entire range of plasma renin activ­
ity.
D. Effect of Changes in Plasma Renin Substrate on Plasma 
Renin Activity Measurements :
In a study of eleven hypertensive patients on oral contra­
ceptive medication, renin substrate (measured by bioassay) was 
found to range from 1980 to 8650 ng/ml, as compared to approxi­
mately 1000 ng/ml found in normal subjects (15,62). In two nor­
mal subjects and one male hypertensive patient entirely similar 
effects were produced by treatment with the estrogen-progestogen 
combination. The increase in substrate in these patients was 
not surprising since renin substrate had previously been shown 
to be elevated during pregnancy (49,59,74) and in animals 
treated with estrogen (75).
To investigate whether the observed increases in sub­
strate concentration could increase the rate of angiotensin.
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FIGURE. 10
RELATIONSHIP OF PLASMA RENIN ACTIVITY 
TO SODIUM EXCRETION IN NORMAL SUBECTS
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Hyperbolic relationship of plasma renin 
activity to the 24 hour urine sodium excretion in 52 normal 
subjects. The data derived from bioassay and radioimmuno­
assay are interchangeable when a correction factor of 2.2 
is applied. Urine sodium excretion is taken as an indicator 
of the state of sodium balance.
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generation, the capacity of plasma to form angiotensin was 
measured in an in vitro system after addition of a fixed a- 
mount of renin to the individual plasma. Significant increases 
in plasma reactivity were consistently observed (Figures 11,12). 
These increases were directly related to the corresponding in­
duced rise in renin substrate concentration. Reactivity in­
creased as the substrate concentration rose to the region of 
200 0 ng/ml. Above this concentration, further increases in 
substrate induced lesser increments in reactivity. These 
results suggest that changes in concentration of substrate 
account for the increased "reactivity" to renin and that 
changes in substrate concentration can markedly affect meas­
urements of plasma renin activity.
However, it is interesting to note that in the study 
illustrated in Figure 11, increased substrate concentration 
only transiently led to increased plasma renin activity. Renin 
secretion apparently slowly fed-back so that eventually plasma 
renin activity returned to normal levels. In addition, in 
normal subjects the range of renin substrate is quite wide 
(Figure 9) and yet no correlation was .found between plasma 
renin activity and plasma renin substrate concentrations (6). 
Thus, physiologically, changes in substrate concentration are 
not normally determinants of plasma renin activity under 
steady state conditions since renin secretion appears to feed 
back to maintain renin activity constant.
Previous studies had suggested that under normal condi­
tions substrate concentration is not rate-limiting so that the
— 47“
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FIGURE 11
ONSET & OFFSET OF ORAL CONTRACEPTIVE HYPERTENSION
IN A SINGLE PATIENT
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Administration of oral contraceptive therapy was 
associated with increases in renin substrate and substrate 
reactivity to renin* The data illustrate that the observed 
transient increase in plasma renin activity on the 12th day 
was largely due to an increase in renin substrate concentration. 
Renin secretion appeared to feed-back in response to 
the increase in.substrate concentration.
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reaction velocity for a given amount of renin is near maximum 
(49,76). Because of these reports, the possibility was 
raised that increases in reactivity to renin might have re-, 
suited from changes in the plasma concentration of an activa­
tor or inhibitor. To test this possibility, a plasma sample 
with substrate concentration of 3,00 0 ng/ml was diluted and 
the reactivity of various dilutions of this sample was com­
pared with that of other samples drawn from the same patient 
as the substrate concentration was rising in response to oral 
contraceptive therapy (Figure 12). The two curves of reactiv­
ity as related to substrate concentration were superimposable. 
This result provides no positive evidence for any activator 
or inhibitor and instead suggests that the increased reactiv­
ity to renin merely results from an increased substrate 
concentration.
Effect of dilution of plasma renin substrate on plasma renin 
measurements : Since the concentration of renin substrate in
normal plasma is rate limiting, dilution of plasma prior to 
incubation for generation of angiotensin I is likely to reduce 
the rate of angiotensin generation and produce falsely low 
measurements of plasma renin activity. A study was carried 
out to investigate the magnitude of the effect (7).
When plasma was diluted by 1.5, 2 or 3-fold the rate of 
angiotensin generation was considerably reduced. Two-fold 
dilution reduced the amount of angiotensin generated to only
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FIGURE 12
EFFECT OF DILUTION OF RENIN SUBSTRATE 
ON SUBSTRATE REACTIVITY 
COMPARED WITH UNDILUTED SAMPLES
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■ Effect of dilution of renin substrate on the rate 
of generation of angiotensin compared with undiluted samples of 
various substrate concentrations. These latter samples were 
obtained at different times in the course of oral contra­
ceptive therapy. It is apparent that increases in substrate 
above normal (i.e., 100 0 ng/ml; bioassay) can markedly 
increase the capacity for angiotensin generation. Changes in 
the capacity of plasma to release angiotensin appear related 
to changes in substrate concentration rather than the result 
of variation in concentration of an activator or inhibitor.
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40% of the amount formed in undiluted plasma and this fell
to 19% in 3-fold diluted plasma (Figure 13).
In a second study (Figure 13), a fixed amount of renin
was added to the diluted and undiluted plasma so that only'
dilution of substrate, and not differences in renin concentra­
tion could affect the rate of angiotensin generation. Two-fold 
dilution of renin substrate reduced the rate of generation of 
angiotensin to 62% and only 14% of the activity was found in 
11-fold diluted plasma. Thus dilution of plasma renin sub­
strate per se can markedly affect the rate of angiotensin 
generation and plasma renin activity measurements.
Since different plasmas may have quite different sub­
strate concentrations (the normal range is from 900 to 2200 
ng/ml), 50% dilution of substrate may lead to considerable 
reduction in the rate of angiotensin generation when sub­
strate concentration is low. However, if the substrate con­
centration is quite high, dilution of substrate may cause 
only slight reduction in the rate of angiotensin generation. 
There is no simple formula to correct for the reduction in 
angiotensin production due to substrate dilution unless the 
rate of angiotensin generation in response to addition of a 
fixed amount of renin is also measured. For this reason, 
dilution of plasma prior to incubation for generation of 
angiotensin is avoided in the methods for measurement of 
plasma renin activity and substrate reactivity.
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FIGURE 13 .
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>-.When plasma was diluted up to three-fold, the 
rate of angiotensin generation was reduced to less than 20%. 
Addition of a fixed amount of renin to each dilution of 
plasma revealed that reduction in plasma renin substrate 
concentration considerably reduced the angiotensin production 
rate.
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E. Effect of Competitive Inhibitor' (Heparin) on Plasma Renin 
Activity.
Plasma renin substrate concentration has been shown to be 
rate limiting in normal plasma so that changes in its concen­
tration can affect the rate of angiotensin generation. Many 
studies have been carried out to determine whether or not 
activators or inhibitors are present in plasma which also 
modify the rate of the reaction (49,50,77-79). Although 
several studies claimed to have demonstrated activators or 
inhibitors (77-79) the physiological relevance of such sub­
stances has yet to be established.
In an early method for measurement of plasma renin activ­
ity in our laboratory, heparin was used as anticoagulant and 
the plasma was dialysed for 24 hours - against O.OOSM EDTA (49, 
53). After another dialysis for 24 hours against distilled 
water, incubation was carried out for generation of angioten­
sin at pH 5.7 in the presence of DPP, We found that, under 
these conditions, the heparin used as anticoagulant acted 
as a competitive inhibitor of the reaction (80),
To characterize the effect of heparin, blood was col­
lected from nine normal subjects using either heparin (three 
different concentrations) or EDTA as anticoagulant or the 
blood was allowed to clot and the serum was assayed. As il­
lustrated in Table 6, the presence of 5.2 x (10 ' U/ml)
heparin reduced angiotensin formation by a mean of 41% and 
2.6 X 10~^M (50 U/ml) produced an 81% reduction in the mean
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TABLE 6
ANGIOTENSIN GENERATION IN VITRO IN SERUM AND IN EDTA AND HEPARINIZED PLASMA
SERUM EDTA HEPARIN
3.5 X 10-3 M 5,2 X 1 0 “ 6 m 1.3 x I0"5 M  2. 6 x 10“5 M
      (10 u/ml)_______ (25_u/tnl)_______ (50 u/ml)
Angiotensin ng/ml 4 h 7.5 6.3 • 4.4 4.0 , 1,4
Mean Values
Standard Deviation i (2,2) (1.4) (1.4) (1.3) (0.6)
p Value* > . 0 5  <.05 <.02 < . 0 0 1
Blood samples taken at a single venepuncture in each of 9 normal subjects.
.
* p Value represents the statistical significance of the difference between the serum as 
compared with anticoagulated plasma.
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yield of angiotensin as compared with serum or samples col­
lected in EDTA,
The effects of heparin were consistently observed whether 
it was added to the samples before or after dialysis. No 
differences were detected in the inhibitory action of similar 
concentrations of heparin added to serum, plasma or whole 
blood, indicating that factors released or removed by the 
clotting process were not involved in the inhibition.
Certain of the data suggested that the degree of in­
hibition of renin by heparin might be related to renin sub­
strate concentration. This relationship was documented by 
a study in which heparin was added to normal serum which had 
been diluted to obtain various substrate concentrations 
(Table 7), Substrate concentration ranged from 0.38 to 3.04 
joM (38 0-3040 ng/ml) in the presence of a constant heparin 
concentration. At the lowest substrate concentration there 
was a 93% reduction in angiotensin formation. As the sub­
strate concentration was raised, the effect of heparin was 
reduced so that, at a concentration of 3,04 uM, the angio­
tensin yield was reduced by only 43%. However, when the 
concentration of either substrate of inhibitor was altered 
by a factor of eight, while maintaining a constant ratio 
of one to the other, the degree of inhibition of the rate 
of angiotensin formation did not vary.
Effect of heparin on enzyme kinetics. The effect of varying 
the renin substrate concentration on the rate of angiotensin 
formation in the presence or absence of heparin is illus-
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TABLE 7
RELATIO N OF HEPARIN IN H IB IT IO N  TO RENIN SUBSTRATE CONCENTRATION  
- *
NORM AL SERUM
Substrate (S) Heparin (I) Reduction in Angiotensin
fiM I Form ation
0.38 26 0.015 93%
0.76 26 0. 029 . 83%
1.52 26 • 0.058 63%
2.20 26 0.085 55%
3.04 • 26 0,117 43%
0.38 13 0.029 89%
0.76 26 0.029 83%
1.52 52 0.029 86%
3.04 104^  0.029 78%
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trated in Figure 14. Data from unheparinized samples indi­
cate that this enzyme system can be described in terms' of 
the Michaelis-Menten equation since a linear relationship 
was observed between the reciprocals of the substrate con­
centration and the corresponding reaction velocity.
Increasing the concentration of heparin progressively 
increased the value of the Michaelis constant without
altering the maximum velocity - The apparent pro­
duced in the presence of heparin was measured at three 
different heparin concentrations (Figure 14). This allowed 
calculation of , the binding constant of the enzyme for 
heparin. The mean value was 4.1 x 10 with a standard 
deviation of 0.55 x lO^^M. The Michaelis constant for 
the natural substrate was shown to be 5.0 x 10“’7m , a value 
less than one order of magnitude different from the for 
heparin. The behavior of heparin in these systems is thus 
that of a reversible competitive inhibitor, whose effects 
are consistently related to the concentration of available 
substrate.
Most of our experiments were carried out at pH 5,7, 
since this was previously shown to be near the pH optimum 
for the ini vitro reaction. Inhibition by heparin was also 
demonstrated at pH 7.4. The per cent inhibition of angio­
tensin formation was independent of the concentration of 
renin,
It has been reported that the velocity of angiotensin 
formation is reduced during incubation of plasma when saline
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FIGURE 14
HEPARIN AS A REVERSIBLE COMPETITIVE INHIBITION OF RENIN
Water Incubation 
pH 5.7
7r
CONTROL Km = 5.0xl0“'^M 
m(qpp) tHEPARIN
4.4 X iO“6M 1 ;n-7 
3.3x I0~6m V 4
4.5 X iO"® M
CONTnOL
- 2
Lineweaver-Burk plot of'the relationship between 
the reciprocals of substrate concentration and reaction 
velocity* Three different concentrations of heparin . 
significantly and proportionately increased the Michaelis 
constant. ' The binding constant, K.^ , for heparin is within 
an order of magnitude of the for the natural substrate.
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is removed from the incubation medium (81), However, the 
differences observed may have been due in part to the use of 
heparin as anticoagulant because in the present study the 
inhibiting action of heparin was consistently greater in 
the absence of saline. Sodium chloride therefore protects 
renin from the effects of heparin.
In Summary. Heparin inhibits the vitro production 
of angiotensin by renin. The inhibition of renin is much 
greater in water than in saline incubations,.and is dependent 
on the concentration of the renin substrate. Heparin inhi­
bition thus occurs as a consequence of reversible competition 
with the renin substrate for the active site of the enzyme.
The data indicate that, in salt-free incubations, this inhi­
bition may be quite specific because the binding constant for 
renin with heparin is nearly of the same order of magnitude 
as that observed for renin with its natural substrate.
Since plasma from patients may contain various drugs 
or other agents, this study points to the importance of 
evaluating the effect of them on the renin system before 
concluding that they act to affect renin secretion.
P. Searching Out Low Renin Patients : Evaluation of Commer­
cial Kits.
Recent studies have revealed an important subgroup of 
patients with essential hypertension who have subnormal plasma 
renin activity (9,13,14,82,83). It is important to accurately 
identify these patients since specific antihypertensive therapy
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can be applied to them (84-87) and, in addition, these 
patients appear to be protected from heart attack and stroke 
relative to other patients with essential hypertension (88).
For these patients the renin value is the only consistent 
feature which distinguishes them from patients with other 
forms of essential hypertension. Methods of the greatest 
sensitivity are therefore required so that truly low values 
can be discriminated from those falling in the normal range.
In order to evaluate the accuracy and sensitivity of 
other methods commonly used for identifying patients with sub­
normal plasma renin activity, three commercial kits were pur­
chased and the same 15 samples were assayed four ways (7).
All kits used EDTA with BAL and 8-hydroxyquinoline as protec­
tive agents and were based on the method of Haber et al (57). 
The Squibb and Schwarz/Mann incubation procedures were iden­
tical, incubating plasma with unadjusted pH for 3 hours; New 
England Nuclear recommended pH 6.0 and 1 hour incubation.
The pH in this latter kit was adjusted by a three-fold dilu­
tion with buffer. No attempt was made to analyze the stabil­
ity or the reproducibility of various batches of the reagents 
supplied with the kits.
Values for plasma renin activity utilizing any of the 
three kits ranged from 17 to 70% of those found using our 
method (Table 8). Since pH 6.0 was used, data using the New 
England Nuclear kit were closest to our own. However the val­
ues using this kit remained lower than ours because of dilu­
tion of substrate during the incubation for which no consis-
-60 —
Renin Kits
TABLE 8 '
PLASMA RENIN ACTIVITE vIN FI;ETEEN SAMPLES USING THREE COMMERCIAL KIT:
Sample # 
LOW RENIN
Sealey
SAMPLES
New England Nuclear Schwarz/Mann Squibb
1 1.4 1.1 0.45 0.35
2 0.80 » 0.60
0.23 0.18
3 0.67 0.27 0.10 0.14
4 0.94 -0.60 0.19 0.24
5 0.90 0.54 0.16 0.19
mean 0.94 . 
NORMAL RENIN SAMPLES
0.62 0.23 0.22
6 3.2 1.8 0.83 0.55.
7 5.4 3.1 1.6 0.87
8 ' 3.2 1.6 0.96 0.61
9 3.3 • 1.5 1.1 0.53
10 4.4 2.6 1.2 0.81
mean 3.9 
HIGH RENIN SAMPLES
2,1 1.1 0.67
11 10.8 7.4 4.5 2,8
12 11:9 9.5 • 5.4 3.8
13 27.3 18.1- 8.1 7.5
14 6.9 4.7 2.7 2.0
15 8.2 6.1 ■ 3.2 2.3
mpan 13.0 9,2 . 4.8 3.7
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FIGURE 15
ANGIOTENSIN I  GENERATED DURING RENIN INCUBATION 
COMPARISON V/ITH 3 COMMERCIAL KITS
26
HIGH RENINNORMAL RENINLOW RENIN
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Comparison of angiotensin I generated in low, ■ 
normal and high renin samples using our own method with 
those recommended by three commercial kits. Most values for 
low renin samples were undetectable using the kits. The 
amounts of angiotensin generated in low renin samples using 
and 18 hour incubation (Sealey) were almost identical with 
the yield from normal renin samples incubated for 3 hours 
so that, using the prolonged incubation times recommended by 
our own method, low and normal renin samples can be evaluated 
with equal accuracy.
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tent correction factor can be applied. It was found that 
unadjusted plasma could end up as high as pH 8.4, and the usé 
of unadjusted pH in both the Squibb and Schwarz/Mann kits re­
sulted in plasma renin values only approximately 25% of those 
derived from our method.
The most dramatic difference between our method and the 
kits was in the ability to measure the low numbers. Even 
the advantage of using the pH optimum in the New England 
Nuclear kit was completely eliminated by their three-fold 
dilution of the plasma prior to incubation and by the use of 
only a one hour incubation. The amounts of angiotensin 
generated from low renin samples were below the lowest limit 
of immunoassay detectability for all three kits (Figure 15).
The study suggested that the major problem with the kits 
involves not the standard or the antibodies provided for the 
radioimmunoassay but the conditions recommended for the 
renin incubation step. The use of unadjusted pH or of di­
luted plasma seriously reduces the sensitivity of the assay. 
Also, it is essential to subtract a blank from each sample, 
thus reducing accuracy. This in turn doubles the number of 
samples to be assayed.
Moreover, no bacteriostatic agents were added to the 
incubation medium and the manufacturers of the kits do not . . 
recommend that the samples be shaken during incubation.
These omissions may well account for lower values with the 
kits than we would have expected due to the use of unadjusted 
plasma. '
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Accordingly, if commercial kits are used, the following 
steps should be incorporated into the procedure. (1) The 
incubation step changed to pH 5.7 in the presence of DFP and 
neomycin, as well as EDTA. (2) For samples with low plasma 
renin activity, the incubation step should be repeated for 
18 hours. (3) Minimum dilution of plasma during pH adjust­
ment. (4) Angiotensin I generation should be prolonged until 
the necessity for blank subtraction is eliminated. (5) A min­
imum volume of plasma should be used in the radioimmunoassay. 
(6) A large source of antibody should be purchased so that 
variability in antibody characteristics does not become a 
problem. (7) For routine laboratories which have little con­
trol over the temperature of the blood after collection (it 
should be chilled) assay of the blank should not be discon­
tinued since high blank values will expose those samples 
which have been allowed to sit at room temperature for an 
extensive period of time. (8) Strict quality control is 
essential in any radioimmunoassay. The same two standard 
plasma samples should be run with each set and if they vary 
by more than + 15%, the set should be discarded and then 
repeated.
Summary :
A radioimmunoassay method for measurement of plasma 
renin activity has been described in which angiotensin I, 
generated by reaction of plasma renin with endogenous renin 
substrate during either 3 or 18 hours incubation, is quanti­
tated. The incubation step is carried out in undiluted
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plasma at the pH optimum (pH 5.7) and. can be extended up to 18 
hours because angiotensinases and. converting enzyme are com­
pletely inhibited by EDTA and DFP. Blank subtraction is elim­
inated and accuracy enhanced by prolongation of the incubation 
time until the blank comprises only a minor fraction of the 
generated angiotensin.
Incubation at alkaline pH was found to be disadvantageous 
because of lower rates of generation of angiotensin I, inabil­
ity to maintain constant pH without addition of buffer and 
because the incubation step could not be prolonged beyond 3 
hours. It was also found, in both acid and alkaline incu­
bations, that dimercaprol (BAL) and 8-hydroxyquinoline are 
considerably less effective than DFP in protecting against 
angiotensinase activity.
The capacity of plasma to form angiotensin I during the 
incubation step was found to vary directly with plasma renin 
substrate concentration. Therefore, dilution of plasma 
prior to incubation was avoided because of the slower re­
action rate, due to dilution of both enzyme and substrate, 
with an inability to correct for the effect of substrate 
dilution.
The radioimmunoassay is sensitive, accurate and repro­
ducible. By assaying a small volume of plasma, distortion 
of the standard curve by plasma is not a problem. Complete 
interchangeability of results derived from bioassay or radio­
immunoassay can be achieved by application of a correction 
factor based on the observed lower pressor activity of angio­
tensin I and utilization'of.substrate during incubation.
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The improved assay sensitivity by radioimmunoassay is 
important because approximately 30% of patients with essen­
tial hypertension have subnormal plasma renin activity and 
the renin measurement is the only consistently distinguishing 
feature of these patients. In a study using three different 
commercial kits, most low renin samples were undetectable and 
could not be discriminated with confidence from normal renin 
samples. However, by using an 18 hour incubation step, low 
renin samples could be detected with the same degree of ac­
curacy as those with normal plasma renin activity.
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II. Me a s u r'eïïi'ent of Al'd'o B t e r on e
Aldosterone was isolated, identified and synthesized in 
a series of important studies in the 1950's by Simpson, Tait 
and their coworkers (89,90). In normal subjects, the concen­
tration of aldosterone in plasma is approximately 10 ng% and 
the adrenal secretion rate is about 100 jtig/day. Because of 
the low concentration of aldosterone in plasma, until re­
cently, methods for measurement of physiological and patho­
logical variations utilized urine rather than blood (9,10,91-95). 
Although aldosterone is excreted into urine in small amounts 
(less than 1 pg/day) large and fairly constant fractions of 
the total adrenal secretion are normally excreted as two 
quantifiable metabolites. About 40% of secreted aldosterone 
is converted to 3,5 tetrahydroaldosterone (3a,11b,21 tri- 
hydroxy-18-oxopregnane“20“one)(96) and another 10% is ex­
creted as the acid-labile conjugate (C-18-glucuronide) (97).
This substance can be converted back to aldosterone by acid 
hydrolysis.
A technical problem in aldosterone measurements is the 
presence in blood and urine of other steroids in concentra­
tions several orders of magnitude greater than that of aldo­
sterone, Hence, aldosterone must be rigorously purified 
prior to quantitation.
Aldosterone was originally quantitated by bioassay and 
later by a fluorometric method (98). However, the first 
sensitive methods utilized a double isotope derivative
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technique for measurement of the 24-hour adrenal secretion 
rate (91,92) and were based on a method developed by Ayres and 
coworkers (97) . A tracer dose of tritiated aldosterone was 
injected into the patient. The tritiated aldosterone was di­
luted by the patient's own hormone and the specific activity 
of a urinary metabolite of aldosterone was calculated.and used 
to estimate the secretion rate of the hormone. A similar 
double isotope dilution assay was later applied to measure­
ment of the urinary excretion rate of aldosterone (9,10,94,95), 
In these later methods the radioactive tracer was added to the 
urine and the specific activity of the acid-labile conjugate of 
aldosterone was measured. This metabolite was chosen because 
tritiated aldosterone could be used as a marker since this 
metabolite is converted to aldosterone by acid hydrolysis.
Double isotope derivative methods for measurement of 
aldosterone in blood were also developed (99-103) but sensitiv­
ity was a problem since normal values fell at the lower limit 
of detection of the method.
The induction in animals of antibodies to steroids (104) 
and the development of radioimmunoassay by Yalow and Berson 
(61) introduced the potential for a new and more sensitive 
approach to aldosterone measurement. Several radioimmunoassay 
methods for measurement of aldosterone in plasma (12,105-109), 
and urine (11,10 8,110,111) have been developed. These new 
methods are faster and more sensitive but there still remains 
the problem that other steroids interfere with the assay.
Thus, extraction and chromatographic procedures must be used
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prior to quantitation by radioimmunoassay.
In the following section the principles of double iso­
tope derivative assay will be reviewed and followed by a 
description of a method utilizing this technique, which was 
developed in our laboratory. A detailed account will follow 
of the radioimmunoassay procedures for urine and plasma 
which were developed and are in current use in our laboratory,
A. Double Isotope Derivative Assay
1. Principles of assay
(a) Isotope dilution: (112)
The technique of isotope dilution is applicable when 
quantitative isolation of the substance to be measured is not 
possible, but quantitation of an aliquot can be carried out.
In the method to be described, radioactive aldosterone 
of known specific activity is added to the pool to be meas­
ured, i.e. it is either injected into the body (secretion 
rate) or added to the urine (excretion rate), The specific 
activity (s.a.) of aldosterone in a urine aliquot relative to 
the specific activity of the added aldosterone is a function 
of the amount of aldosterone in the original pool. Quantita­
tive recovery is not necessary and the fraction which is 
finally quantitated need not be known.
If a = ;amoles of aldosterone added 
b = yUmoles in pool (to be measured) 
c = yumoles in aliquot
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I -, 1nq = cpm in 'a
n- = cpm in 'c '
Then :
no n-i nic-noa
—  := ----- , and thus b = -------
c (a+b) n^
In the aldosterone assay, 'a ' is negligible relative to "c";
thus
^1^ ^1 counts per minute added
h - n2 “ hg/c " s.a. of isolated portion
Thus under most conditions the specific activity of the radio­
active aldosterone added to the pool is not crucial.
For application of the derived equations for measurement 
of the amount of aldosterone in a given volume of urine, a 
known amount of radioactive aldosterone is added to the urine 
(n^). After extractions and chromatography the specific 
activity of an aliquot is determined (n^/c). From this value 
using equation (1) the amount of aldosterone in the original 
urine (b) can be calculated,
(b) Isotope derivative assay :
The second stage of the double isotope dilution technique 
involves quantitation of 'c ', that is, measurement of the 
amount of aldosterone in the isolated portion. To this end, 
a radioactive derivative of aldosterone is prepared using a 
reagent of known specific activity(113), In the method to be 
described aldosterone is acetylated with acetic anhydride.
The amount of incorporated into aldosterone diacetate
becomes a measure of the amount of aldosterone in the aliquot.
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^ , „ cpm^'^C (in ' c ' )
s.a. acetic anhydride
Only one of the two atoms in each molecule of acetic
anhydride is incorporated into aldosterone diacetate. How­
ever, since two acetates are incorporated into each aldoster­
one molecule, the equation remains unchanged.
(c) Double isotope derivative assay:
The combined equation now becomes :
_______  ^   cpm^H aldo added
n2/(cpm^^C/s.a. ac.an.) ” 3h/14ç* x s.a. ac.an.
The ratio of to in the final aliquot, and not the
absolute amount of either source of radioactivity, is used in 
the calculation. Thus quantitative conversion of aldosterone 
to the diacetate is not essential and quantitative isolation 
of the aldosterone derivative need not be achieved.
The specific activity of acetic anhydride is technically 
difficult to measure accurately because the compound is quite 
volatile. Instead, desoxycorticosterone acetate is pre­
pared and the specific activity of DOGA is calculated with
each set. The specific activity of acetic anhydride is twice 
the specific activity of DOGA since there is only one acetate 
in DOGA. In addition, since the molecular weight of DOGA and 
aldosterone are similar (372 c.f. 360) 'b ' can be expressed
as micrograms without further modification of the equation.
Therefore
H - cpm^H aldo added
X s.a. DOCA'^'x 2
* 3h/1^C ratio in the isolated aliquot 
t = cpm per ug
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2. Requirements for application of isotope dilution tech­
niques : ( 9 ,91 ) ,
When measuring the excretion rate in urine of the acid- 
labile conjugate the metabolite must first be hydrolyzed to 
re-form the original steroid and recovery of the tracer does 
not account for variability in conversion to aldosterone.
Hence hydrolysis must be carried out very systematically.
The pH should be adjusted to exactly pH 1.0 and the time 
period for hydrolysis should be strictly controlled.
For measurement of aldosterone secretion rate the triti­
ated aldosterone is injected into the patient and must mix 
rapidly with endogenous aldosterone. Complete mixing of 
radioactive aldosterone with endogenous aldosterone is essen­
tial and it should be metabolized in identical fashion (9,91). 
The choice of metabolite for measurement of either secretion 
or excretion rates is not crucial as long as it is derived 
solely from aldosterone. All of the labelled metabolite 
destined for urinary excretion must be excreted during the 
collection period. The fraction of secreted aldosterone 
converted to the metabolite is not critical, but it should 
be constant.
Labelled and unlabelled hormone must react similarly in 
the purification and extraction procedures. This will be 
discussed further under the topic "isotope fractionation" 
(9,10).
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3. Method for measurement of the urinary excretion -rate of 
aldosterone : (Table 9) (9,10)
A flow sheet of the method is presented in Table 9. The 
tritiated aldosterone which is added to urine in the first step 
should be checked for radiochemical purity. Both a Bush B5 
system and the first chromatography system (Step 4, Table 9) 
can be used. If the latter chromatogram is run for both 6 
and 4 0 hours, impurities remaining at the origin and running 
with the solvent front can be detected.
After addition of tritiated aldosterone^ the acid-labile 
conjugate of aldosterone is hydrolyzed for 24 hours at pH 1.0 
to form free aldosterone which is then extracted into methyl­
ene chloride. The extract is washed with sodium hydroxide 
and then the pH is returned to neutrality by washing consecu­
tively with acetic acid and water. Prior to acétylation the 
extract undergoes preliminary purification on descending paper 
chromatography. The aldosterone is eluted then acetylated 
with acetic anhydride. aldosterone diacetate is
purified on two more descending chromatography systems before 
the final step of celite column chromatography. The combined 
3h/14c j-a^ tio of the peak tubes from-the column is used to 
calculate the amount of aldosterone in the original urine using 
the calculations derived previously.
The first chromatography system removes both hydrocorti­
sone and corticosterone prior to acétylation. In this way 
the amount of acetate incorporated into the extract, and
not associated with aldosterone, which has to be removed
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TABLE 9
FLOW SHEET FOR MEASUREMENT OF THE 
EXCRETION RATE OF ALDOSTERONE BY DOUBLE ISOTOPE DILUTION
1. Complete 24 hour urine collection
2. Hydrolysis
150 ml urine aliquot:
After 24 hours (23.5-24.5):
3. Ethyl acetate extract
Wash with:
Add:
Evaporate to dryness
Add 25,000 cpm H aldosterone
Adjust to pH 1.0 (0.95-1.1) with 50% H„SO.
Extract with 500 ml ethyl acetate
2 X 50 ml O.IN NaOH 
50 ml O.IN HAc 
50 ml distilled water 
10 ml 95% ethanol
4. 1st Chromatography -(count 1/50 aliquot prior to chromatography)
Paper:
Stationary Phase:
Mobile Phase: 
Marker:
Development: . 
Location:
El ution:
7.5 cm Whatman #1
22% propylene glycol in acetone
(Dip paper prior to application of sample)
Toluene
Isatin
AO Hours
H aldosterone located by strip scanner 
5 ml methanol
5. Partition (count 1/50 aliquot prior to partition)
Evaporate to dryness 
Add:
Wash with:
Evaporate to dryness 
Add:
Evaporate to dryness
5 ml methylene chloride 
3 x 1  ml distilled water
2 X 5 ml benzene
6. Acétylation (in well ventilated hood)
Add: ■
Add:
After 18 hours add: 
Add:
Evaporate to dryness 
Add:
Add;
Evaporate to dryness
0.03 ml pyridine
0,03 ml '^C acetic anhydride
1 drop distilled water
2 X 5 ml benzene/ethanol (2/l;v/v)
0.1 ml unlabelled aldosterone diacetate (50ug) 
2 drops rhodamine B
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y
TABLE 9 CON'T
7. 2nd Chromatography 
Paper:
Stationary Phase:
Mobile Phase: 
Markers: 
Development: 
Location:
Elution:
3 cm Whatman #1
55% formamide/methanol
(Dip paper prior to application of sample)
50% methylcyclohexane/toluene
Aldosterone diacetate; rhodamine B
16 hours
UV
5 ml methanol
8. 3rd Chromatoqraphy (count 1/50 aliquot prior to chromatography)
Add:
Add:
Evaporate to dryness 
Paper:
Reagents;
Stationary Phase:
Mobile Phase: 
Markers:
Development:
Location:
Elution:
0.1 ml aldosterone diacetate
2 drops rhodamine B
3 cm Whatman #1 .
Mesitylene/methanol/water (3/2/1) 
mesitylene
(Dip paper after application of sample) 
Methanol/water
Aldosterone diacetate and'rhodamine 8 
8 hours . .
UV
5 ml methanol
9. 4th Chromatography (count 1/50 aliquot prior to column)
Add:
Evaporate to dryness 
Reagents :
Support:
Stationary Phase:
Mobile Phase:
Flow rate;
Marker;
Location:
Evaporate to dryness 
Count to locate peak 
Peak eluted in 8 to 10 tubes
2 drops Sudan IV .
Isooctane/MeCl^/methanol/water 
(1500/450/900/T58)
Acid washed celite (12g) in 40 x 1.0 cm column
7 ml methanol/water
Isooctane/methylene chloride
0.3-0.5 ml/min
Sudan IV (void volume)
About 80 ml (2 ml fractions)
10. Calculation:
Count for 2 x 1 0  minutes: 
Count for 2 x 10 minutes: 
Count for 2 x 1 0  minutes:
Each peak tube from column 
Aliquot of H aldosterone (added to urine) 
*^C DOCA (for estimation of specific 
activity of acetic anhydride)
Aldosterone excretion rate = cpm H aldo added x urine total volume 
(ug/day) s.a.DOCA X 2 x 150
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subsequently is considerably reduced. . After acétylation, 
aldosterone diacetate is purified until radiochemical purity 
is achieved.
Zaffaroni paper chromatographic systems were chosen, 
rather than Bush systems, because of their high capacity. 
Chromatography #3 (99,114) is a reverse phase system in which 
the relative running rates of various steroids are switched. 
Compounds which run ahead of aldosterone in more conventional 
systems are more polar in this system and are less likely to 
merge with the main aldosterone diacetate peak. Another ap­
proach to rapid purification which was investigated was mild 
hydrolysis to. form aldosterone monoacetate. This approach 
was discarded because of variability in the yield of mono­
acetate and because two additional steps are required 
(hydrolysis of the acetate and an additional chromatography).
Column chromatography was chosen for the final step be­
cause constancy of the ratio in successive tubes can
be taken as an indication of radiochemical purity. A constant 
ratio in successive paper chromatography systems can 
also provide similar proof, but at least one additional system 
is necessary. Another reason for choosing column chromato­
graphy was the accurate identification of the peak. When 
using paper chromatography the area to be eluted is often less 
simple to define. This is not a major problem in the first 
three chromatographic systems because rather generous amounts 
can be eluted and associated impurities can be removed on 
subsequent systems. However, in the last chromatography,
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only the narrow band containing aldosterone diacetate should 
be eluted.
The acétylation step is a potential source of problems. 
Although 100% yield is not essential, maximum recovery at each 
step is required in order to maintain adequate overall recovery 
of the method. Any water associated with the extract during 
acétylation will reduce the yield of aldosterone diacetate be­
cause of rapid hydrolysis of acetic anhydride to acetic acid. 
Therefore, the extract is dried thoroughly prior to acétylation 
by refluxing in the presence of benzene. Propylene glycol 
present during acétylation also reduces the yield of aldoster­
one diacetate. Trace amounts can be carried over from the 
first chromatography system and must be removed prior to 
acétylation by partition between methylene chloride and water.
The specific activity of the acetic anhydride used for 
acétylation is measured by preparation of DOCA (see Prin­
ciples of Assay). DOC is acetylated (Step 6, Table 9) and 
the DOCA is then crystallized a minimum of three times to .
constant specific activity. The specific activity of both 
crystals and mother liquor must be identical.
At least three sources of acetic anhydride of different 
specific activity should be available so that urine samples 
with different aldosterone content can be acetylated to yield 
similar ratios. The optimum ratio of is be­
tween 2 and 10. During simultaneous detection of and
not much is picked up by the channel (less than
1%) . However, about 40% of the is detected by the
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channel and accurate discrimination of the two isotope re­
quires that tritium is present in slightly higher amounts.
An aliquot of the urine extract is routinely counted 
after each step to keep track of the recovery of tritiated 
aldosterone. In this way the source of any problem may be 
identified quickly. Since three weeks are required to com­
plete one assay, rapid identification of the source of error 
is essential. Another check of the accuracy of the method 
is the inclusion in each set of known amounts of aldosterone.
Despite the time needed for analysis and the number of 
steps involved, the double isotope derivative assay is an 
accurate method. As long as radiochemical purity is achieved 
in the final step there is little source for error. The use 
of tritiated aldosterone as a marker accounts for losses at 
each stepjexcept the initial conversion of the■acid-labile 
conjugate to aldosterone^ and the preparation of a radioactive 
derivative is a precise method of quantitation.
4. Isotope fractionation :(9,10)
In the double isotope derivative method for measurement 
of aldosterone just described, radiochemical purity of aldo­
sterone diacetate in the final step can be confirmed by con­
stancy of the ratio of in successive fractions eluted
from the column. During-development of the method many 
different systems for the final column were investigated but 
in all of them the ratio of to rose progressively in
the peak tubes. Because of this, to change the relative run-
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FIGURE 16
ISOTOPE FRACTIONATION DURING COLUMN CHROMATOGRAPHY
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aldosterone^'^Cdiacetate elution pattern 
from a celite partition column chromatography system. The 
3h/TAc ratio gradually and consistently increased across the 
peak. Mean displacement of the two isotopes was calculated 
to be 0.6%.
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ning rates of possible impurities and thus improve purifica­
tion, aldosterone diacetate was converted to the monoacetate. 
However a constant ratio of ^H to could not be achieved.
Finally pure standards were acetylated with acetic anhy­
dride and when, under these ideal conditions, a constant 
ratio could not be demonstrated in several different columns, 
the possibility of isotope fractionation was considered-
There are six possible moieties in the aldosterone di­
acetate mixture which can differ in molecular weight by only 
4 (10%) : (1) ^H aldosterone diacetate (2) aldosterone
diacetate (3) aldosterone ^ ^ ^ 2 diacetate (4) ^H aldosterone 
diacetate (5) ^H aldosterone '^^^2 ^iacetate and (6) aldo­
sterone diacetate. It is conceivable that these slightly 
different compounds might run differently on various chroma­
tographic systems.
To investigate whether or not isotope fractionation 
occurs in partition column chromatography, pure aldoster­
one diacetate was prepared and applied to a 2 0 g celite
partition column (Step 9, Table 9, p . 75 ). 1.5 ml frac­
tions were collected so that the peak was divided into about 
30 fractions (Figure 16) . The ratio rose consistently
across the peak. Mean displacement of the two isotopes, 
calculated by probit analysis, and corrected for differences 
in dispersion of the two peaks, was approximately 0.6%.
In another study isotope fractionation was analyzed using 
paper chromatography (Step 7, Table 9, p.75 ). The radioac­
tive peak was cut into multiple zones. In this system frac­
tionation was less, but still identifiable (approximately 0.3%)
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In a third study, pure aldosterone diacetate was
again run on paper chromatography and the- peak was cut into 
four zones, each of which was then applied separately to celite 
partition columns. Isotope fractionation was readily identi­
fiable in both systems (Fig. 17) and the combination of the two 
steps increased the displacement of the isotopes to almost 1%.
Other investigators have confirmed and extended our stud­
ies (115,116). A study by Cejka and Venneman (115) demonstrated 
that the presence of tritium in the molecule has the greatest 
influence on displacement. They found the greatest displace­
ment (1.8%) between aldosterone and unlabelled aldosterone, 
and were unable to demonstrate any displacement of diace­
tate from diacetate. This data supports our own observa­
tions (10) that aldosterone diacetate was displaced more 
than diacetate from unlabelled diacetate.
The greater chromatographic displacement caused by 
introduction of into the steroid than by addition of
to the acetate, may be because tritium is 2 00% heavier than 
hydrogen whereas is only 17% heavier than The
greater percent increase in size of the hydrogen molecule 
and its closer association with the steroid ring may change 
the conformation of the molecule and thus alter the relative 
running rates on chromatographic systems-
Analysis of the data suggests that peak enrichment should 
be avoided during all purification steps, and especially prior 
to acétylation. For this reason, wide bands should be cut in 
all paper chromatographic systems. Since H aldosterone is
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FIGURE 17
ISOTOPE FRACTIONATION DURING PAPER THEM COLUMN CHROMATOGRAPHY
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Isotope fractionation during paper and column 
chromatography of aldosterone i4C diacetate. A paper 
chromatogram of pure compound was run and the radioactive 
spot was located and cut into four segments. Each segment 
was eluted, counted, then individually chromatographed 
on a celite partition column. A progressive and significant 
increase in the 3h/14q ratio was apparent across the peak. 
AM% is the displacement of the two isotopes on each column.
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more polar than the unlabelled compound, when the peak is 
identified by location of radioactivity (first chromatography) , 
wider margins should be cut towards the solvent front. The 
reverse approach should be used for peaks in which the unla­
belled compound is located (second and third chromatographies).
It was found that the most accurate method of calculating 
the correct ratio was to divide the area under the
tritium peak by the area under the peak (10). The use of
the ratio in the peak tube alone led to considerable error but 
ten percent truncation of the peak caused an error of less 
than 10%. Therefore, routinely, all tubes from the column 
which contain 2 0% of the counts in the peak tube are used to 
calculate the ratio. Each tube is counted separately
and the sum of the counts are computed prior to the final 
calculation. Most accurate values would be achieved if the 
peak were divided into thirty fractions. However, the error 
introduced by using only 8-10 fractions is less than 8% as 
long as symmetrical cuts of the peak are made.
In summary, isotope fractionation is a problem in all
chromatographic systems used in the measurement of aldosterone.
However, knowledge of the characteristics of the effect can
prevent errors throughout the purification steps. A constant 
o 14
■^ H/ C ratio cannot be achieved in the final column but a con­
sistent rise in the ratio across the peak is a good, although 
less reliable, indicator that radiochemical purity has been 
achieved. Column is preferable to paper chromatography for 
the last chromatographic system because the peak tubes can be 
chosen with precision,
-83-
Aldosterone: Secretion rate
5, Measurement o f .the secretion rate of aldosterone :
The method is identical to that described in Table 9 (page 74) 
except 1-2 jic of tritiated aldosterone are injected into the 
patient immediately preceding the 24 hour urine collection.
No additional tritiated aldosterone is added in step #2. In 
the final calculation the counts added to the urine are re­
placed by the counts injected.
The measurement of the secretion rate of aldosterone 
has been replaced by excretion rate measurements for several 
reasons. Firstly it was demonstrated that, under most condi­
tions, the fraction of aldosterone excreted as the acid- 
labile conjugate is quite constant at 10% of the secretion 
rate (9). Excretion measurements are preferable in studies 
requiring serial determinations since radioactivity is not in­
jected into the patient. In addition quantitative injection 
of tritiated aldosterone is not always reliable and when all 
of the aldosterone is not. injected directly into the vein the 
assay has to be discarded. Sometimes it takes several days 
before all of the radioactivity is excreted. This also 
occurs and is a real problem in patients with renal failure. 
Another disadvantage of secretory measurements is that larger 
volumes of urine may have to be extracted^ unless a large 
amount of radioactivity has been injected, and this requires 
chromatography systems with greater capacity.
However, measurement of the excretion rate can be mis­
leading in patients with renal or liver disease. Approxi­
mately 50% of the acid-labile conjugate is formed by the
-84-
Aldosterone: Isotope dilution: Summary
kidney and the rest is made by the liver (117,118). In the 
presence of kidney disease there is both delay in excretion 
and a smaller fraction is converted to the acid-labile con­
jugate (119). In patients with liver disease, in whom the 
kidney becomes a major source of metabolism of aldosterone, 
as much as 5 0% of secreted aldosterone can be converted to 
the acid-labile conjugate (118).
6. Summary :
The measurement of either the secretion rate of aldoster­
one or the rate of urinary excretion of its acid-labile conju­
gate by double isotope derivative assay involves the use of 
multiple chromatography systems and the formation of a radio­
active derivative of aldosterone. The two methods are compli­
cated, expensive and time consuming but they have the advan­
tage of accuracy because of the use of radioactive markers 
which account for losses during extraction and chromato­
graphic procedures.
The problem of isotope fractionation during the chroma­
tographic procedures can be overcome by taking wide cuts, 
during preliminary purification steps and by accurately 
identifying the final peak on column chromatography.
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B. Radioimmunoassay of Aldosterone.
The demonstration that antibodies to steroids could be 
induced in rabbits by injection of a conjugate of the steroid 
to bovine serum albumin (10 4), opened the door to measurement 
of steroids by radioimmunoassay. Recently, several radioimmuno­
assay methods have been developed for measurement of aldosterone 
in blood (12,105-109) and urine (11,108,110,111) utilizing 
antibodies induced in either sheep or rabbits. Conjugation 
of aldosterone to albumin was achieved by coupling through 
either a 3-oxime or 21-hemisuccinate derivative.
To date, antibodies to aldosterone lack the specificity 
needed for direct quantitation. Although cross-reactivity 
with other steroids is generally less than 1%, the high con­
centration of other steroids in blood and urine requires even 
greater antibody specificity.
Radioimmunoassay of aldosterone is a much more sensitive 
method than double isotope dilution and is capable of detect­
ing picogram amounts. However, the increased sensitivity 
resulted in, perhaps unforeseen, complications. The relatively 
large amounts of aldosterone measured by the double isotope 
derivative assay had caused considerable laboratory contamina­
tion. This contamination had not previously been a problem 
because it was below the limit of detection by double isotope 
dilution. Another problem is that steroids cannot be used 
as markers in chromatography systems prior to radioimmuno­
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assay because the amounts needed for detection are very high 
and chances for contamination are great. Therefore, 
for measurement of aldosterone in plasma we adopted a chromato­
graphic system which does not require the use of markers. In 
addition extraction, purification and radioimmunoassay steps 
are all carried out using disposable glassware.
f
Methods for measurement of aldosterone in both urine (11, 
120) and plasma (12) have been developed in our laboratory. The 
two measurements fulfill different requirements. The 24 hour 
excretion of aldosterone is an integration of the 24 hour adre­
nal secretion rate whereas blood measurements reflect the level 
at only one point in time and are thus subject to wide fluctua­
tions. Double isotope derivative assays of urine and plasma 
aldosterone are interchangeable with those measured by radioim­
munoassay (Figure 18) (11,121). Urine aldosterone measurements 
are simpler and less time consuming than the plasma method 
but have the disadvantage that, in certain clinical situations 
such as malignant hypertension, renal and liver diseases or 
nephrectomy the excretion rate does not accurately reflect 
the rate of secretion because of alterations in metabolism 
or excretion. Blood measurements are especially applicable 
to the study of acute changes in aldosterone and also for 
analysis of those clinical situations in which urine measurement 
may be suspect.
When compared with the double isotope derivative assay, 
the technique of radioimmunoassay is more rapid, sensitive and
87
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FIGURE 18
RELATIONSHIP OF URINARY ALDOSTERONE EXCRETION  
TO SODIUM EXCRETION IN NORMAL SUBJECTS
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Hyperbolic relationship of urine aldosterone- 
excretion to urine sodium excretion in normal subjects. 
There is complete overlap of values measured by double 
isotope derivative assay or radioimmunoassay.
— 88“
Aldosterone: RIA
has higher capacity. However, greater accuracy is only achieved 
with very strict quality control. Radioimmunoassay, although 
more sophisticated than in vivo bioassays, is still a biologi­
cal assay and is fraught with many inexplicable variations.
In general, once a successful radioimmunoassay technique has 
been developed, minimum changes should be attempted because, 
surprisingly frequently, one small change can affect the whole 
assay. In contrast, the double isotope derivative technique, 
while time consuming and relatively insensitive, has built-in 
safeguards which protect the reproducibility of the assay.
1. Principles of radioimmunoassay
Aldosterone is quantitated by utilizing (a) its affinity 
for highly specific antibodies and (b) competition between 
radioactive and unlabelled aldosterone for binding sites on 
the antibodies (63) . The sample to be quantitated is added 
to a mixture of radioactive aldosterone and antibody in pro­
portions such that half of the radioactive aldosterone is 
bound to antibody and the other half remains free. The ex­
tent to which radioactive aldosterone is displaced from the 
antibody by the unknown sample is a measure of the amount of 
aldosterone in the sample. The aldosterone content of the 
unknown sample is determined precisely by comparing it to 
the displacement caused by addition of unlabelled aldosterone 
standards.
In practice, a mixture of antibody and labelled aldoster-
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one is added to a series of tubes containing known amounts of 
aldosterone or unknown sample. After 18 hours, the bound 
aldosterone is separated from the free by adsorption of the 
free aldosterone onto dextran coated charcoal. After centri­
fugation the bound aldosterone is decanted and counted in a 
scintillation spectrometer, while the free (charcoal plug) is 
discarded. From these counts the amount of aldosterone in 
the unknown sample can be calculated.
2. Urine aldosterone excretion (acid-labile conjugate): 
(11,120)
(i) Preliminary purification
Details of the method are illustrated in Table 10, 
Immunologically cross-reacting corticoids are pre-extracted 
into methylene chloride and discarded prior to acid hydroly­
sis. The methylene chloride insoluble acid-labile conjugate 
of aldosterone is then hydrolyzed with acid to liberate - 
aldosterone which is subsequently extracted into methylene 
chloride. Thus, separation of aldosterone from immunologi- 
cally cross-reacting compounds is accomplished simply by 
extraction, acid hydrolysis and then re-extraction. The 
methylene chloride extract is washed to remove non-specific 
cross-reacting substances and then aldosterone is quanti­
tated by radioimmunoassay. Losses incurred during this 
preliminary purification step, are accounted for by addition 
of radioactive aldosterone to the hydrolyzed urine.
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TABLE 10
PURIFICATION: HYDROLYSIS: EXTRACTION
(18 samples and 2 standard urines can be run as one batch)
Pre-extraction  o f  im p u r i t ie s : 
3 ml urine + 15 ml MeCl^ Mix well
Check pH
Check pH ( 0 . 9 5 - 1 . 1 )
Hydrolysis a t pH 1 :
Pre-extracted urine + 1 drop each 6N & 3N HCL 
(+ add it iona l drops 3N or IN HCL)
Leave fo r  24 hours a t room temperature
E x tra c t io n :
3
1 ml hydrolysed urine + 2000 cpm H aldosterone
+ 15 ml MeClo
15 ml MeCl^ e x trac t + 1.5 ml o f  O.IN NaOH
+ 1.5 ml O.IN NaOH 
+ 1,5 ml O.IN HAc 
+ 1.5 ml water
Dissolve ex tra c t in 2 ml ethanol
Transfer: 1 ml fo r  recovery estimation (recovery v ia ls )
2 X 0.4 ml a liquo ts  fo r  radioimmunoassay
* 2000 cpm are also p ipetted in to  3 counting v ia ls  fo r  accurate estimation o f  the
number o f  counts added to each urine sample (standard recovery v ia ls ) .
Wait 30 minutes 
Mi x wel1 
Discard urine 
Mix w e l l ;  discard NaOH 
Mix w e l l ;  d iscard NaOH 
Mix w e l l ;  discard HAc 
Mix w e l l ;  discard water 
Evaporate to dryness .
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The volume of urine extracted.after hydrolysis is only 
1 ml (150 ml was used in the double isotope derivative assay) 
and in the radioimmunoassay step 1/50th or less of this is
3
assayed. The H aldosterone which was added to detect losses 
during extraction, does not interfere with the radioimmuno­
assay step since the counts added to the assay tube account 
for less than 3% of the total counts,
(ii) Radioimmunoassay
The aldosterone content of the urine extract is depen- ■ 
dent on both the excretion rate of aldosterone and the 24- 
hour urine volume. Prior to radioimmunoassay the extract is 
diluted if the aldosterone concentration is expected to be 
high.
Two different amounts of urine extract (10 and 20 ul) 
are assayed. The use of a maximum volume of 2 0 ul facili­
tates the evaporation of ethanol in the extract prior to 
radioimmunoassay. The rack of tubes is simply placed in a 
vacuum oven for 15 minutes.
Ten and 20 ul of three different aldosterone standards 
are added in duplicate to the standard curve (Table 11).
Tubes are also included in the standard curve for measurement 
of the total counts (T), the binding of tritiated aldosterone 
in the absence of antibody (non-specific binding) and the 
binding of aldosterone to antibody in the absence of unla­
beled aldosterone (B^). In addition, two standard urine 
samples of known aldosterone content are assayed with each set
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TABLE n
STANDARD CURVE:
TUBE // ALDO STANDARD
1,2
3,4
5,6
7,8
9,10
11,12
13,14
15,16
17,18
ng/ml
0.5
0.5
2.0
2.0
8.0
8.0
VOLUME
jul
10
20
10
20
10
20
ALDO
ng
.005
.010
.020
.'040
.080
.160
to ta l counts; no charcoal (T) 
non-specific  b inding; no antibody 
no added aldosterone (B )
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A unique feature of this radioimmunoassay is the prepara­
tion of a mixture of antibody and radioactive aldosterone, 
prior to addition to the standard or unknown samples. This 
step reduces inaccuracies caused by pipetting'separately buf­
fer, tritiated aldosterone, and then antibody to each tube. 
Thus, only two pipettings are needed instead of four. This H 
aldosterone/antibody solution can be stored for up to a month 
without loss of assay sensitivity.
After 18 hours at 4°C the aldosterone bound to antibody 
is separated from free aldosterone by adsorption of the free 
onto dextran-coated charcoal. This step causes the most 
problems. Charcoal quickly adsorbs free aldosterone but it 
also adsorbs very slowly antibody bound aldosterone. Thus, 
relatively more antibody bound aldosterone is adsorbed in 
those tubes to which charcoal is added first, and this 
causes the bound counts to appear to be higher in the last 
tubes. Because of this, the duplicates of the standard curve 
are divided and charcoal is added to one half at the begin­
ning and to the other half at the end of the series. In this 
way the effect of charcoal to adsorb antibody bound aldoster­
one is averaged out.
Technically, addition of charcoal is the most variable 
step in the assay. The charcoal must be mixed vigorously, 
to maintain homogeneous suspension, added rapidly, and the 
tubes centrifuged immediately so that the charcoal is in 
suspension in the sample for a very short time. Different
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TABLE ;12
' •
Sample
1
Counts 
bound 
. .(B) ■ B/Bo
B/Bq
1-B/Bq
(Ï)
Aldo
pg
Standard Curve Standard Recovery Counts
1
2
3
4
6387
7035
6186
6189
.80
.88
.78
.78
4.0
7.3
3.5
3-5
5
5
10
ID
23553 
23464 • 
23467
mean =» 23495
5
6
5090
5232
. 64 
.65
1.8
1.9
20
20
7
Ç
3972 '■ 
3901
.50
.49
1.0
0.96
40
40 •
9
10
2687
2753
.34 ■
.35
0.52
0.54
80
80
11
12
1909
1868
.24
.23
0.32
0.30
160
160
13
14
16095
15573
total counts (T)
■ 15 
16 .
545
652
4% non specific binding
17(Bo) 
18
7856
8073
Counts
50% binding
B/Bq*
-
Sample
{
bound
(B)
l“B/Bo
(V)
Aldo
pg
Recovery
counts
Chem*
DF
Aldo
(pg)
Error
Standard Urine Samples
X(52)*** 
X* (104)
3550
2625
.46
.31
0.85
0.45
49
102
10147 1.16 . 57 
121
H 0 %
+14%
2(18) 
Z ' (36)
5606
4238
.70
.53.
2.3
1.13
15.1
34
10696 1.10 16.6
37.4
-8%
+4%
Unknown Samples -
RIA**
DF
Urine
vol
(ml)
507
507'
5148
3832
.65
.48
1.86
0.92
20
44
10147 i h 4 500
250
1200
508
503*
5349
3919
.67
.49
2.0
0.96
18
42
10696 1.10 250
125
980
515
515'
3436
2384
.43
.30
0.74
0.43
56
108
10478 1.12 100
50
1320
*Chera, DF *= standard recovery counts (recovery counts X 2).
**RIA DF c: dilution of sample prior to assay and volume of sample assayed (
**Humbers in parenthesis = pg aldo in standard urine sample.,
Aldo Mean ' • 
ug/day value -error
13.7
15.0
4.85
5,65
8.28
7.90
14.4 8%
5.3 8»
8,1 2S
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FIGURE 19
ALDOSTERONE STANDARD CURVE
10.0
5,0
0.50
0.30
0,10
10 20 40 80 1605
pg ALDOSTERONE
Picograms of aldosterone added to each tube 
of the standard curve plotted on log/log paper against a 
function of the change in the counts bound caused by addition 
of unlabelled aldosterone,.
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batches of charcoal have widely different adsorptive capacity 
and each should be individually evaluated. It has been sug­
gested that coating of charcoal with dextran is not essential 
(64) but we have been unable to confirm this.
After centrifugation the supernatant (bound) and the 
recovery vials are counted. The standard curve is calculated 
as illustrated in Table 12 (65) and plotted on log/log paper (Fig
19). Next, the two standard urine samples are calculated and 
the amount of aldosterone is derived from the standard curve.
If the error in these samples (i.e. the percent difference 
from the true value) is less than + 20%, the set is acceptable 
and the unknown samples are then calculated. Otherwise the 
whole set should be repeated. Duplicate values of unknown 
samples should not vary by more than t 15%. If they do they 
should be repeated.
The modified logit plot (Fig. 19) has the advantage of 
forming a straight line. Routinely, the data is calculated 
using a computer (Table 13). The counts from the spectrometer 
are punched onto paper tape which is then.fed into the com­
puter. The standard curve is calculated automatically. The 
standard error (SE) of the curve is calculated and any point 
which differs from the line by more than 2 SE is discarded 
and the line recalculated. This procedure is repeated until 
all points fall within 2 SE.
Several parameters are useful for checking accuracy and
for indicating the source of problems in the radioimmunoassay.
The concentrations of the standard urine samples are chosen
so that they span a wide portion of the standard curve. In
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RAA5 CALCULATION RUN '
MERGED DEC 09 7 3 SUN 12;2A BY JES FILE:UA2 7
RUN ON 1/ 1/7/1
SY S T EM* ****•!< +t ****** ^ t ** >1«
BACKGROUND 9 CPM
t o t a l  c o u n t s  3226 CPM
MSP go,
156/1 CPM 
- BINDING ■ /l8%
ERRORS 1 % 
ERR0P=6% 
ERRORS 1 %
s t a n d a r d  CURVE CALCULATI ON ■
»
LOGY ~ -.9 32 *LOGX + 1.65 6
S.E.= 0.035 , COEE.COR= -.9973
LOGIT 1= 6/4.56.
X
5 
5 
1 0 
1 0
20 
20 
40 
4 0 
BO 
BO 
160 
160
Y
9 . 23 
12.71 
5.30 
6. 07
2. 79
3. 1 1 
1 . 54 
1.63 
0 . 8  1 
0.8 6 
0.4 0 
0.45
Y(CALC)
1 0. 3 /I 
10.84 
5. 68 
5 . 68 
2.98 . 
2.9 8 
I . 56 
1 . 56 • 
0.8 2 
0.8 2 
0.4 3 
0.43
RECOVERY STANDARD:2343 
STANDARD URINE CALCULATIONS
PG ALDO %ERROR
47. 5 -9 ( 52)
89. 6 - 14 C 104)
2 1.1 5 ( 20)
43.7 9 ( ,40) .
a v e r a g e EPT^OR= -1.91%
CALCULATION OF UNKNOWNS
1
POS // UG/DAY PG PG ERROR- Cl EM/DE RIA/DE
33 1 2. 5 22 4 0 4% . 17 0. 5
36 2 26. 8 28 59 2% .16 10.0
39 3 6.8 6 16 7% . 12 5. 0
4 2 4 2 0.2 46 9 0 0% . 17 ■ 5. 0
45 5 13.4 18 , 37 1 % . 1 /I 2.5
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this way if either end of the standard curve is incorrect it
will be detected,
A useful guide to changes in the radioimmunoassay is data
derived from measurement of the non-specific binding (Table 12,
tubes 15 and 16)(NSB, Table 13). If the duplicates of these
tubes are variable, erratic addition of charcoal may have
occurred. Data from these tubes also provide a simple check
of the consistency of individual operators.
The aldosterone content at logit — 1.0 can be used to
detect radical changes in the standard curve (Table 13). This
parameter may vary even when the standard urine samples check
perfectly and changes need not indicate error but only some
variability in the assay. In the aldosterone radioimmunoassay,
125logit 1.0 should be quite constant since, unlike I iodinated 
compounds, tritium labelled compounds are quite stable. Shifts 
in the logit 1.0 can indicate contamination, radioactive 
breakdown and inadequate addition of charcoal,
In summary, radioimmunoassay of urine aldosterone is a 
method of high capacity. It involves many steps, each of which 
is technically easy. Accuracy is dependent on the use of a 
highly specific antibody and rigid quality control, and is 
aided by the use of an automated device for calculation of the 
data.
3. Radioimmunoassay of plasma aldosterone (12,122)
Differences between plasma and urine aldosterone measure­
ments are in the preliminary purification steps. The low con-
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centration of aldosterone in plasma requires that a larger 
volume than urine, be assayed. Thus, the extract from the equiv­
alent of 1 to 40 ul of urine is added to the radioimmunoassay 
whereas the extract from the equivalent of 100 to 80 0 ul of 
plasma is assayed. These larger volumes of plasma require 
more stringent purification from other cross-reacting steroids 
present in much higher concentrations.
Purification of plasma by pre-extraction of cross-reacting 
steroids into methylene chloride is not possible. Instead, 
chromatography on a celite gradient partition column is used.
To ensure consistent elution patterns of steroids from the 
column, lipids are first removed by partition between cyclohex- 
ane and aqueous alcohol.
For plasma, the number of-counts and the amount of aldo­
sterone in the tritiated aldosterone, added to detect losses 
in preliminary purification steps, must be taken into account 
in the calculations.
(i) Extraction and partition
Details of the method are illustrated in Table 14.
Prior to extraction an educated guess is made of the aldoster­
one content of the unknown plasma. On the basis of this, 
either 0.5, 1, or 2 ml of plasma is extracted into methylene 
chloride. To minimize the formation of emulsions, the pH of 
plasma is increased prior to extraction by addition of sodium 
hydroxide and the methylene chloride is pre-chilled. The pH 
of the methylene chloride extract is returned to neutrality 
by acid and water washes and lipids are then separated by
lOO-
Aldosterone: Plasma RIA
TABLE 14
Preassay Purification of Aldosterone
Extraction ;
0.5-2.0 ml plasma Discard
+ 20 ul aldo (2000 cpm)
+ 5-20 ul 1.2N NaOH
 — )  Plasma
Washes ;
15 ml M e C l g ------
Methylene chloride extract
+ 1.5 ml HAc -------
+ 1.5 ml HgO ------
+ 1.5 ml H,0 -------
HAc
«20
Partition :
Re-extraction :
Washed methylene chloride extract 
('evaporate to dryness)
+ 0.5 ml ethanol
+ 1.7 ml H2O
,+ 6.5 ml cyclohexane —
Aqueous ethanol extract
+ 15 ml MeCl, ----- - ----
Cyclohexane
Aqueous ethanol
+ 1.5 ml H tO HgO
Gradient Partition 
Chromatography?
Partitioned methylene chloride extract 
(evaporate to dryness)
+ 0.05 ml EtAc
,+ 0.2 ml isooctane s/
Celite column 
(3g + 1 ml 40% ethylene glycol)
+ 3.5 ml 15% EtAc/isooc i Eluate (1)
tane
+ 3.5 ml 4 0 % EtAc/isooc-— Eluate- (2) 
tane
+ 3.5 ml 60% EtAc/isooc- 
V  tane
60% EtAc/isooctanQ eluate (3)
(evaporate to dryness)
4/
Radioimmunoassay
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cyclohexane partition. Aldosterone is then re-extracted into 
methlene chloride which is evaporated to dryness prior to 
chromatography.
(ii) Column chromatography:
A single gradient partition column chromatography system 
is used which employs celite as an inert support. 40% ethylene 
glycol in water (stationary phase) is first mixed thoroughly 
with the celite. The mobile phase is ethylacetate/isooctane 
and the percent of ethylacetate is increased in three steps. 
Cross-reacting corticosteroids are washed from the column with 
15% then 4 0% ethylacetate/isooctane and then aldosterone is 
eluted with 60% ethylacetate/isooctane.
The transfer of the extract onto the column is a crucial 
step affecting the overall recovery of the method. For optimum 
transfer it is necessary first to dissolve the extract in 
ethylacetate because aldosterone is poorly soluble in 15% 
ethylacetate/isooctane. The column is run under slight pres­
sure to maintain an elution rate of about 10-15 drops per min­
ute. Higher pressure causes the ethylene glycol to be washed 
off the column and this interferes with the radioimmunoassay 
step. The use of slight pressure on tightly packed columns 
helps to achieve uniformity of running rate which has the 
technical advantage that 20 columns can be run at one time 
without confusion.
The elution pattern of aldosterone relative to other 
steroids is consistently reproducible. Aldosterone is always 
eluted by 60% ethylacetate/isooctane and the'other cross-
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reacting steroids are consistently eluted by a lower percentage 
of ethylacetate. Alternate approaches to purification such as 
paper or thin layer chromatography require that a marker is run 
with each system. Since tiny amounts of steroids can be de­
tected by radioimmunoassay, addition of steroids as markers 
inevitably leads to contamination and results in high blanks 
and inconsistent answers. Because of possible contamination, 
all glassware used in the assay, including the columns (5 ml 
disposable pipettes), is disposable, The reagents used in the 
purification steps do not interfere with the radioimmunoassay 
and thus the method is practically blank free.
An advantage of this particular chromatography system is 
that both corticosterone and hydrocortisone are eluted before 
aldosterone. In most other chromatography systems aldosterone 
is eluted between these two steroids and adequate purification 
from both in one system is difficult to achieve.
(iii) Radioimmunoassay
This step is similar to that used for urine except that 
1/5 and 2/5 of the aldosterone eluted from the column are 
assayed. The number of counts in the plasma extract added to 
the assay are computed prior to calculation and are added to 
the total counts. Finally, the amount of aldosterone in the 
radioactive "tracer" added to detect losses is calculated and 
this value, approximately 2 0 pg, is subtracted from the final 
result.
A blank is run with each set, but the value is almost al­
ways below the lowest point of the standard curve and can be 
ignored. ,
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(iv) Method sensitivity and relationship to urine aldosterone
The use of column chromatography as a preliminary purific­
ation step combined with a highly specific antibody in the 
radioimmunoassay enables accurate detection of as little as 
1 ng% aldosterone in plasma. No increase in the assay was 
found when other steroids such as hydrocortisone were 
added to plasma’ in concentrations as high as 10 0 pg%.
Plasma aldosterone concentration in normal subjects was 
found to change dynamically with the rate of urinary sodium 
excretion in a fashion similar to that observed for urine 
aldosterone excretion measurements (Figure 20). When the 
plasma aldosterone values from normal subjects were related 
to the concurrent 24-hour urine aldosterone excretion (Fig­
ure 21), a high degree of correlation was found between the 
two measurements (r=0,864). In general, when noon plasma 
aldosterone is 10 ng%, urine aldosterone excretion is approx­
imately 10 ^g/day and this increases proportionally so that 
when plasma aldosterone is 10 0 ng% urine aldosterone has in­
creased to approximately 10 0 pg/day. Therefore, in normal 
subjects plasma aldosterone and urine aldosterone excretion 
change commensurately with changes in sodium balance. How­
ever, as indicated already, there are clinical.situations in 
which urine aldosterone measurements do not accurately re­
flect the plasma level.
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FIGURE 20
RELATIONSHIP OF PLASMA ALDOSTERONE TO URINE 
SODIUM EXCRETION IN NORMAL SUBJECTS
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Hyperbolic relationship of plasma aldosterone 
to the concurrent 24 hour urine sodium excretion in 27 
normal subjects. The relationship to sodium excretion is 
quite similar to that described by plasma renin activity 
and urine aldosterone excretion.
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FIGURE 21
RELATIONSHIP OF PLASMA ALDOSTERONE TO URINE ALDOSTERONE
IN NORMAL SUBJECTS
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Linear relationship of urine aldosterone excretion 
to plasma aldosterone in normal subjects.
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C. SUMMARY
A method has been presented for measurement of a urinary 
metabolite of aldosterone using a double isotope derivative as­
say. Tritiated aldosterone is added to urine and the specific 
activity of aldosterone in an isolated portion is used to calcu­
late the urinary excretion rate. The amount of aldosterone in 
the isolated portion is quantitated by measuring the amount of 
C incorporated into a diacetate derivative, which is prepared 
with acetic anhydride of known specific activity*
The method involves acid hydrolysis of the metabolite 
to form free aldosterone, then extraction and four chromato­
graphy steps in addition to preparation of aldosterone di­
acetate. The double isotope derivative assay is accurate but 
has the limitation of poor sensitivity, limited capacity, ex­
pense, as well as being time consuming.
During development of the method, isotope fractionation 
*3 14
of H from C aldosterone diacetate was demonstrated in both 
paper and column chromatography systems. This is not a prob­
lem in the assay as long as wide cuts of the peaks are taken 
on paper chromatography and the peak is accurately identified 
on the final column system.
More recently, methods have been developed for quantitation 
of aldosterone in urine and plasma by radioimmunoassay. The 
methods are much simpler and more sensitive. However, pre­
liminary purification from cross-reacting steroids is neces­
sary prior to radioimmunoassay. For urine this is accomplished 
by extracting cross-reacting steroids into methylene chloride
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prior to acid hydrolysis of the metabolite to liberate aldo­
sterone. A celite partition column accomplishes the separation 
of plasma aldosterone from cross-reacting steroids.
Radioimmunoassay has made available simple and sensitive 
methods for detection of aldosterone in both urine and plasma. 
However, the potential for undetected errors is greater than 
in the double isotope derivative assay and strict quality 
control is essential.
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III. Measurement of Natriuretic Hormone
These studies were designed to investigate whether or not 
there is a natriuretic substance involved in the regulation of 
sodium excretion (22-24). The possibility of such a hormone 
has been suspected since de Wardener and his associates (21,
123) showed that dogs could excrete a saline load under condi­
tions involving no change in the parameters then known to be 
involved in the regulation of sodium excretion, i.e. glomeru­
lar filtration and aldosterone.
A meaningful assay for a natriuretic substance must in­
volve changes in the rate of urine sodium excretion in an 
assay animal. Prior to our studies, other groups had suggested 
the existence of a natriuretic hormone by demonstrating activity 
assays which measured toad bladder or frog skin short-circuit 
current (124,125) and PAH uptake or sodium transport in kidney 
slices (126,127). However, in no instance was the suspected 
substance shown to be natriuretic in an assay animal. Hence 
our first approach was to develop a reliable assay in which . 
changes in urine sodium excretion reflected changes in activ­
ity.
Concurrently, extraction concentration and purification 
procedures were investigated utilizing blood and urine from 
patients in whom a natriuretic hormone might be expected to 
be present in high concentration, Both urine and plasma were
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studied in the hope that the substance, like aldosterone, 
might be excreted into the urine in large amounts. In fact 
this was found to occur and many of the physiological studies 
were carried out using urine extracts. The active material 
was separated from vasoactive peptides and the osmolarity 
of the injected extract was carefully monitored so as to rule 
out the possibility that natriuresis was induced by increases 
in arterial pressure or by osmotic diuresis.
Initially, urine and plasma from sodium loaded patients 
with primary aldosteronism were used as the source of poten­
tial activity. However, in later studies, sodium loaded 
normal subjects and sheep also provided active material.
Bioassay for Detection of Natriuretic Activity :
1. Type of Rats :
(a) Rats with congenital diabetes insipidus : (22).
Rats of the Brattleborough strain with diabetes insipi­
dus were chosen since they cannot respond to injections of 
noxious extracts of urine or plasma with a sudden decrease 
in urine flow due to ADH release. In addition, in the basal 
state these animals have very high urine flows and adequate 
urine collections can be achieved using a bladder rather 
than ureteral catheter. Thus, surgery is minor and a stable 
and more physiological assay preparation is achieved. An 
additional advantage of the high urine flows was the ability 
to automate the urine collection system.
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However, rats with fully developed diabetes insipidus 
were found to be sodium depleted and excreted dilute urine 
with low sodium concentration. Fortunately, heterozygous 
rats with diabetes insipidus were not as sodium depleted yet 
had high urine flows and rarely responded adversely to injec­
tion of the extracts. Therefore heterozygous rats with dia­
betes insipidus were routinely used as assay animals. In these 
animals urine flows approximating 20 0 ul/minute were achieved 
with rates of sodium excretion of from 0.5 to 4 uEq/minute,
(b) Normal rats : (23,24)
After extraction procedures had been developed, a few 
assays were performed in normal rats to demonstrate that 
the activity was not specific for a special type of rat or 
for rats in water diuresis. Two preparations were set up:
(1) Normal hydropénie rats (ureteral catheters); sample in­
jected intravenously. Urine flow = 3 ul/min., UNaV — 0.3 
uEg/min. (2) Normal hydropénie rats; sample injected into 
the renal artery.
Although these assays were technically more difficult 
and less stable, natriuretic activity was easily demonstrable.
2. Assay Preparation : (22)
150 to 300 g rats were prepared by injecting 5 mg/lOOg 
body weight sodium pentobarbital and 0.13 mg/100 g atropine 
intraperitoneally. The bladder was catheterized through a 
small midline incision and one jugular vein was catheterized 
for injection of samples, A tracheostomy tube was inserted 
and carefully aspirated throughout the study since associated 
blood pressure changes caused by breathing disturbances could
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markedly alter urine flow.
To induce a high rate of urine flow after surgery, the 
rat was given slowly by stomach tube up to 7 1/2% of its 
body weight of a dilute solution of sodium chloride (20 mEg/
L). The rat was then placed on a balance located over a timed 
fraction collector. When urine flow reached approximately 
100 pX/ min., 10 or 20 minute urine samples were collected 
whilst fluid lost was automatically replaced by oral administra­
tion of a 10 mEq/L solution chloride containing 18 mg/100 
ml pentobarbital. With this system, in which the weight of 
the animal was kept constant, fluid balance and anesthesia 
were maintained constant throughout the day. The-urine volume 
and sodium and potassium concentrations were measured for 
each 10 or 20 minute collection.
To prepare normal rats (2 3) 15 0-300 g female rats were 
anesthetized, tracheostomized and infused with isotonic 
saline (0.05 ml/min.) through a jugular vein catheter. The 
left kidney was ligated, but not removed, through a midline 
abdominal incision and a catheter was placed in the right 
ureter 2 cm below the renal pelvis so that ureteral peristal­
sis was not inhibited. The saline infusion was reduced to
0.02 ml/min. and 20 minute urine samples were collected under 
mineral oil. Extracts were injected into the jugular vein.
In a modification of this assay the aorta was occluded 
below the level of the right kidney and a catheter was placed 
in the aorta so that sample, when injected, passed in retro-
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grade fashion directly into the kidney.
Ordinarily, from 2 to 4 hours elapsed before the first 
test sample was injected. This preparation time was for 
anesthesia, operating procedures, administration of the oral 
load, and establishment of a stable rate of urine sodium 
excretion.
A bolus of 0.5 ml of isotonic saline was routinely 
injected first. If an increase in sodium excretion occurred 
in response to this the animal was discarded. The unknown 
samples were given as either a bolus in 0.1 to 0.5 ml or 
occasionally as a constant infusion for 30 minutes at 0.02 
ml/minute. Positive natriuretic responses were usually com­
pared with the response to extracts from the same subject 
when not salt loaded.
The natriuretic response.induced in the assay animal 
seemed related to the general health and preexisting state 
of salt balance of the assay animals. Insensitivity and an 
unsteady baseline could be caused by a fall in body tempera­
ture below 9 7*^ F, by too much anesthetic agent, or by occult 
bleeding.
Extraction and Purification Procedures
1. Preliminary Screening of Urine and Plasma for Natriuretic 
Activity : (22)
The objectives of the fractionation procedures were 
(a) to eliminate salts and small osmotically active or vaso­
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active molecules, (b) to fractionate, according to molecular 
size, substances in plasma and urine and (c) to concentrate 
them as much as possible.
In initial studies, fractionation was carried out using a 
series of different gel filtration columns. 24-hour urines 
were lyophilized, reconstituted in 100 ml of 0.1 M acetic 
acid and centrifuged. The supernatant was desalted on a 
5 x 3 0  cm column of polyacrylamide gel (Bio-Gel P2).
0,1 M acetic acid, was used as a buffer in all columns. Three 
fractions were collected; the first (about 40 0 ml), comprised 
substances of molecular weight greater than 200, except for 
those specifically retarded by the gel. The second fraction 
(about 800 ml) contained the salt peak which was discarded.
A third fraction of about 1200 ml, collected after the salt 
peak, was lyophilized and prepared for assay.
After lyophilisation, the first fraction was dissolved 
in 24 ml buffer and 3 ml aliquots were applied to each of 
the following three 1.5 x 25 cm Sephadex columns : G25P, G75
and GIOO. The eluate from each of these columns was divided 
into five fractions. Fraction I contained substances com­
pletely excluded by the gel (Table 15). Fraction IV con­
tained the salt peak and fraction V included substances 
eluted after the salt peak. Fractions II and III, collected 
between fractions I and IV, were arbitrarily divided as 
illustrated in Figure 22. 10 mg bovine serum albumin and 
0.05 ml of 1 N mercaptoacetic acid were added to each frac-
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TABLE 15 
LOCATION OF ACTIVE FRACTIONS
Gel
Mol wt. f ra c t io n ­
a tion  range
Fraction No.
I ,  pro­
te in  peak I I I I I
IV,
sal t  
peak V
P2 2,000-200 +? .
G25F 5,000-1000 +++ - -
G75 70,000-3000 ++ - -
GIOO 150,000-4000 + ++
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FIGURE 22 '
2 HOUR URINE FROM Pg COLUMN APPLIED TO 
G76 SEPHADEX 1.5 x25cm 0.1 M ACETIC ACID BUFFER
Fraction No.
2.0 
1.8 
1.6 
1.4 
1.2
OPTICAL , ^ 
DENSITY ! 0
2 8 0  m / j  0 . 8  
0:6 
0 . 4  
0.2 
0
0 10 20  30 4 0  50
ml ELUTED FROM COLUMN
6 0  70
Sheep 59
50
4 0
SODIUM 
CONG. 
20 m E q / L0,D.
Sheep urine, which had undergone preliminary 
purification on a Bio-Gel P2 column, was applied to a G75 
Sephadex column (1.5 x 25 cm) using O.IM acetic acid buffer. 
A plot is shown of the absorption at 280 m^ u and the sodium 
concentration of fractions I to V.
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tion prior to lyophilization and storage at - 2 0 These 
two procedures reduced loss of activity during storage and 
they were routinely applied to all samples. Altogether 17 
fractions were assayed (Table 15).
On the day of assay the samples were reconstituted in
0.3 ml of 0.45% saline. A 0.1 ml volume, representing the extract 
from 1 hr of urine, was injected into each of two assay 
animals. Positive assays were observed only in fraction I 
from G25F, in fractions I and II from G75, and in fraction III 
from GIOO (Table 15).
Essentially the same fractionation procedures were em­
ployed for plasma samples. However, to remove plasma proteins 
the samples were first diluted, adjusted to pH 5.5, and 
placed in a boiling water bath for 2 0 minutes. This approach 
was used after it had been established that (a) boiled urine 
did not lose natriuretic activity and (b) the activity of 
positive plasma samples (deproteinized on Sephadex- columns) 
remained after boiling.
Those fractions were identified which contained the 
small pressor peptides angiotensin I, angiotensin II, and 
arginine vasopressin (Figure 23). They were found close to 
the salt peak on G25F and in the void volume on Bio-Gel P2. 
Clearly these peptides were not associated with any fraction 
which exhibited natriuretic activity.
2. Simplified Procedure for Preparation of Urine and Plasma 
for Assay : (22)
24-hour urines were lyophilized, reconstituted in 100 ml
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FIGURE 23
LOCATION OF VASOACTIVE PEPTIDES DURING FRACTIONATIONS
lOg BIOGEL P 2 1.5 X 25cm COLUMN 
Void Volume -  13 cc oceMc odd buffer)
ng
ANGIOTENSIN
PRESSOR Angiotensin Z  
35 response /
-3 0  ‘Ti'TiHfl
Angiotensin
ADH
10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40
200
180
160
140
SODIUM 
100 mEq/L
8 0
6 0
4 0
20
0
FRACTION NO. mH—
IE
G 25F SEPHADEX 2.5 x 35 cm (0.1 M acetic odd buffer ) 
Void Volume ™ 6 2 cc
PRESSOR
RESPONSE
mmHg
AngiO'- 
tensin I
Angio­
tensin JZ
80 100 120 140 160
ml ELUTED FROM COLUMN
180
280
2 4 0
200
160
120
80
4 0
0
SODIUM
m E q/L
Location of vasoactive peptides on Bio-Gel P2 
and on Sephadex G25F used for fractionation of urine and 
plasma samples. 7 50 ng angiotensin I and angiotensin II, 
dissolved in 2 ml of isotonic saline, were applied at 
different times to each column and their location was 
identified in a rat pressor bioassay. 10 pressor units 
of vasopressin were also applied to the Bio-Gel P2 column 
and subsequently located by pressor bioassay.
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0.1 M acetic acid, and centrifuged. The supernatant
was applied to a G 50M (medium mesh) column (2.5 x 60 cm),
The fractions eluted before the salt peak were combined and 
lyophilized to a white fluffy powder. A quantity representing 
2 hr of sample (assuming no losses) was reconstituted in 0.2 
ml of 0.45% saline. A 0.1 ml volume.of this was injected into 
the assay animal. The osmolarity of the final solution was
repeatedly found to be in the region of 20 0 mOsm/liter.
3. Preparation of a Large Batch of Natriuretic Extract : (23)
A large batch of natriuretic material was prepared using 
a preliminary ultrafiltration step. Fifty liters of urine 
were centrifuged for 20 minutes at 8000 rpm, and passed 
through 5-yi and then 0.45-yi Millipore filters. Subsequently, 
the urine was passed through an Amicon UM 10 filter. This 
latter filter theoretically holds back material of molecular 
weight greater than 10,000. The retentate was divided into 
6 portions and applied to G-50 M and then G-lOO Sephadex 
columns to accomplish the final desalting and purification.
Some Properties of the Natriuretic Extract : (17 ,22-24)
1. Typical Response in Assay Animal
The assays illustrated in Figure 2 4 were carried out 
in a heterozygous rat with diabetes insipidus. Sensitivity 
was greatest in animals excreting somewhat more than 0.5 pEq 
sodium per minute. While this is a high rate of sodium ex­
cretion for such a small animal, their endogenous natriuretic
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FIGURE 24
EFFECT OF 2 DOSES 
OF NATRIURETIC FACTOR IN TYPE I ASSAY
SODIUM 
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/ jEq/min p
POTASSIUM 2
/jEq/min 0
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URINE 200
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5 and 10 mg of urine extract derived from a 
sodium loaded subject were dissolved in 0 .1  ml 0,45% saline 
and injected into the same heterozygous rat with diabetes 
insipidus. Urine sodium excretion increased in response 
to both extracts. The higher dose gave the greater response 
In these assays, urine flow increased slightly but potassium 
excretion was constant.
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stimulus may not be high since volume expansion was achieved 
with water loading rather than sodium loading.
In these particular assays (Figure 24) sodium excretion 
increased from 2.5 to 5.5 ^Eq/minute in response to 5 mg of 
urine extract and from 3 to 7.5 juEq/minute in response to 
10 mg of urine extract. Hence, there was a relationship be­
tween dose and response in the assay animal. Some of the 
positive responses involved the loss of more than 500 ^Eq
i.e., more than 5% of the total body sodium content. No 
change in glomerular filtration rate occurred in response to 
the natriuretic extract (Figure 25) so that in some assays 
5-10% of the filtered load was excreted.
All positive assays were associated with marked increases 
in urine sodium concentration and changes in
urine flow were usually small or absent. Furthermore, there 
was no apparent association between the magnitude of the 
natriuresis and changes in urine flow.
In a few assays there were slight increases in potassium 
excretion, but most were similar to the ones illustrated in 
Figure 24 in which no change in potassium excretion was ob­
served. The physiological implications of the lack of change 
in urine flow and potassium excretion are considered in a 
later section.
The occasionally observed delay in onset of natriuretic 
activity and its rather prolonged effect for up to 3 hours 
suggest that another active substance might be released
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FIGURE 25
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Extracts from 2 pools of urine derived from normal 
subjects on either high or low sodium intakes were injected 
into the jugular vein of a rat with mild diabetes insipidus. 
Natriuresis was induced only by the high salt extract 
and was observed to be independent of changes in potassium 
excretion, urine flow, hematocrit, or glomerular filtration
rate (GFR).
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Biochemical characteristics
from the large molecular weight substance we have detected. 
Alternatively, the hormonal agent itself, like aldosterone,, 
may first enter cells and induce secondary changes.
Characteristics of the natriuretic response were quite 
similar, although less striking, in normal hydropénie rats. - 
When samples were injected directly into the renal vein an 
immediate natriuretic response was always observed, followed 
by the more characteristic delayed natriuresis. However, 
the immediate response was always associated with an increase 
in blood pressure and was probably not due to an effect on 
tubular sodium transport mechanisms. The increase in blood pres­
sure was only evident when the samples were injected directly 
into the kidney.
2. Specificity of the Natriuretic Response :
There was no response in the assay animal to injections 
of similar volumes of isotonic saline (0,1-0.5 ml) or to 
injections of extracts which were derived from subjects who 
were either not sodium loaded or who had been sodium deprived 
for 3 to 5 days. In addition, at the end of natriuresis, the 
rate of sodium excretion consistently returned to baseline.
3. Biochemical Characteristics :
On the basis of elution characteristics on several 
Sephadex columns and retention of the natriuretic activity 
by an Amicon UM 10 filter, the molecular weight of the sub­
stance appears to be above 10,0 00 and may be as high as 
50,000. This large size is compatible with the observation
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that the activity is non-dialysable.
The substance may be a protein since activity was de­
stroyed by trypsin and by treatment with trichloracetic 
acid. However, it was not destroyed by boiling.
Further characterization of the biochemical properties . 
is required but may have to be delayed until a simpler assay 
is developed which allows assay of several samples in the 
same animal. The limiting feature of the investigation is 
the fact that rarely can more than two samples be assayed 
accurately in the same rat and two assays can take more than 
12 hours to complete.
Summary. These studies were designed to examine the ques­
tion of whether or not there is a natriuretic humoral sub­
stance which participates in the regulation of urine sodium 
excretion.
Procedures for concentration and fractionation of plasma 
and urine were developed concurrent with a sensitive bioassay 
for detecting induced changes in renal sodium excretion. The 
assay utilized rats with mild diabetes insipidus which were 
maintained in sodium and water balance.
A natriuretic humoral substance was demonstrated in 
plasma and urine from salt-loaded normal man and sheep, and 
in patients with primary aldosteronism and essential hyper­
tension who were maintained on a high sodium intake.
The substance■appears to have physiological relevance
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since it was not detectable in sodium-depleted subjects and 
it consistently appeared in sodium-loaded subjects.
The natriuretic activity was demonstrable in normal 
hydropénie rats as well as in rats with congenital diabetes 
insipidus. The induced natriuresis usually develops slowly 
and may last for several hours. The natriuresis is not 
usually associated with increases in water or potassium ex­
cretion. It occurs without measurable changes in glomerular 
filtration rate or arterial blood pressure. Altogether these 
results suggest that the substance acts at least in part to 
depress sodium reabsorption in the distal tubule at a site 
where sodium is normally reabsorbed without water.
Fractionation studies suggest that the natriuretic sub­
stance has a molecular weight of from 10,000 to 50,000, 
Further study will be necessary to determine whether or not 
this particular substance proves to be a physiologically 
important natriuretic hormone. However, of special relevance 
is its action to depress distal tubular sodium reabsorption 
because a large body of evidence indicates that depression of 
proximal tubular sodium reabsorption is not, by itself, suf­
ficient to cause a sodium diuresis (128-130) [See page 183].
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PART II
PHYSIOLOGY OP THE RENIN"ANGIOTENSIN-ALDOSTERONE SYSTEM
Part II: Introduction
In the preceding sections, methods have been presented 
for measurement of the components of the renin-angiotensin- 
aldosterone hormonal system and for detection of natriuretic 
factors in urine and plasma. The following analysis will be 
concerned with the role of this hormonal system in regulation 
of sodium and potassium balance and blood pressure homeo­
stasis.
In general, the hormonal system appears to act as two, 
almost independent negative feed back control systems which 
regulate (1) sodium balance and blood pressure and (2) sodium 
and potassium homeostasis. The first system responds to 
reductions in arterial pressure, renal perfusion pressure or 
blood volume. When any of these events occur, renin secre­
tion is increased and arterial pressure is restored both by 
the vasoconstrictor action of angiotensin II and by aldoster­
one induced sodium retention which increases tissue perfusion 
and turns off the signal for renin release. The second con­
trol system regulates potassium balance. An increase in 
plasma potassium directly stimulates adrenal aldosterone 
secretion. Increased circulating aldosterone promotes renal 
potassium loss which returns potassium balance to normal and 
thus turns off the stimulus for increased aldosterone bio­
synthesis. However, since changes in sodium balance affect 
both of these arbitrarily separated systems, in the following 
memoir the hormonal system will be analysed with respect to 
sodium balance and blood pressure homeostasis on the one hand
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and sodium balance and potassium balance on the other hand.
Before turning to the operation of the system and its 
function in regulating electrolyte balance and blood pressure, 
the responses and interactions of the hormonal components 
will be examined in more detail.
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A. Renin Secretion and Its Relation to Plasma Renin Activity
I. Determinants of Plasma Renin Activity
Renin occupies a key role in the hormonal system which
regulates blood pressure and electrolyte homeostasis (Figure 1) 
(page 7). When, as a result of such events as sodium depletion, 
hemorrhage, transudation or alimentary loss, effective blood 
volume contracts and arterial pressure falls, the kidney's 
perfusion is threatened and it reacts by secreting renin into the 
blood stream. This initiates the process whereby the other 
hormonal components of the system are activated and work 
to restore equilibrium..
The kidney is the major source of plasma renin for both 
man and animals (131-133). Renin has also been found in other 
tissues such as the submaxillary gland, placenta and uterus 
(134-136). However, there is no evidence that plasma renin 
is ordinarily derived from any of these other sources.
The nature of the renal sensor device which transmits 
the signal to the renin containing juxtaglomerular cells for 
the release of renin is the subject of some controversy (5). 
Postulated mediators include [1] a baroreceptor or stretch recep­
tor in the afferent arteriole which responds to changes in 
arterial pressure (137) and [2] changes in the amount of 
sodium passing the macula densa area of the loop of Henle 
(13 8). Both the macula densa and the afferent arterioles are
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in physical contact with the juxtaglomerular cells and both 
could transmit messages to these cells to release renin.
(3) Circulating catecholamines and neural stimulation have 
also been shown to affect renin secretion (139,140) and it 
is likely that each of these mechanisms is important. In 
fact it is possible that they all act through a final common 
pathway.
Renin, released into the blood, acts on plasma renin 
substrate to generate angiotensin I which is converted to 
angiotensin II during passage through the lungs (Figure 1, page 7) 
Since plasma renin substrate concentration is normally rate 
limiting (15,59,141), the rate of angiotensin genera­
tion in response to secreted renin could vary depending on 
the concentration of circulating substrate.
Plasma Renin Substrate in Normal and Hypertensive Man :
To study whether or not differences in plasma renin 
substrate can be primary determinants of plasma renin activ­
ity, plasma renin substrate was related to the concurrent 
measurement of plasma renin activity in 28 samples collected 
from 19 normal subjects in whom urine sodium excretion was 
above 4 0 mEq per day (6). Mean plasma renin activity in 14 sam­
ples with substrate concentration less than an arbitrary cut 
off point of 1450 ng/ml (range 919-1447) was 2.6 ng/ml/hr. 
t 1.32 (SD). In 14 samples in which plasma renin substrate 
concentration was greater than 1450 ng/ml (range 1463-2228)
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mean plasma renin activity was almost identical, 2.7 ng/ml/ 
hr. + 1.52 (SD). Thus differences in renin substrate do not 
appear to be physiological determinants of plasma renin activ­
ity. Renin appears to be the dynamic component of the renin 
system which reacts to changes in renin substrate to maintain 
an appropriate rate of angiotensin generation.
In another study of patients who were taking oral contra­
ceptive medication and in whom renin substrate rose progres­
sively during the first few weeks of medication, the initial 
increase in renin substrate was at first accompanied by a 
rise in plasma renin activity (62). However, this increase was 
not sustained in most patients, and plasma renin activity 
gradually returned to normal levels (Figure 11, p. 48).
Both of these studies support the view that when sub­
strate concentration varies, renin secretion feeds back to 
maintain the rate of angiotensin generation.
Renin substrate concentrations in normal and hyperten­
sive patients, measured by radioimmunoassay, are presented 
in Table 16 (6,16). There was no significant difference in
renin substrate from any of the sources. The slightly higher 
mean substrate concentrations in patients with essential 
hypertension is in agreement with the observations by Gould 
and Green (142) that males with essential hypertension have 
higher substrate levels than normotensive males. The absence 
of statistical significance in the present study may be ex­
plained by the failure to discriminate between males and
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TABLE 16
PLASMA RENIN SUBSTRATE IN NORMAL AND HYPERTENSIVE PATIENTS
RENIN SUBSTRATE
ng/ml (SD)
NORMAL SUBJECTS (N=19) 1517 346
ESSENTIAL HYPERTENSION
High Renin (N=9) 1670 318
Normal Renin (N=23) 1644 364
Low Renin (N=18) 1855 348
RENOVASCULAR HYPERTENSION (N=5)
A rte ry  1690 194
Vena Cava* 1739 252
Right Renal Vein 1688 239
L e ft Renal Vein 1668 318
*  Blood co lle c te d  from vena cava below leve l o f kidneys
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'females in the analysis.
In a study of normal subjects on different sodium in­
takes , there was no consistent relationship between sodium 
intake and plasma renin substrate concentration (6), This 
is in contrast with the report of Rosset and Veyrat (143) 
in which substrate concentration was inversely related to plasma 
renin activity. In addition, in our studies there was no 
difference in the concentration of renin substrate in patients 
with essential hypertension who had high, normal.or low plasma 
renin activity (Table 16). In animal studies it has been found 
that infusion of renin or angiotensin II at low doses causes 
an increase in substrate concentration but at higher doses 
of renin, substrate concentration falls in plasma, probably 
because of excess utilisation (144,145).
When renin substrate was measured in plasma collected 
from the renal veins, aorta and vena cava of five patients 
with renovascular hypertension, no differences in mean values 
were found (Table 16)(16). Hence, in this study there is no 
evidence for clearance of renin substrate by the kidneys.
Altogether, the data indicate that although in normal 
subjects and patients with essential hypertension, plasma renin 
substrate concentrations in different individuals can span 
a two-fold range, mean values are quite similar in the different 
groups. Physiologically, changes in renin substrate are not 
normally determinants of plasma renin activity. However, since 
measurements of plasma renin activity depend on a first order
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reaction, acute changes in substrate concentration could 
markedly affect the rate of angiotensin generation and 
thus could transiently affect plasma renin activity until 
renin secretion adjusts (Figure 11).
Studies of the Metabolic Clearance Rate of Renin
Peripheral plasma renin levels are determined by both 
the secretion rate of renin and the metabolic clearance rate. 
Thus, under steady state conditions, the metabolic clearance 
rate of renin is equal to renal renin secretion. . It has 
been shown by Haecox and associates that there is little, if 
any, clearance of renin by the kidneys (14 6), Most available 
data point to the liver as the prime route of metabolism of 
renin (146-15 0). Schneider and co-workers and others have 
shown in the dog that, in general, clearance of renin by the 
liver is proportional to blood flow through the liver (148- 
15 0). Thus, changes in liver blood flow exert an important 
modulating effect on plasma renin levels. However, there is 
no evidence that alterations in liver blood flow ordinarily 
exert a rate limiting influence on plasma renin levels since 
increases in plasma renin activity caused by reductions in 
the metabolic clearance rate are normally compensated for by 
suppression of renal renin secretion (150).
An unanswered question regarding the metabolic clear- . 
ance rate of renin is whether or not a constant fraction of 
plasma is cleared over a wide range of plasma renin activity.
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Analysis of studies of metabolic clearance rate in dogs 
(15 0) suggests this possibility. However in these studies 
renin secretion and liver blood flow both changed at the 
same time and it was not possible to determine from this data 
whether changes in renin secretion per se had an effect on 
the metabolic clearance rate.
Under steady state conditions the clearance rate of 
renin must equal the secretion rate. If the liver always 
clears a constant fraction of the plasma renin, then plasma 
renin would be a direct reflection of renal renin secretion 
and under steady state conditions peripheral plasma renin 
would have a constant direct relationship to renal renin 
secretion. However, if the fraction of renin cleared by the 
liver were shown to fluctuate with changes in renin secre­
tion then the relationship of renin secretion to peripheral 
renin would not be constant.
Renin secretion can be calculated from the product of 
renal plasma flow and the increment in renin added to the 
renal vein (V-A) (where V = renal vein renin and A = arterial 
renin). Thus, under conditions of constant renal plasma 
flow, (V-A) is directly proportional to renin secretion 
(151). If a constant fraction of plasma is cleared of 
renin then, under steady state conditions, (V-A) in relation 
to peripheral renin (A) should be constant. Hence measure­
ment of renin in simultaneously collected arterial and 
renal venous blood could provide information about the
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metabolic clearance rate of renin.
Patients with essential hypertension who had no evidence 
of liver or renal disease were chosen for the study (16) 
since these patients as a group normally exhibit a wide range 
in plasma renin activity (88). Thus a wide spectrum of 
peripheral plasma renin values were obtained under conditions 
in which both liver and renal blood flows would be expected 
to be normal. Many patients with essential hypertension come 
to arteriography because of suspicion of renovascular hyper-, 
tension. All patients with hypertension who underwent arteri­
ography were studied under controlled conditions and those 
who had no evidence of renovascular disease and who were clas­
sified as having essential hypertension form the basis for 
this study.
Renin activity and renin substrate were measured in four 
sources of plasma from 43 patients with essential hypertension 
Blood was collected from the right and left renal veins, the 
vena cava (below the level of the kidneys) and the aorta.
The study was carried out under steady state conditions, 
after the patients had been on a constant diet for a minimum 
of three days and after they had been in the supine position 
for at least two hours.
The patients were subdivided into three groups on the 
basis of their peripheral plasma renin activity, considered 
in relation to the concurrent 24-hour urine sodium excretion. 
Eleven patients were classified as low, 2 8 as normal and four
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had high plasma renin activity. This spectrum of plasma renin 
activity is fairly typical of the population of patients with 
essential hypertension (8 8) .
Renin substrate was normal and similar in the four 
sources of plasma at all levels of peripheral plasma renin 
activity. Hence it can be assumed that differences in plasma 
renin activity reflect differences in plasma renin concentra­
tion .
Plasma renin activity in blood collected from the aorta 
was similar to that found in blood collected from the vena 
cava (Figure 26). The slope and intercept of the line which 
best fit the relationship of arterial to caval plasma renin 
activity did not differ from the line of identity. This sup­
ports the view that plasma renin is derived exclusively from 
the îtidney and removed exclusively by the liver. Pragmati­
cally, it means that venous and arterial plasma renin values 
can be used interchangeably and they will be designated as 
(A) in the following analysis. (V) will represent renal vein 
renin values.
Plasma renin activity was similar in blood collected 
from the right or left renal vein (Figure 27) which suggests 
that there is no consistent physiological difference in the 
secretory capacity of the right and left kidneys. However, 
as expected, renal vein renin was almost invariably higher 
than arterial renin (Figure 28).
The key observation of the study was that the increment
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FIGURE 26
ESSENTIAL HYPERTENSION  
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Relationship of renin activity in blood 
collected from the aorta to that found in blood collected 
from the vena cava, below the kidneys, of patients with 
essential hypertension. The line which best fits the 
points is not significantly different from the line of 
identity. This supports the view that venous and arterial 
plasma renin activity are identical.
•141-
PRA determinants : MCR
FIGURE 27
ESSENTIAL HYPERTENSION  
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Relationship of renin activity in blood 
from the right renal vein to that from the left renal 
vein of 4 3 patients with essential hypertension. The 
line expressing the relationship is not different from 
the line of identity and the intercept is not significantly 
different from zero. Therefore, renal vein renin in 
the right renal vein is similar to that found in the 
left renal vein of patients with essential hypertension.
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FIGURE 28
ESSENTIAL HYPERTENSION  
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Relationship of renal vein renin to arterial 
(or venous) renin in patients with essential hypertension.
The slope of the line is not different from the line of
identity, indicating that the relationship of renal vein
renin to arterial renin is constant at all levels of
plasma renin found in essential 'hypertension. The intercept
of 1.24 indicates that the renal vein renin in patients
with essential hypertension is normally 124% of arterial renin
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of renin added to the renal vein (V-A) is a constant propor­
tion of the arterial renin at all levels of plasma renin 
activity found in essential hypertension. The slope of the 
line which best fit the relationship of renal vein renin to 
arterial renin was a line parallel to the line of identity, 
with a significantly positive intercept. In this group of 
patients, renal vein renin activity was 12 4% of peripheral 
plasma renin over a wide range of plasma renin activity 
(Figure 28). This value is similar to that reported by Brown 
and co-workers (12 5%) for samples with plasma renin concentration 
that were not abnormally high (152),
The constancy of this relationship suggests that under - 
steady state conditions the metabolic clearance rate of renin 
is always proportional to the plasma concentration of renin.
In other words, the fraction of blood that is cleared of 
renin by the liver is constant irrespective of the blood 
level of renin. Thus, in essential hypertension, peripheral 
plasma renin is directly proportional to renal renin secre­
tion, i.e., renin secretion = (arterial renin) x constant.
II. Practical Applications of Differential Renin Measure­
ments ;
(i) Renin Secretion Rate : In patients with presumably normal
renal blood flows the renal vein renin increment (V-A) was 
shown to be consistently 24% of the peripheral level (A),
Thus, renal vein renin is equal to A + 0.24A.
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Renin secretion can be calculated from the product of 
renal plasma flow and the renal vein renin increment (V-A). 
(V-A) is equal to 0.24A (Table 17) and renal plasma flow in 
patients with essential hypertension can be presumed to 
be normal and equal to roughly 30 0 ml/minute from each 
kidney. Therefore, as illustrated in Table 17, renin secre­
tion = 144A.
Thus, under steady state conditions similar to those 
of the present study, renal renin secretion per minute 
is approximately 144 times peripheral plasma renin.
Confirmation of this formula can be found in a study 
of renin secretion by Kaneko and co-workers (153) in which 
renal plasma flow*was measured in patients with essential 
hypertension. From their data renin secretion per minute 
was calculated to be 136 times peripheral plasma renin.
Thus, calculated and measured values are quite similar.
(ii) Renal Plasma Flow: Variations in renal plasma flow
must influence the renal vein renin increment (V-A) since 
reductions in flow would result in less dilution of secreted 
renin by renal vein blood and (V-A) would increase (16,151). 
Since,
Renin secretion = renal plasma flow x (V-A)
Renal plasma flow = renin secretion/(V-A) = " (V-K^/A
Thus renal plasma flow is inversely related to (V-A)/A.
However peripheral renin is normally derived from two 
kidneys,
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TABLE 17
RELATIONSHIP OF RENIN SECRETION TO PERIPHERAL 
PLASMA RENIN
V-A = Renal vein renin increment
V-A/A ” V-A expressed as fraction of peripheral renin
V-A/A ~ 0.24 .^hen renal and liver blood flows are normal
V-A = 0.24A
Renin secretion = renal plasma flow x (V-A)
/
==, 600ydc 0.24a  when renal plasma flow is normal 
= 144A
/  ■Renin secretion per minute = 144 times peripheral plasma renin
-1.46
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i.e. Renin secretion = RPFg(V^-A) + RPF2 (V2 -A)
But, renin secretion = 144A
Therefore 144A = RPF^(V%-A) + RPF2 (V2~A)
Rearranging: RPFi = -(ÿJ^TÂ "
This equation provides a basis for estimating renal 
plasma flow from each kidney. However, since there are two 
unknowns in the equation (RPFq and RPF2) absolute determi­
nation of renal plasma flow from each kidney can only be 
calculated from two different sets of data, preferably 
collected from two different physiological settings (e.g., 
sodium depletion and sodium loading). However, since 
one of the components of the right hand side of the equation 
has negative value, a maximum value for renal plasma flow 
from each side can be estimated from one set of measurements
When (Vj_-A)/A is greater than 0.48, the value for 
144/(V^-A)/A must be less than 300 and renal plasma flow to 
that kidney must be less than 3 00 ml/minute. Therefore, 
irrespective of the renin secretion and renal plasma flow 
from the contralateral kidney, a value of (V-A)/A greater 
than 0.4 8 from either kidney is always associated with re­
duced plasma flow.
This formula has an important application in the study 
of patients with renovascular hypertension. This will be 
discussed in detail in a later section (page ). However, 
it is relevant to point out that in classic Goldblatt hyper­
tension, reduction in blood flow to one kidney is associated
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with hyper-secretion of renin from that kidney and complete 
suppression of renin secretion from the contralateral kid­
ney, Under these circumstances, (V2-A) = 0) and the right 
hand side of the equation for calculation of renal plasma 
flow is reduced to zero, then, renal plasma flow from the 
sole secreting kidney can be calculated with precision. It 
follows that the closer (V2“A) is to zero from the unin­
volved kidney, i.e., the lower the secretion rate of renin, 
the more accurate the estimation of renal plasma flow from 
the suspect kidney.
In a companion study of 28 patients with suspected uni- 
lateral renovascular hypertension who came to surgery, the 
combination of the following three indicators (2 8) consist­
ently predicted curability: (1) Reduction in renal plasma
flow to the suspected kidney (V-A/A > 0.48); (2) suppression
of renin from the unaffected kidney (V-A/A < 0,38) and 
(3) elevated peripheral plasma renin activity (i.e., in­
creased secretion of renin). Thus'increased understanding 
of the determinants of plasma renin concentrations in vari­
ous blood vessels has proved useful in evaluating the pres­
ence or absence of curable renovascular hypertension.
Ill. Summary
Plasma renin activity appears to be regulated to sus­
tain an appropriate rate of angiotensin production. Although 
changes in both renin substrate and the metabolic clearance 
rate of renin can affect plasma renin activity, available
-148-
PRA determinants: Summary
evidence- suggests that renal renin secretion is the dynamic 
component of the system which responds to physiological 
stimuli. Thus renal renin secretion appears to be that 
component of the system which responds to stimuli which 
reflect a need for changes in angiotensin production. In 
addition, we have shown that in patients with essential 
hypertension plasma renin activity directly reflects renal 
renin secretion.
The constant relationship of plasma renin activity to 
renal renin secretion has been used to evaluate changes in 
renal plasma flow. In patients with renovascular hypertension 
who have unilateral secretion of renin, increases in renal 
vein renin in relation to arterial renin are inversely related 
to reductions in renal blood flow. When bilateral renin 
secretion occurs, a renal vein renin increment greater than 
14 8% arterial renin is always associated with renal plasma 
flows of less than the normal value of 300 ml/minute.
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B. Renin and Aldosterone and Their Interrelationship in Re­
sponse to Changes in Sodium and Potassium Balance :
In the previous section data were presented to support 
the view that plasma renin activity is directly related to 
renal renin secretion so that changes in plasma renin activ­
ity can be used as an indicator of changes in the secretion 
rate of renin. Since angiotensin II is the effector hormone 
of the renin limb of the hormonal system, its blood level 
would be expected to be the most meaningful indicator of 
changes in renin secretory activity. However, many meth- 
ods for measurement of angiotensin II are not sufficiently 
sensitive to detect low levels of the hormone with confid­
ence. Plasma renin activity measurements can be used in­
stead since all evidence suggests that angiotensin I genera­
tion, i.e. plasma renin activity, reflects angiotensin II 
levels (154), there being no evidence that lung converting 
enzyme activity is ever rate limiting.
In this section, the responses of renin and aldosterone 
to extreme changes in sodium and potassium balance will be 
evaluated in normal man and in rats. Although it has been 
generally accepted that renin and aldosterone are important 
for regulation of sodium excretion at low and normal sodium 
intakes, the role of the hormonal system in regulating salt 
balance at high levels of sodium intake has not been clari­
fied. In addition, some investigators have recently
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postulated that angiotensin II may not be the sole mediator 
of the increased aldosterone biosynthesis which occurs in 
response to sodium deprivation (155-157). In the following 
presentation new data will be analysed to determine if there 
is a need to postulate another trophic stimulus for aldoster­
one, in addition to plasma potassium and angiotensin II.
I. Effect of Variations in Sodium Intake on Renin and 
Aldosterone
The well known relationship of plasma renin activity to 
variations in sodium intake is illustrated in Figure 10 
(page ) (2,6,158,159). These data are derived from a
study of 52 normal subjects, most of whom were maintained 
on constant dietary regimen. The 24-hour urinary sodium 
excretion, plotted on the abscissa, is taken as an index 
of the state of sodium balance. Measurements were usually 
made after the subjects had been on a constant diet for 
five days. In some subjects, however, daily analyses were 
made, beginning on the first day of the constant regimen 
and continuing for up to eleven days.
The plot confirms that plasma renin activity moves 
dynamically in relation to the rate of urinary sodium excre­
tion. Thus plasma renin activity increases with 
sodium deprivation and, conversely, falls to a minimum when 
salt is present in excess.
As illustrated in Figures 18 (page 88) and 20 (pagelOS),
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urine aldosterone and plasma aldosterone exhibit an entirely 
similar relationship to changes in sodium balance (2,9,11).
This provides strong circumstantial evidence that the aldosterone 
secretory response to changes in sodium balance is mediated via 
changes in renin activity. The greater spread in plasma renin 
values compared to aldosterone measurements may be explained 
by the more rapid response of renin secretion to various 
stimuli. Large amounts of renin are stored in the kidney (30) 
and can be released rapidly (16 0), whereas angiotensin II 
stimulates aldosterone biosynthesis (161) and this slower re­
sponse may result in less marked fluctuations in hormonal 
levels.
The close association between renin and aldosterone 
secretions is illustrated in Figure 2 9 which summarizes data 
from 157 studies of 61 normal subjects in whom the daily 
aldosterone excretion was related to the concurrent plasma 
renin activity (18). Included are data from subjects main­
tained on various constant dietary regimens and from subjects 
eating random diets. The plot reveals a highly significant 
direct relationship between the activity of these two hormones. 
The observed correlation coefficient of 0.84 is impressively 
high, but does not exclude the operation of other factors in 
this close hormonal interaction.
As might be expected, a similar direct relationship 
was found between plasma aldosterone levels and plasma renin 
activity in normal subjects in response to changes in sodium 
intake (Figure 30) (122) .
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-FIGURE 29,
RELATIONSHIP OF URINE ALDOSTERONE EXCRETION 
TO PLASMA RENIN ACTIVITY 
IN NORMAL SUBJECTS
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Relationship of plasma renin activity to the concurrent 
level of urine aldosterone excretion in 61 normal subjects. 
Both parameters are plotted on logarithmic scales. The 
correlation coefficient of 0.84 is strikingly high, especially 
when one considers the considerable interindividual variation 
in the renin-aldosterone relationship which occurs even in 
normal subjects.
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FIGURE 30
RELATIONSHIP OF PLASMA ALDOSTERONE TO-PLASMA'RENIN ACTIVITY
IN NORMAL SUBJECTS
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Plasma aldosterone is linearly related to plasma renin 
activity in 27 normal subjects.
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II. Renin and Aldosterone During Sodium Loading :
The hyperbolic relationships inscribed by changes in 
renin and aldosterone activity in relation to urine sodium 
excretion strongly suggest that these two hormones play an 
important interrelated role in sodium conservation since 
their activity increases sharply during sodium depletion. 
However, a question which remains unsettled is whether or 
not the two hormones play any role when diatary sodium in­
takes are relatively high. To investigate this question the 
data in Figures 10 (page 46 ) and 18 (page 88 ) were replotted
(17). The mean urine sodium excretion associated with a given 
range of renin or aldosterone activity was calculated and the 
mean value for each increment of hormone activity and its 
standard deviation were plotted.
As illustrated in Figure 31, under circumstances of sodium 
loading, when renin and aldosterone activity are low, these 
two hormones continue to be serially inversely related to 
sodium excretion and continue to change in concert, Thus 
when normal subjects have a plasma renin activity of from
1 to 2 ng/ml/hr., mean sodium excretion was found to be about
2 00 mEq/day, But at plasma renin activities of less than 
1 ng/ml/hr., mean sodium excretion was still higher in 
this study approximately 250 mEq/day. Statistical treatment 
of these differences indicates that they are highly signifi­
cant at all of the higher rates of sodium excretion. Entirely 
similar results were obtained from an analysis of the be­
havior of aldosterone excretion.
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FIGURE 31
RELATIONSHIP OF URINE SODIUM EXCRETION 
TO PLASMA RENIN ACTIVITY OR URINE ALDOSTERONE EXCRETION
IN NORMAL SUBJECTS
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Mean urine sodium excretion is plotted for eight 
different ranges of plasma renin activity and eleven ranges 
of urine aldosterone excretion. The data are derived from 
62 normal subjects. The vertical lines represent the standard 
deviation of urine sodium excretion for a given hormone 
range. Urine sodium excretion continues to increase sig­
nificantly as both hormones fall, suggesting a causal rel­
ationship, even at low levels of the hormones.
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These data suggest that changes in both renin and aldo­
sterone secretory activity are physiologically meaningful 
and interrelated even at very low levels of secretory ac­
tivity. Thus renin and aldosterone appear to affect sodium 
balance at both high and low levels of sodium intake and 
excretion.
Oscillations in the System During Sodium Loading :
The responses of renin and aldosterone during sodium
I
loading are illustrated in another study in which three 
normal subjects received a constant high sodium intake of 
270 mEq/day for 11 consecutive days (11). The diet was 
instituted after 9 days of sodium depletion. The results 
of this study are^presented in Figure 32.
In all three subjects there was an initial period of 
sodium retention, lasting for 4 days, in which the intake 
exceeded the output. This was followed by a second phase 
in which the rate of sodium excretion actually exceeded 
the intake. This phase lasted for 4 days and was followed 
by another period of mild positive sodium balance lasting 
for at least the next 3 days when the study terminated. .
Thus the high sodium intake caused marked sodium retention. 
The diet of 270 mEq/day resulted in mean net positive sodium 
balance of some 2 70 mEq at the end of the 11 day period. 
However, this equilibrium point was only achieved after a 
period during which the subjects had retained approximately 
400 mEq of sodium.
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FIGURE 32
DAILY FLUCTUATIONS IN SODIUM U ALDOSTERONE
DURING FIXED HIGH SODIUM INTAKE
100
60 50
4 0
3 0
4 0
2020
URINE
ALDO STERO NE
EXCRETION
jug/day
0.5
0.4
0.3
0.22 -
3 5 0
3 0 0
2 5 0
200
150
100
50
Sodium Intake
URINE
SODIUM
EXCRETION
mEq/doy
5 0 0
4 0 0
CUMULATIVE  
. SODIUM  
B A L A N C E  2 0 0  
mEq.
3 0 0
GO
I 2 3 4 5  6 7 8 9  10 n
DAY
All subjects previously 
sodium depleted
MEAN VALUES FROM 3 NORMAL SUBJECTS
PLASMA
RENIN
ACTIVITY
ng/ml/hr
(•)
Fluctuations in sodium excretion, sodium balance, plasma 
renin activity and aldosterone excretion during a maintained 270 mEq 
sodium diet. Mean values + SD from three normal subjects are 
presented. Each subject exhibited similar and corresponding fluct­
uations in urine sodium, plasma renin and aldosterone. The highest 
levels of sodium excretion were associated with the lowest rates 
of aldosterone excretion.
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Both aldosterone excretion and plasma renin activity, 
measured daily, fell serially in each subject as urinary 
sodium excretion increased so that the highest rates of 
urine sodium excretion were associated with the lowest 
levels of renin and aldosterone. Note that in the third 
phase, when urinary sodium excretion began to fall, renin 
and aldosterone both exhibited a slight but consistent rise. 
These data strongly suggest that the phasic, albeit rela­
tively slight, changes in sodium excretion which occur 
during circumstances of prolonged sodium loading are medi­
ated by aldosterone in response to changes in renin secre­
tion .
These data also indicate that renin and aldosterone 
secretion are more closely related to the rate of sodium 
excretion than to the state of overall sodium "balance."
Thus on day 3 when sodium balance was almost at its peak 
aldosterone and renin levels were double those of the lowest 
values. Moreover, during the natriuretic phase, cumulative 
sodium balance declined while aldosterone and renin remained 
constant, but low. This is not to say that aldosterone and 
renin do not in the first place respond to changes in "bal­
ance." Some function of a change in balance obviously is 
the stimulus which induces a change in hormonal activity. 
However, the hormonal response appears sluggish so that 
large overshoots in balance occur, both positively and 
negatively, before equilibrium is achieved by continuing
-159-
RAAS: Pota s s ium
adjustment of the hormonal secretions.
These consistent daily patterns of renin and aldoster­
one activity in relation to urine sodium excretion suggest 
that in normal subjects daily fluctuations in aldosterone 
do in fact have a modulating effect on urine sodium excretion 
tion, even at high levels of sodium intake.
In summary, there is a close relationship between 
renin and aldosterone and sodium excretion in normal sub­
jects which points to a close causal relationship in the 
three parameters. The relationship obtains over a wide 
range of intakes, suggesting that renin and aldosterone 
play a physiological role in regulating salt balance during 
sodium loading as well as during sodium depletion, However 
these studies do not rule out the possibility that other 
factors are involved in the regulation of any or all of the 
three parameters.
Ill. Effect of Changes in Potassium Balance on Plasma 
Renin Activity ;
Changes in sodium balance have been shown to exert a marked 
affect on renal renin secretion. Sodium depletion increases 
renin secretion and sodium administration decreases it (158) .
The direct effect of potassium on aldosterone secretion is also 
well documented (162-165). However, until recently, the direct 
effect on potassium on renin secretion was less clear. Potassium 
adminstration had been shown to suppress renin secretion (16 6-168)
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but the effect of potassium deprivation had not been studied.
1. Experimental studies in rats.
Studies were designed to investigate the effect of 
potassium on renin secretion by employing an animal model 
in which extreme and rigidly controlled changes in both 
potassium and sodium balance could be imposed (19). Rats, 
weighing between 2 75 and 285 g were divided into nine groups 
of ten animals each. The nine groups encompassed all possible 
combinations of three levels of dietary intake (low, medium, 
or high) for both sodium and potassium. A 12 day balance 
study was carried oxit in which sodium and potassium intake 
and excretion were carefully monitored and then the animals 
were maintained on the same regimen for an additional 35 
days (total 53 days) at which time they were sacrificed 
by decapitation.
Among all nine groups no consistent or impressive 
changes were observed in the concentrations of renin sub­
strate . Accordingly, changes in serum renin activity were 
most likely a reflection of changes in serum renin concen­
trations.
As expected, sodium deprivation produced significant 
increases in serum renin levels. Thus on the medium 
intake, sodium deprivation caused an increase in renin 
activity from 1.1 to 3.3 ng/ml/hr. However, changes in the 
potassium intake exerted a highly significant modulating 
influence on this characteristic renin response (Figure 33).
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FIGURE 33
INHIBITION OF SERUM RENIN RISE 
DUE TO SODIUM DEPLETION 
BY INCREASING DIETARY POTASSIUM LEVELS
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Effect of three different levels of potassium intake 
on serum renin activity in normal rats. Potassium dep­
rivation resulted in significant increases in renin and 
augmented the response of renin to sodium depletion. 
Increasing dietary potassium progressively blunted renin 
secretion.
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Thus, on the high potassium intake the typical response to 
sodium depletion was greatly attenuated. The control value 
for serum renin was lower (0.9 ng/ml/hr.) and it increased 
to only 1,6 ng/ml/hr. despite an even greater degree of 
sodium depletion associated with the high k”* administration. 
Conversely, the basal renin level, as well as its response 
to sodium depletion, was greatly augmented by potassium 
depletion. In this latter situation sodium depletion caused 
the values to rise from 2.7 to 6.0 ng/ml/hr. The highest 
of all renin values occurred in the low K"*", low Na^ dietary 
group.
2. Companion studies in man
The response of plasma renin activity to less extreme 
changes in potassium balance was investigated in man (20). 
Potassium administration reduced plasma renin activity in 
18 of 28 normal or hypertensive subjects. Suppression of 
renin often occurred despite the slight sodium diuresis 
induced by potassium administration. The renin suppression 
was directly related to induced changes in plasma potassium 
concentration and urinary potassium excretion.
In six studies potassium deprivation invariably in­
creased plasma renin activity even though a tendency for 
sodium retention often accompanied this procedure.
Figure 34 presents the details of a representative 
study in a normal subject who was studied under metabolic 
balance ward conditions. Potassium administration produced
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FIG U R E 34
EFFECT OF PO TASSIUM -LOADING
ON PLASMA RENIN A C T IV IT Y*
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Study of the effect of increased potassium admin­
istration for five days in a normal subject maintained 
on constant dietary regimen- Plasma renin activity was 
serially suppressed. As expected, urinary aldosterone, 
sodium and potassium excretion all increased.
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a serial and progressive fall in plasma renin activity.
It also induced a slight sodium diuresis during the first 
three days of the experimental period. The serial suppres­
sion of plasma renin activity thus occurred in the face of 
an induced natriuresis, a change which would be expected 
to stimulate plasma renin activity.
It is interesting to note the aldosterone excretion 
increased in response to potassium administration, despite 
the fall in plasma renin activity.
Analysis
These long-term balance studies in rats and in man 
define an impressive inverse relationship between, on the 
one hand, potassium administration, plasma potassium con­
centration, the rate of urinary potassium excretion and 
potassium balance and on the other hand, the concurrent 
level of plasma renin activity.
The influence of the changes in potassium metabolism on 
circulating renin levels could not be explained by induced 
changes in sodium balance. Indeed, the suppressing effect 
of potassium administration on renin activity was often 
observed despite the fact that the potassium feeding occa­
sionally induced natriuresis and hyponatremia which would 
ordinarily induce increased renin secretion. Furthermore, 
the striking increases in serum renin activity associated 
with k ’*' depletion were never associated with sodium diuresis 
and in some situations may in fact have occurred despite
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induced sodium retention.
Thus, potassium administration affects the renin- 
angiotensin-aldosterone system in two ways. It both sup­
presses renin secretion and increases aldosterone production. 
Potassium deprivation has entirely opposite effects. Accord­
ingly, potassium might exert a much greater stimulatory 
effect on aldosterone secretion if plasma renin levels were 
not concurrently suppressed. The reason for the suppressive 
effect of potassium on renin secretion is not clear, but it 
may be related to the simultaneous actions of aldosterone 
to maintain both sodium and potassium balance. (See section 
C, page 172).
IV. Sodium Depletion : Effect of Concurrent Changes in
Sodium and Potassium Balance on Renin and Aldosterone 
Secretions
Since both sodium and potassium balance have now been 
shown to affect both renin and aldosterone secretion, either 
directly or indirectly, it was of interest to examine the 
effect of concurrent changes in balance of both of these 
cations on renin and aldosterone secretions.
In a study of five normal subjects who were sodium 
deprived for nine days, sodium and potassium balance were 
carefully monitored (18). It was noted that as sodium de­
pletion was induced, potassium balance became progressively 
positive so that a mean accumulation of some 60 mEq occurred 
(Figure 35). In keeping with these changes, a general trend
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FIGURE 35
EFFECT OF SODIUM DEPLETION  
ON POTASSIUM BALANCE AND INDUCED CHANGES  
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Positive potassium balance induced by sodium depletion. 
Mean data and standard errors are presented from five normal 
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renin is represented by dots and aldosterone by bars. Potassium re­
tention induced a change in the ratio of aldosterone to renin secret* 
ion such that relatively less renin was neede to maintain adequate 
aldosterone levels during continued sodium depletion.
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was observed for plasma potassium levels to increase. How­
ever, the range of variation in plasma potassium was consid­
erable so that plasma levels were not reliable indicators of 
the serial changes in cumulative balance.
As expected, during the first five days, sodium depri­
vation produced serial increases in both aldosterone excre­
tion and plasma renin activity. In fact, at first glance, 
they appeared to rise in concert. However, when the aldo­
sterone/ renin ratio was calculated for each day it was 
found that the ratio rose progressively during sodium 
deprivation rather than remaining constant. The observed 
changes in cumulative potassium balance may well explain 
the change in the.ratio. As described in the previous 
section, the positive potassium balance would be expected 
to increase aldosterone secretion (162) while retarding the in­
creases in renin secretion (19,20) in response to continued 
sodium depletion and this would cause an increase in the 
aldosterone/renin ratio.
These findings suggest that the summation of changes 
in plasma renin activity and potassium balance provides 
an adequate explanation for changes observed in aldosterone 
secretion during sodium deprivation. They also serve to 
illustrate that changes in balance of sodium and potassium 
are intimately related so that a change in intake of only 
one of the two cations does not preclude changes in balance 
of the other and these changes are not necessarily reflected 
in differences in plasma electrolyte concentration. Thus
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in studies of sodium deprivation in which evidence for 
the existence of unknown aldosterone stimulatory factors 
are sought (155,15 6) , the effect of changes in both sodium and 
potassium balance must be taken into account before the exis­
tence of other factors is postulated.
V, Summary: The Coordinated Hormonal Control of Sodium
and Potassium Homeostasis 
The data just presented can provide the basis for 
a cybernetic scheme for sodium and potassium homeostasis
(18). Figure 36 describes this "double-cycle feedback" 
cybernetic system involving renin, angiotensin and aldosterone 
which simultaneously controls sodium and potassium homeostasis, 
For simplicity, angiotensin has been omitted since a large 
body of evidence indicates that the plasma level of this 
hormone is determined by changes in plasma renin activity.
The Sodium Cycle. The outer cycle of Figure 36 de­
scribes the system for regulation of sodium balance via 
changes in renin and aldosterone secretion. In this cycle, 
any stimulus producing sodium or volume depletion activates 
renal renin secretion and this in turn stimulates aldoster­
one secretion. Aldosterone then causes sodium retention 
with attendant hydremia, and this effect, by restoring 
renal perfusion, operates to turn off the original signal 
for renin secretion and bring the aldosterone secretory 
rate back to the null point.
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FIGURE 36
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The Potassium Cycle. The inner cycle describes the 
system which maintains potassium balance. Ingested potas­
sium ions, by raising plasma potassium^ stimulate aldoster- 
secretion. Aldosterone in turn, by acting on the renal 
tubules, restores plasma potassium to normal by promoting 
renal potassium excretion. As potassium levels in the 
blood fall, aldosterone secretion is again turned off and 
restored to the null point. Simultaneously, changes in 
plasma potassium also produce direct effects on renal renin 
secretion so that a rising plasma potassium level suppresses 
renin secretion and vice versa. The changes in renin secre­
tion induced by changes in plasma potassium may operate to 
amplify or retard.the capacity for renal excretion of potas­
sium. It should be noted that the concurrently induced 
changes in plasma renin activity tend to modulate the ef­
fects of potassium on the aldosterone secretory mechanism 
so that although potassium stimulates aldosterone secretion, 
this action is dampened by a concurrently induced decrease 
in plasma renin activity. Accordingly, potassium might 
exert a much greater stimulatory effect on aldosterone 
secretion if plasma renin levels remained constant.
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C. Aldosterone : Integration of Its Effect with Changes in
Intrarenal Physical Factors.
There is an apparent conflict in the simultaneous 
regulation of sodium and potassium balance by one hormone, 
aldosterone. Changes in sodium and potassium balance act 
in opposite directions to modify aldosterone secretion 
(Figure 36), Positive potassium balance (K"^  gain) increases 
aldosterone secretion but positive sodium balance (Na“^ gain) 
decreases it. Sodium depletion (Na'^  loss) increases aldo­
sterone but potassium depletion (K"^  loss) depresses secre­
tion. At the same time aldosterone has been shown to act to 
retain sodium but promote potassium excretion. Hence, one 
would expect that sodium depletion-induced increases in 
aldosterone would cause potassium loss and potassium-induced 
increases to cause sodium retention. This does not happen.
In fact, the tendency is for the converse situation to occur 
(18,162,168-172).
I. Effect of Changes in Sodium or Potassium Intake on the 
Overall Balance of the Other Cation 
The influence of sodium depletion on potassium balance 
is illustrated in Figure 35 (page 167)(17,18), During nine 
days of sustained sodium deprivation in five normal subjects, 
potassium balance became slowly but progressively positive so 
that a mean accumulation of some 60 mEq occurred. This 
positive balance is to be contrasted with the neutral or
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slightly negative balance during the three day control period. 
AS expected, sodium deprivation induced a serial rise in both 
aldosterone excretion and plasma renin activity. Thus, sodium 
depletion and associated hyperaldosteronism did not induce 
hypokalemia (Figure 36) but actually caused potassium reten­
tion and a tendency towards hyperkalemia.
In another study (19) of the effect of various sodium 
and potassium intakes in rats, potassium loading caused sig­
nificant natriuresis in both sodium depleted rats and in rats 
on normal sodium intake. There was also some tendency for 
increasing amounts of sodium in the diet to induce kaliuresis. 
Thus changes in sodium or potassium intake seem to affect the 
other cation in the opposite direction to that expected on 
the basis of induced changes in aldosterone secretion.
II. Effect of Changes in Distal Sodium Supply on Urine
Sodium and Potassium Excretion :
To reconcile this seeming paradox, other factors which 
respond to changes in sodium and potassium intake and which 
are involved in the regulation of urine sodium and potassium 
excretion must be considered (173).
The amount of sodium excreted in the urine is dependent 
on the rate of glomerular filtration (GFR) minus the net sum 
of sodium reabsorbed from the proximal tubule, loop of Henle, 
distal convoluted tubule and collecting duct. Recently, 
active sodium secretion has been demonstrated but only in 
response to injection of uremic serum (174)« Under physio-
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logical conditions, maintenance of sodium balance depends on 
adequate reabsorption of sodium from the nephron.
Reabsorption of sodium from the loop of Henle appears 
to be load dependent and there is no evidence to suggest 
that changes in either sodium or potassium balance alter the 
fraction of sodium that is reabsorbed in this portion of the 
tubule (175). However, changes in both sodium and potassium 
balance have been shown to affect both GFR (176-181) and 
proximal sodium reabsorption (180,182-188). Increases in 
both sodium and potassium balance act to increase GFR and 
depress proximal sodium reabsorption. Both of these two 
changes increase the amount of sodium passing out of the 
proximal tubule. Since reabsorption from the loop of Henle 
is load dependent (175), increases in net sodium leaving the 
proximal tubule must result in an increase in the amount of 
sodium presented to the distal tubule. Conversely a fall in 
either sodium or potassium balance, by reducing GFR and in­
creasing proximal tubule sodium reabsorption, results in 
depression of distal tubule sodium supply. A summary of the 
effects of changes in sodium and potassium balance on distal 
sodium supply are presented in Table 18A.
It can be appreciated that if sodium reabsorption in 
the distal tubule and collecting duct, like the loop of 
Henle, were load dependent, then changes in distal sodium 
supply would inevitably result in changes in urine sodium 
excretion (Table 18B).
Filtered potassium is almost completely reabsorbed
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TABLETS
A. EFFECTS OF CHANGES IN SODIUM AND POTASSIUM BALANCE ON 
DISTAL TUBULE SODIUM SUPPLY
Increased sodium ba lance > Increased d is ta l Na^ supply
Decreased sodium balance- > Decreased d is ta l Na supply
Increased potassium balance— > Increased d is ta l Na^ supply 
Decreased potassium balance— > Decreased d is ta l Na supply
B. EFFECTS OF CHANGES IN DISTAL SODIUM SUPPLY ON URINE
SODIUM EXCRETION
+ +Increased d is ta l Na^ supply— > Increased urine  Na^ excretion
Decreased d is ta l Na supply— > Decreased urine Na excretion
C. EFFECTS OF CHANGES IN DISTAL SODIUM SUPPLY ON URINE
POTASSIUM EXCRETION
+ +Increased d is ta l Na^ supply— ^Increased urine  excretion
Decreased d is ta l Na supply— ^Decreased urine  K excretion
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prior to the distal convoluted tubule (18 9). Urine potassium 
excretion appears to be dependent almost entirely on secre­
tion in the distal tubule (18 9-191). Thus maintenance of 
potassium balance depends on adequate secretion of potassium 
into the nephron. Evidence suggests that changes in distal 
sodium supply also affect potassium excretion (175,190).
Since sodium reabsorption in the distal tubule is not accom­
panied by commensurate chloride reabsorption, a negative 
electrochemical gradient develops across the distal tubule 
and potassium passes from the cells into the tubule in an 
attempt to restore neutrality (192). Hence, increases in net 
sodium reabsorption would result in increased electronega­
tivity and thus an increase in net potassium secretion. It 
can be appreciated that, even if fractional sodium reabsorp­
tion in the distal tubule remained unchanged, increases in 
the sodium load to the distal tubule would result in a net 
increase in the amount of sodium reabsorbed and thus in­
creased potassium secretion would occur. Therefore, changes 
in distal sodium supply can affect potassium excretion 
(Table 18C). Increases in distal sodium supply cause more 
potassium elimination and decreases result in a fall in urine 
potassium excretion.
When changes in intrarenal physical factors are consi­
dered alone, sodium induced increases in distal sodium supply 
ought to cause potassium elimination and potassium induced 
increases ought to cause sodium diuresis. Conversely, sodium 
depletion should be accompanied by potassium retention and
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potassium deprivation should be associated with a marked in­
crease in sodium balance. In fact, the tendency is for these 
changes to occur, but the magnitude of the effect is quite 
small.
III. Coordination of Changes in Distal Sodium Supply with 
Changes in Aldosterone.
Reabsorption of sodium in the distal tubule is not exclu­
sively load dependent. Aldosterone markedly affects distal 
sodium reabsorption (193,194) and thus affects potassium 
secretion at least in part via resultant increases in the 
electrochemical gradient. Therefore, in analysing the renal 
response to changes in sodium and potassium balance, changes 
in distal sodium^supply and aldosterone must be considered 
together.
The effect of variations in sodium and potassium balance 
on aldosterone and distal sodium supply and the effect of 
the induced changes in aldosterone and distal sodium supply 
on urine sodium and potassium excretion are illustrated 
diagramatically in Figure 37. Sodium loading results in an 
increase in distal sodium supply and reduction in aldosterone 
secretion. Both of these changes augment urine sodium excre­
tion . However, although the increase in distal sodium supply 
promotes urine potassium excretion, the concurrent fall in 
aldosterone acts to reduce net distal sodium reabsorption and 
thus retard potassium excretion. Altogether, these two 
changes protect potassium balance and result in no net change
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FIGURE 37
EFFECT OF CHANGES IN SODIUM AND POTASSIUM  
BALANCE ON DISTAL SODIUM SUPPLY, ALDOSTERONE, 
AND URINE SODIUM AND POTASSIUM EXCRETION
SODiUM POTASSiUM
DISTAL
SODIUM
SUPPLY
/
ALDOSTERONE
STIMULUS’. Sodium Intake Potassium Intake
EFFECT! Urine Sodium Excretion Urine Potassium Excretion
The upper panels represent diagramatically the increase 
in distal sodium supply which occurs in response to increasing sodium 
and potassium intake and the resultant increase in urinary 
excretion of both ions, assuming no change in aldosterone.
Th,e lower panels represent the opposite effects of dietary sodium 
and potassium on aldosterone and the opposing effects of aldo­
sterone on sodium and potassium excretions, assuming no change 
in distal sodium supply.
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in potassium excretion.
Alternatively, increasing potassium intake results in 
augmentation of both distal sodium supply and aldosterone 
excretion, both of which promote potassium elimination. How­
ever, although increased distal sodium supply should result 
in sodium loss, the concurrent elevation of aldosterone 
secretion increases net distal sodium reabsorption and the 
net effect is no change in sodium excretion.
IV. A Cybernetic System for Sodium and Potassium Homeo­
stasis.
The coordination of changes in distal sodium supply 
with changes in aldosterone secretion is illustrated in 
Figure 38 (18). In the lower panel, factors which alter 
distal sodium supply and the effect of these changes are 
superimposed on the hormonal variations discussed in the 
previous section.
This diagram illustrates the effect of changes in in­
take of one cation on its own excretion and on the excretion 
of the other cation. For example, sodium loss, via increased 
aldosterone production and decreased distal sodium supply 
results in renal sodium retention which feeds back to turn 
off the initial signal. However, increased aldosterone pro­
motes potassium excretion but decreased distal sodium supply 
retards potassium excretion. Thus, while the system compen­
sates to prevent further sodium loss, potassium balance is 
maintained neutral.
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FIGURE 38
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Upper panel: Hormonal double cycle feedback system for 
simultaneous■sodium and potassium homeostasis. Lower panel: 
Complementary changes in renal tubular sodium transoprt consequent 
to changes in sodium and potassium balance.
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The effect of changes in one or both cations on aldo­
sterone and distal sodium supply and the result of the com­
pensation by hormonal and intrarenal physical factors is 
presented in Table 19, Under all conditions the system is 
able to maintain sodium and potassium balance. Thus, even 
when both sodium and potassium intake change together the 
system is almost perfectly balanced. Concurrent increases 
or decreases in both cations together result in increases 
or decreases in distal sodium supply but have no effect on 
aldosterone secretion. Hence excretion or retention of both 
ions is concurrently achieved. However, opposite changes in 
sodium and potassium intake cause marked compensation of the 
aldosterone component, with little change in intrarenal 
physical factors.. Since aldosterone affects each cation in 
the opposite direction, balance is achieved.
The effect of the collecting duct to modulate urine 
sodium excretion and the hormonal response to extreme condi­
tions of sodium loading will be considered in the next sec­
tion.
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TABLE 19
COORDINATION OF THE EFFECTS OF CHANGES IN DISTAL SODIUM SUPPLY 
AND ALDOSTERONE ON URINE SODIUM AND POTASSIUM EXCRETION
Increased Sodium Intake
Increased Distal Na+ Supply 
Decreased Aldosterone 
Net Change:
Increased Potassium Intake
Increased Distal Nat Supply 
. Increased Aldosterone 
Net Change;
Decreased Sodium Intake
Effect on 
Nat excretion
increased
increased
increased
increased 
decreased 
no change
Effect on 
Kt excretion
increased 
decreased 
no change
increased
increased
increased
Decreased Distal Nat Supply 
Increased Aldosterone 
Net Change:
Decreased Potassüum Intake
Decrease^d Distal Nat Supply 
Decreased Aldosterone 
Net Change:
Increased Nat and Kt Balance
decreased
decreased
decreased
decreased 
increased 
no change
decreased 
increased 
no change
decreased
decreased
decreased
Increased Distal Nat Supply 
No Change Aldosterone 
Net Change:
Decreased Nat and Kt Balance
Decreased Distal Nat Supply 
No Change Aldosterone 
Net Change:
increased 
no change 
increased
decreased 
no change 
decreased
increased 
no change 
increased
decreased 
no change 
decreased
Increased Nat; Decreased Kt Balance
No Change Distal Nat Supply 
Decreased Aldosterone 
Not Change ;
Decreased Nat: Increased Kt Balance
no change 
increased 
increased
no change 
decreased 
decreased
No Change Distal Nat Supply 
Increased Aldosterone 
Net Change:
no change 
decreased 
decreased
no change 
increased 
increased
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D. Natriuretic Hormone : Its Role in Sodium Homeostasis :
Considerable interest and debate centers around whether 
or not there is convincing evidence for the existence of a 
natriuretic hormone. The possibility of such a hormone has 
been suspected since de Wardener and his associates (21,123) 
showed that dogs could excrete a saline load under conditions 
in which no change occurred in the parameters then known to 
be involved in the regulation of sodium excretion; i.e., 
glomerular filtration and aldosterone.
Studies from several groups, utilizing cross-circulation 
techniques demonstrated evidence for a natriuretic hormone 
(21,123,195-198), but others reported negative findings (199, 
200). Other groups, utilizing such assays as toad bladder 
and frog skin short-circuit current (124,125), and PAH uptake 
or sodium transport in kidney slices (126,12 7) had positive 
assays in samples collected under conditions in which natri­
uretic activity might be present. However, the active 
material was not shown to increase urine sodium excretion.
Concurrent with the search for a natriuretic hormone was 
the development of evidence that changes in intrarenal physi­
cal factors can alter the rate of sodium reabsorption in the 
proximal tubule (185,188). The natriuretic hormone had been 
thought by some investigators to affect proximal tubular 
sodium transport, since during saline diuresis the amount of 
sodium reabsorbed from the proximal tubule is reduced (183). 
The means by which changes in proximal tubular sodium reab-
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sorption occur are still not completely understood. However, 
evidence suggests that the rate of removal of resorbate from 
the peritubular environment of the proximal tubule is the 
determinant (185,188,2 01) and there is only scanty evidence 
for hormonally induced changes in active sodium transport. 
Fractional sodium reabsorption in the proximal tubule appears 
to fluctuate with changes in hydrostatic pressure in the post- 
glomerular circulation (202-204). In addition, changes in 
viscosity and oncotic pressure in the peritubular capillaries 
have also been shown to affect the rate of sodium reabsorption 
(202,205). Therefore, although a hormonal effect on sodium 
reabsorption in the proximal tubule has not been ruled out, it 
may not be necessary to postulate one.
However, reduction in proximal tubule sodium reabsorption 
by itself is inadequate to account for sodium diuresis since 
proximal sodium reabsorption can be reduced when urinary 
sodium excretion is not increased (128,129). These results, 
and other more recent data (130,206) suggest that differential 
changes in sodium reabsorption, which are not the result of 
changes in aldosterone, can occur in a more distal portion of 
the nephron. Thus saline or hyperoncotic albumin infusions 
equally depress aldosterone excretion and proximal sodium re­
absorption, but only saline infusion results in large increases 
in urinary sodium excretion (128-130,207). Therefore the site 
of action of a natriuretic hormone which would be important 
for regulation of urine sodium excretion, should be in a 
distal portion of the nephron. In fact, recent evidence
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suggests that the collecting duct may be the site for final 
regulation of sodium excretion (130,206).
The bioassay, extraction and purification procedures, 
described on pages 109-125 , were used to demonstrate 
that there is a substance which appears in the urine and 
blood of salt-loaded man or sheep which can induce natri- 
uresis when injected into an assay animal (17,22-24). The 
response is characterized by increased sodium excretion 
which is accompanied by inconsistent and usually small 
changes in potassium excretion and urine flow. Because of 
the nature of the response we suggested that this substance 
could be a natriuretic hormone which acts in the distal 
tubule to promote sodium excretion. The natriuretic mate­
rial appears to be a protein-like substance with a molecu­
lar weight in the region of 50,0 00.
Physiology of the Natriuretic Substance :
(1) Response to changes in sodium intake in normal subjects ;
Table 20 presents data from assays of urine and plasma 
extracts from normal subjects on two different sodium in­
takes. Positive assays were found only in extracts from 
salt-loaded subjects. The mean increase in sodium excretion 
in the assay animal was 25 times greater than the response 
to extracts prepared from sodium depleted normal subjects. 
Similar directional changes were observed with two plasma 
extracts, although the magnitude of the response was less,
— 18 5—
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TABLE 20
ASSAY RESULTS; CUMULATIVE Na'*' LOSS IN ASSAY ANIMAL 
1. Effect of dietary sodium intake in normal subjects
Low Na diet
(a) Urine
2*
15
27.
19
0
29
-15
18
0
10
27
Mean 12
(b) Plasma
Mean
4*
4
4
High Na ^ diet
289*
369 
196 
178 
297 
111 
404 
98 
529 
346 
876 
339 
221 
39 
224 
Mean 301
39*
77
Mean 58
2. ••Effect of saline infusion in normal subjects and 
hypertensive patients
(a) Urine
356*
209 
435 
77 
355 
219
30*
10
0
Mean 13
(b) Plasma
Mean
2*
-5
0
15 
7
-7
16 
17
5
0
2
_2
4
Mean 292
36*
69
306
96
77
363
76
120
276
415
61
323
161
242
15
33
252
147
92
Mean 16 6
* = Change in cumulative Na balance
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FIGURE 39
ASSAY OF
NATRIURETIC AGENT IN PRIMARY ALDOSTERONISM
Urine Extract 0.5ml
4
Plasma Extract 0.5 ml
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6
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10 MINUTE URINE SAMPLES
- Positive assays for natriuretic activity]in extracts 
of urine and plasma taken from a patient with primary aldo­
steronism. Assay animals were rats with diabetes insipidus 
in maintained water diuresis.
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(2) Response to changes in sodium intake in hypertensive 
patients ;
Urine and plasma extracts from salt-loaded patients 
with hypertension also induced natriuresis in the assay 
animal. Figure 39 presents assays of extracts from a 
patient with primary aldosteronism who was maintained on a 
high sodium intake. Both urine and plasma extracts induced 
impressive increases in sodium excretion in the test animal. 
Sodium excretion increased from 1 to 4.5 pEq/minute in one 
assay and from 3 to 8 pEq/minute in the other. Cumulative 
losses were 266 and 221 pEq. Extracts from all hypertensive 
patients studied had a similar effect.
(3) Response to saline infusion :
On the right side of Table 20 data are presented from 
assays of plasma and urine extracts derived from normal 
subjects and hypertensive patients who received saline 
infusions. Prior to infusion, a 2 hour control urine speci­
men was collected and 60 ml of blood was drawn. Two liters 
of saline were then infused during the next hour and a 
second blood specimen was drawn. The second urine collec­
tion included the hour of infusion and 3 hours after the 
infusion was completed.
There was little response to control extracts, suggest­
ing that sodium loading is needed to expose the presence of 
the hormone. Samples collected during saline infusion were
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consistently natriuretic and the natriuretic response in 
the assay animal seemed to be greater with urine than with 
plasma extracts.
Taken altogether, these studies suggest that there is 
a natriuretic substance which circulates in blood and is 
excreted into urine in response to increases in sodium bal­
ance. Natriuretic activity appears when urine aldosterone 
excretion is falling (Figure 40) suggesting that when aldo­
sterone is excreted in increased amounts, natriuretic 
activity is very low. However, when aldosterone exerts the 
least action, i.e., during positive sodium balance, the
s
natriuretic substance is present in blood and urine in its 
highest concentrations.
(4) Effect of natriuretic extract on glomerular filtration 
rate (GFR):
No changes in GFR were detected in response to injec­
tion of natriuretic extract. One example of the studies in 
which GFR was measured (23) is illustrated in Figure 25, 
(page 122) . The natriuretic response was not accompanied by 
any change in urine flow, potassium excretion, hematocrit or 
glomerular filtration rate. The percent of the filtered 
load of sodium excreted increased from 1,3% to 3%. Thus, 
the hormone appears to act on tubular sodium reabsorption 
and not via changes in filtration rate.
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FIGURE 40
ALDOSTERONE EXCRETION AND NATRIURETIC HORMONE AC TIV ITY
NORMAL SUBJECTS
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■ Reciprocal relationship of natriuretic activity to 
urine aldosterone excretion in normal subjects.
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(5) Site of action of natriuretic activity:
Figure 41 presents an analysis of the relationship 
between induced changes in urine flow and sodium excretion.
The percent change in sodium excretion is plotted logarith­
mically on the abscissa. There is no relationship between 
the magnitude of the natriuretic response and changes in 
urine flow. The curved dotted line represents the change 
in urine flow relative to sodium excretion which would be ex­
pected if increases in sodium excretion were accompanied by 
commensurate increases in urine flow. Such a situation might 
occur during water diuresis if the hormone acted to depress 
sodium reabsorption in the proximal tubule. In all assays 
(the assay rat was always in water diuresis) the response 
fell to the right of this line, indicating that the natri­
uresis was associated with increased urine sodium concen­
tration. Thus, the natriuretic substance must act, at least 
in part, in a more distal portion of the renal tubule where 
dilution normally takes place.
No consistent changes in potassium excretion were ob­
served during the natriuretic response. This observation is 
also compatible with the absence of a proximal action of the 
hormone since decreased proximal sodium reabsorption would 
cause increased sodium delivery to the sodium-potassium 
exchange site and this would be expected to result in increased 
urine potassium excretion . The absence of any change in 
potassium excretion in many assays (Figures 25,(page 122 )f 39)
suggests that the site of action might be beyond the distal
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RELATION OF NATRIURESIS TO DIURESIS IN ACTIVE SAMPLES
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Relationship between the percent change in urine flow 
and the percent change in the rate of sodium excretion plotted 
on a logarithmic scale. Data are presented for all positive 
natriuretic assays. The curved line represents those increases . 
in UNaV in which the only component which increased is the urine 
flow. Any points in which there was an increase in urine sodium 
concentration fall to the right of this line. Since all points 
fall to the right of this line, the results suggest that the 
natriuretic agent depresses distal tubular sodium reabsorption 
at the diluting segment.
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convoluted tubule, where potassium is secreted, perhaps in 
the collecting duct. This would be in accord with some 
recent studies which have demonstrated that, in response 
to saline or hyperoncotic albumin infusions, no differences 
in fractional reabsorption of sodium can be measured in 
fluid collected from the late distal tubule (130) but urine 
sodium excretion is much greater in animals receiving the 
saline infusion. These and other investigators (175,206) 
suggest that the collecting duct may be the site at which 
the final amount of sodium in the urine is determined.
(6) Organ source :
In a preliminary investigation of the organ source we 
extracted the pituitary, brain, spleen, kidneys, liver, 
thyroid, parathyroid, pancreas, heart and lungs of a sheep 
that had been salt-loaded for several months. Fractiona­
tion procedures similar to those used for blood and urine 
were used. The organ source which exhibited the most im­
pressive natriuresis was the liver. The characteristics 
of the natriuretic response were quite similar to those 
induced by plasma and urine extracts. However, since this 
was by weight the largest organ extracted and probably con­
tained large amounts of blood, it is possible that the 
effect was not due to storage or synthesis by the liver. 
Also, lesser degrees of natriuretic activity were found in 
other organs (for example kidneys, heart, lungs and spleen) 
so that the data do not permit us at this time to positively
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identify the organ source of the natriuretic substance. 
Summary:
We have demonstrated that there is a natriuretic sub­
stance in urine and plasma of salt-loaded normal and hyper­
tensive man and sheep. This substance was undetectable in 
subjects on a normal or low sodium diet. Thus the substance 
may have physiological relevance.
These observations have been confirmed by other inves­
tigators using assays which detected changes in sodium 
excretion in the rat (18 8,2 08) or changes in sodium and 
potassium transport in fragments of renal tubules (2 09) .
These other.investigators were also able to distinguish be­
tween extracts from sodium depleted or sodium loaded sub­
jects.
The molecular weight of the natriuretic material ap­
pears to be around 50,000 but this is only a gross estimate 
since it is derived from elution characteristics on gel 
filtration columns and ultrafiltration. The active substance 
may be a polymer of a smaller molecule, or perhaps a fragment 
of the large molecule. Other investigators, using different 
assays and different fractionation procedures, have suggested 
that the molecular weight of their active agent is around 
1000. We investigated lower molecular weight fractions from 
gel filtration columns but were unable to completely sepa­
rate them from vasoactive substances or fractions with very 
high osmotic activity, both of which could induce natri-
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uresis even in the absence of a substance affecting tubular 
sodium transport.
The site of action of the hormone appears to be in the 
late distal tubule or collecting duct since the natriuresis 
was not accompanied by any consistent changes in urine flow, 
potassium excretion or glomerular filtration rate.
In the previous section it appeared that aldosterone 
and distal sodium supply could adapt and compensate for 
all possible combinations of changes in sodium and potassium 
balance. However, as discussed earlier in this section, 
there is evidence during massive saline loading in the rat 
that final adjustment of urine sodium excretion can occur 
in the collecting duct under conditions of constant aldo­
sterone secretion.
Available evidence suggests that aldosterone can affect 
sodium reabsorption in both the distal convoluted tubule and 
the collecting duct (210) . However, secretion of potassium ap­
pears to be largely confined to the earlier site, i.e., the 
distal convoluted tubule. Since distal potassium secretion 
is associated with approximately a ten to fifty fold greater 
reabsorption of sodium (191) final regulation of sodium excre­
tion at the same site seems unlikely. Aldosterone has been 
shown to affect both sodium and chloride excretion. Aldo­
sterone has also been shown to act in the collecting duct, 
where potassium secretion is minimal or absent. Thus the 
final regulation of urine sodium excretion could be under 
aldosterone control, but at a site distal to the potassium
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secretory site.
The natriuretic hormone could act to modify the sodium 
chloride retaining action of aldosterone. Alternatively, 
it could directly affect the sodium pump, alter the permea­
bility to sodium ions or perhaps enhance the back diffusion of 
sodium into the tubule. Thus, the natriuretic hormone might 
be part of an emergency mechanism which copes with extreme 
changes in salt balance such as are found during saline 
loading or in end-stage kidney disease. A reactive natri­
uretic mechanism could operate to complement the more slug­
gishly responding control effected by the renin-aldosterone 
system.
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E . Relationship of Sodium Balance and the Renin-Angiotensin- 
Aldosterone Hormonal System to Blood Pressure Homeostasis :
In the previous sections the hormonal system has been 
analysed with respect to its involvement in maintenance of 
sodium balance and potassium balance. This aspect of the 
hormonal system appears to function as an almost independent 
negative feed-back control system. From the analysis in 
Section C (pages 172-182) it can be appreciated that sodium 
balance and potassium balance can be maintained almost 
independently of each other, despite being under the control 
of one hormone, aldosterone, and despite the fact that 
potassium secretion is dependent on the net amount of sodium 
delivered to the distal tubule. Therefore it is not unrea­
sonable to consider the second control system —  for sodium 
balance and blood pressure homeostasis —  separately since 
changes in sodium balance which affect blood pressure are 
unlikely to alter the equilibrium of potassium (Figure 42).
As illustrated in Figure 1 (page "f ), the hormonal system 
can directly affect blood pressure via the vasoconstrictor 
action of angiotensin II. In addition, it can be appreci­
ated that changes in sodium balance, by affecting blood 
volume, can also influence blood pressure via alteration in 
filling of the arterial tree (211-213), Thus the second 
limb of the hormonal system, aldosterone induced sodium 
retention, can also directly support blood pressure. The
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interrelationship of these two components of blood pressure, 
vasoconstriction and arterial filling, is illustrated by a 
study by Ames and coworkers (214) in which prolonged infu­
sions of angiotensin II were administered to man (Figure 43). 
Angiotensin II infusion caused an immediate and sustained 
increase in blood pressure. However, after three days it was 
found that diminishing amounts of angiotensin II were needed 
to sustain the increase in blood pressure. This gradual in­
crease in potency of the peptide appeared related to the 
accompanying sodium retention, secondary to angiotensin II 
mediated increases in aldosterone production. Thus the 
vasoconstrictor action of angiotensin was greatly potentiated 
by concurrently induced volume expansion (.215) .
The question arises as to the mechanism of this increased 
sensitivity to angiotensin II during positive sodium balance.
One explanation is that the accompanying increased filling of 
the arterial tree directly increased blood pressure so that 
less and less angiotensin induced vasoconstriction was needed 
to sustain the blood pressure elevation. An alternate or per­
haps additional explanation is that, under conditions of pos­
itive sodium balance the vascular tree is more sensitive to 
the vasoconstrictor action of angiotensin. Such a possibility 
is supported by studies which have demonstrated that the 
pressor response to exogenous angiotensin II is greater in 
sodium depleted than in sodium loaded man and animals (3,216-218).
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Angiotensin infusion caused an increase in b ood
pressure which was accompanied by increased urine aldosterone
excretion and marked sodium retention. After three days 
progressively less angiotensin was required to sustain the 
blood pressure increase. The increased pressor sensitivity 
appeared to be consequent to the sodium retention.
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Studies of Angiotensin II Vascular Receptors :
To study the mechanism whereby changes in the pressor 
action of angiotensin II occurs antibodies specific for 
angiotensin II were injected into rats maintained on differ­
ent sodium intakes (25). The minimum volume of antibody-rich 
serum required to eliminate the blood pressure response to 
injection of 50 ng of angiotensin II was determined- As 
illustrated in Figure 44, wide differences were observed 
in the volume of antibody required depending on the sodium 
intake of the rats. However, at each level of sodium in­
take entirely similar amounts of antibody were needed.
Thus, rats on normal sodium balance required 0.3 ml of 
antibody to eliminate the pressor responsiveness to angio­
tensin II, whereas only 0.15 ml were needed in sodium de­
pleted rats but 1.2 ml were required for sodium loaded 
rats.
Our interpretation of these studies was that the 
amount of antibody required to block the pressor response 
to angiotensin II is a measure of the affinity of vascular 
receptors for angiotensin II. Vascular receptors are 
visualized as competing with the antibody for binding of 
exogenous angiotensin II. Thus the more avid the vascular 
receptors, the more antibody required to block them.
Hence, under circumstances of sodium loading, vascular 
receptors appear to have greater binding affinity for 
angiotensin II than during sodium deprivation. An alter-
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FIGURE 44
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are visualized as competing with the antibody for binding of 
exogenous angiotensin.
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native interpretation is that during sodium administration 
a larger number of receptors are unoccupied because of the 
lower level of circulating angiotensin (219).
Whatever the true interpretation, increased vascular 
affinity for angiotensin II could explain in part the increased 
pressor responsiveness to angiotensin II which was found 
during prolonged infusions, after aldosterone-induced sodium 
retention has occurred.
The Role of the Renin-Angiotensin-Aldosterone System in 
Normal Blood Pressure Homeostasis :
It is quite apparent that the renin-angiotensin-aldo- 
sterone system c^n affect blood pressure both by altering 
the capacity of the blood vessel via angiotensin II induced 
vasoconstriction and by affecting the filling of the arterial 
tree by aldosterone induced sodium retention and volume ex­
pansion (Figure 45) (211,212). Of interest is the question of 
whether or not the renin-angiotensin-aldosterone hormonal 
system is normally involved in the minute to minute mainten- ■ 
ance of blood pressure. Recent studies utilizing angioten­
sin II inhibitors have demonstrated that angiotensin blockade 
of sodium deprived animals causes a fall in blood pressure 
(27,220). However almost no effect was seen in animals mainr 
tained on a normal sodium intake (27,221). These studies sug­
gest that in animals the vasoconstrictor action of angiotensin 
only participates in maintenance of blood pressure when blood
203-
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volume is compromised. However, in man, angiotensin II seems 
to be more important since marked depression of blood pressure 
has been noted in subjects who were studied on a tilt table 
during angiotensin II blockade (222) . This confirms that the 
increases in renin seen during change in posture (22 3) are 
important for support of blood pressure.
Altogether it appears that the vasoconstrictor action of 
angiotensin is important for maintenance of blood pressure 
during adjustment to the upright position, during sodium 
deprivation and under any circumstance in which blood volume 
and perfusion pressure are compromised. In this construct, 
the system is viewed as being part of a contingency mechanism 
which responds to situations in which blood pressure is com­
promised.
The system appears to function as follows :
Renin is released rapidly from the kidney in response 
to reductions in blood pressure or in "effective" blood 
volume. Renin then reacts with renin substrate, present in 
blood in high concentration, to liberate angiotensin I (Fig­
ure 45). Angiotensin I is converted rapidly to angiotensin 
II during passage through the lungs and blood pressure is 
quickly restored by the vasoconstrictor action of angioten­
sin II. Meanwhile, angiotensin II acts more slowly to 
stimulate aldosterone production. Only small amounts of 
aldosterone are stored in the adrenal and aldosterone takes 
up to an hour to act, probably because it first increases
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protein synthesis in the target organ, kidney (194). Thus, 
the secondary sodium retaining response of the system slowly 
restores sodium balance and improves "effective" blood 
volume which turns off the signal for renin release. More­
over, the sodium retention gradually potentiates the vascular 
reactivity or vasoconstrictor action of angiotensin II so 
that less and less is needed to sustain the blood pressure.
Therefore, as illustrated in Figure 46, arterial pres­
sure is protected by the renin-angiotensin-aldosterone system 
in three ways. (1) The primary release of renin results in 
increased plasma angiotensin II and direct vasoconstrictor 
support of blood pressure. (2) Secondary increases in aldo­
sterone induce sodium retention and thus help to increase 
blood volume and pressure and tissue perfusion and (3) sodium- 
induced increases in vascular receptor affinity potentiate 
the responsiveness of angiotensin II as the induced sodium 
retention and volume expansion act to shut off the signal for 
renin release.
In this context, the hormonal system is seen as acting 
as an emergency mechanism which responds to reductions in 
arterial pressure. Obviously, other factors which include 
the neural system respond more rapidly to sustain perfusion 
pressure (224) and these are followed and gradually super­
seded by a somewhat slower angiotensin II vasoconstrictor 
effect. The net effect of vasoconstriction is to maintain 
perfusion pressure at the expense of reduced blood flow.
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FIGURE 46
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The other limb of the renin-aldosterone system restores blood 
flow and tissue perfusion by aldosterone induced sodium re­
tention and consequent volume expansion. Therefore the two 
components of the hormonal response act in sequence first to 
maintain perfusion pressure and then to restore the compromised 
blood volume. The first response is supportive, the second 
restorative.
The Causal Role of the Renin System in Renovascular Hyper­
tension.
Since the vasoconstrictor action of angiotensin II is 
accompanied by sodium retention (mediated by aldosterone), 
angiotensin II excess can maintain chronic hypertension.
Other vasoconstrictor substances cannot sustain chronic 
hypertension since increased blood pressure normally results 
in pressure natriuresis and this tends to restore blood 
pressure to the null point so that more and more hormone is . 
needed to sustain blood pressure elevations (214). However, 
the dual actions of angiotensin II to cause both sodium 
retention (via aldosterone) and vasoconstriction can result 
in sustained hypertension because the pressure natriuresis 
can be offset by the sodium retaining action of aldosterone. 
Thus the renin-angiotensin-aldosterone system is admirably 
constructed to sustain chronic increases in blood pressure.
A causal role for renin has long been suspected in 
renovascular hypertension —  both experimental and natur-
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ally occurring (2,212,225). However, the participation of 
renin in maintenance of this form of hypertension has been 
questioned since renin is not always elevated in renovas­
cular hypertension (226-229) and not all patients who have 
evidence of the disease are cured by renal surgery (230,231).
To investigate the role of renin in experimental 
renal hypertension two different rat models were employed.
In one model, one renal artery was clamped to less than 
5 0% of its diameter and the contralateral kidney was left 
in place. This model is associated with increased periph­
eral plasma renin due to hypersecretion of renin from the 
clipped kidney, but renin release is suppressed from the 
contralateral kidney (232,233). The second model is 
similar, but the contralateral kidney is removed. Renin 
secretion is not increased in this form of experimental 
hypertension (232,233). In two sets of studies, either
angiotensin II antibody was injected into these two rat
1 8models or a specific angiotensin II inhibitor (sar -ala - 
angiotensin II) was infused (2 6). The elevated blood pres­
sure was reduced by both procedures for angiotensin blockade 
only in the animals with two kidneys (Figure 47). An insigni­
ficant fall in blood pressure was observed in the rats with 
only one kidney.
These data suggest that angiotensin II is critically 
involved in the pathogenesis of the two kidney form of 
renal hypertension but appears to play no role in the main-
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FIGURE 47
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Infusion of a specific angiotensin II inhibitor, 
sar-l-ala-8-angiotensin II, to hypertensive rats lowered 
blood pressure only in the model in which one renal artery 
was clamped, the other kidney left in place. Blood pressure 
was not lowered in the uninephrectomized model with the 
remaining renal artery clamped.
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tenance of hypertension in the one kidney model. Thus when 
renin is not elevated, it does not appear to participate in 
the maintenance of renovascular hypertension. This study 
points to the key role that renin can play in hypertension, 
but it also serves to illustrate that the kidney has an 
alternate means for sustaining hypertension.
The role of sodium in maintaining the elevated blood 
pressure in the one kidney model was revealed in a subse­
quent study by Gavras and his co-workers (27) who demon­
strated that blood pressure could be reduced in these 
hypertensive animals by angiotensin II inhibitor after a 
period of sodium deprivation. Thus, sodium depletion con­
verted the hypertension from being caused by another factor 
(presumably excessive volume) (213,234) to one which was 
dependent on abnormal renin secretion.
The physiological basis for the differences in renin 
secretion and in the hypertensive process in these two 
experimental forms of renal hypertension has application 
to the study of human renovascular hypertension. In the 
two-kidney animals, the decrease in renal perfusion caused 
by the clip around the renal artery has been shown to re­
sult in increased renin secretion from that kidney (151,235) 
and in the studies just described this excess renin has been 
shown to be the cause of the increased blood pressure. In 
addition, reduction in perfusion pressure to the clipped 
kidney resulted in its becoming a sodium-retaining kidney
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(2 34) but at the same time the elevation in systemic arte­
rial pressure has been shown to result in pressure natri­
uresis in the contralateral normal kidney (236,237). This 
sodium loss may have provoked further increases in renin 
secretion from the ischemic kidney. In contrast, in the 
one kidney model, contralateral pressure natriuresis can­
not occur. The resultant chronic sodium retention turns 
off renin release and it also sustains a volume dependent 
hypertension.
Renovascular Hypertension in Man.
In the following analysis, information gleaned from 
the studies of experimental renal hypertension have been 
applied to the naturally occurring forms of renovascular 
hypertension. There has been some controversy as to 
whether or not renin is involved in maintaining the blood 
pressure elevation in human renovascular hypertension 
(2,212,225). The use of peripheral and renal vein renin 
measurements to predict curability by unilateral repair or 
nephrectomy has not been consistently successful. Since 
mortality from associated surgery is as high as 10% in some 
studies (230,231,238) it is important to be able to identify 
accurately patients potentially curable by surgery.
Since most patients with renovascular hypertension 
have two kidneys, theoretically in man one might expect to 
find the analogue of the two-kidney experimental hyperten­
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sion, i.e., increased peripheral plasma renin caused by 
unilateral hypersecretion of renin in association with 
suppression of renin from the contralateral kidney. How­
ever, bilateral renal ischemia is not uncommon. Bilateral 
renovascular hypertension might be similar to the one- 
kidney form of experimental hypertension since contra­
lateral pressure natriuresis might not ensue if the con­
tralateral kidney is also underperfused and cannot excrete 
salt normally. Cure of hypertension in these patients by 
uninephrectomy might not be expected since reduction in 
renal mass, while removing some excess renin, might result 
in more sodium retention because of reduction in the number 
of nephrons and cause elevation of blood pressure by volume 
expansion. Thus, the hypertension might be converted from 
a renin-dependent form into a volume-dependent form (211).
Hence, it is important to identify accurately those 
patients who might benefit from uninephrectomy from those 
with bilateral disease in whom repair of the renal artery 
might be the process of choice in order to increase func­
tioning renal mass and thus perhaps increase sodium excretion
Theoretically, to identify two-kidney renovascular 
hypertension in man, the following parameters should be 
identifiable: (1) elevation of peripheral plasma renin
activity; (2) suppression of renin secretion from the contra­
lateral kidney —  an indication that that kidney is normal 
and (3) renal ischemia of the suspect kidney.
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In a study of 28 patients with suspected renovascular 
hypertension who came to surgery (2 8) we were able to 
analyse, retrospectively, the value of these three para­
meters in predicting curability. All patients who had 
elevated peripheral plasma renin were cured by surgery 
with the exception of one who had post-operative graft 
closure. However, of 10 patients who had normal plasma 
renin, 2 were cured, 3 improved, and in 5 hypertension was 
not reduced by surgery. Hence, elevated peripheral plasma 
renin is a good indicator for cure, but its absence does not 
preclude curability.
Suppression of renin secretion from the contralateral 
kidney is a good^ indication that the kidney is functioning 
normally and could sustain the patient in the event of uni­
lateral nephrectomy. Contralateral suppression is defined 
in Figure 48. Since renin is not cleared to any great extent 
by the kidney, when a kidney is secreting no renin^ renal vein 
renin should equal arterial renin and all of the renin which 
contributes to the peripheral level should be derived from 
the other kidney. However, in the absence of contralateral 
suppression of renin secretion V (renal vein renin) minus A 
(arterial renin) would have positive value.
Theoretically, V-A ~ 0 is a good indicator for cure, but 
pragmatically it is difficult to predict definitively that 
the two values are idential. This problem is compounded by 
the fact that in patients with essential hypertension V-A is
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FIGURE 48
RENAL VEIN RENIN ANALYSIS 
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Since renin is not cleared to any great extent by 
the kidney, renal vein renin is equal to arterial renin when 
renin secretion is suppressed. Incomplete suppression of renin 
secretion is associated with renal vein renin greater than arterial 
renin. Contralateral suppression of renin secretion is difficult 
to identify accurately since, normally renal vein renin is only 
24% higher than arterial renin (upper figure).
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normally only 24% higher than arterial renin (see page 14 6 ). 
Therefore although contralateral suppression is a good theo­
retical indicator, it is difficult to identify accurately.
For this reason, the third parameter —  identification 
of renal ischemia —  becomes more important. Hosie and co­
workers (151) pointed out that renal vein renin concentration 
can be increased both by increasing renin secretion and by 
reducing renal blood flow. In a previous section, it was 
demonstrated that renal plasma flow is inversely related to 
renal vein renin when considered in relationship to arterial 
renin [(V-A)/A] and renal blood flow can be calculated from 
renal vein renin measurements when renin is secreted from 
only one kidney (16). Under these conditions, (V-A)/A > 0.48 
is always associated with reduced renal blood flow. (V-A)/A 
was estimated for both kidneys of the 28 patients included 
in the study (Figure 49). All but one of the cured or im­
proved patients had an elevated (V-A)/A from the suspect 
kidney and all exhibited contralateral suppression (V-A)/A ^
0.38 (i.e. mean + 2 SD of cured patients). The one excep­
tion was patient J.O. in whom the combined renal vein renins 
were only 10% higher than the arterial level. This low 
value suggests that renal venous blood was not collected 
since this value is not high enough to sustain the periph­
eral level (see page 145).
Seven of 8 patients in whom surgery was not successful 
either failed to demonstrate elevated (V-A)/A from the sus-
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FIGURE 49 - ,
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Preoperative stenotic and contralateral renal vein renin 
relative to arterial renin in 28 patients^ All cured or improved 
patients (18) had contralateral renin suppression (shaded area =
0.0 8 + 2 SD) and all but JO, in whom there was a technical error, 
had abnormally elevated (V-A)/A from the stenotic kidney [shaded area= 
(V-A)/A < 0.48] indicating renal plasma flow reduction. In contrast, 
no patient who failed to respond to successful surgery (7) met both 
of these criteria. RK had postoperative graft occlusion,
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pect kidney (N=4) or secreted renin from the presumably 
normal kidney (N=3). The one patient in whom we would 
have predicted cure had post-operative graft occlusion,
A scoring system has been developed which mathemati­
cally evaluates the weight of each of the three parameters
(1) elevated peripheral plasma renin, (2) contralateral 
suppression, i.e. (V-A)/A < 0.38, and (3) renal ischemia, 
i,e, (V-A)/A > 0.48. Using this system we have been able 
to predict consistently the curability of patients suspected 
of having curable renovascular hypertension.
Summary
The renin-an’giotensin-aldosterone hormonal system appears 
to participate in normal blood pressure regulation and in 
causation of some forms of renovascular hypertension. The 
system restores reductions in perfusion pressure by the direct 
vasoconstrictor action of angiotensin II followed by restora­
tion of blood volume via aldosterone mediated sodium retention 
which turns off the signal for renin release, while potentiat­
ing the vasoconstrictor effect of angiotensin II.
The hormonal system can sustain chronic hypertension be­
cause the increased arterial pressure associated with angio­
tensin II excess is not associated with sustained pressure 
natriuresis since it is accompanied by aldosterone mediated 
sodium retention.
An understanding of the mechanisms which can sustain
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experimental renovascular hypertension, together with an 
appreciation of the normal relationships of renal vein renin 
to arterial renin has enabled differentiation of those pa­
tients with renovascular hypertension who can be cured by 
surgery. The success of this approach lends credence to the 
idea of the dual nature of blood pressure support -- i.e., 
volume and vasoconstriction —  and supports the view that 
the renin-angiotensin-aldosterone hormonal system can be 
importantly involved in maintenance of hypertension.
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This memoir has considered the regulation of sodium and 
potassium balance and blood pressure homeostasis by the renin- 
angiotensin-aldosterone hormonal system.
First, improved methods for measurement of renin and 
aldosterone have been described. Plasma renin activity is 
measured by a radioimmunoassay in which angiotensin I, gener­
ated by the reaction of plasma renin with its substrate during 
3 or 18 hours incubation, is quantitated. Blank subtraction 
is eliminated and accuracy enhanced by complete inhibition 
of angiotensinases and converting enzyme. Improved assay 
sensitivity has been achieved which is important for detect­
ing about 30% of ’patients with essential hypertension who 
exhibit subnormal renin levels. However, using three other 
methods recommended by commercial kits/ most low renin samples 
were undetectable and indistinguishable from many normal 
renin samples.
A double isotope derivative method was described for 
measurement of the urinary acid-labile conjugate of aldoster­
one. Though time consuming, the method provides accuracy and
reproducibility. Evidence is presented for isotope fraction- 
3 14ation of H from C aldosterone diacetate during column and 
paper chromatography. Data from this method are inter­
changeable with those derived from a more recent radioim­
munoassay method which provides greater sensitivity and 
capacity. Procedures were developed for radioimmunoassay to
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separate aldosterone from cross-reacting steroids. For urine 
samples, the acid-labile conjugate of aldosterone is separated 
merely by extracting cross-reacting steroids into methylene 
chloride. For plasma aldosterone, a celite partition column 
accomplishes separation.
To investigate the existence of a natriuretic hormone, 
extraction, concentration and purification procedures were 
developed in conjunction with a semi-automated rat bioassay . 
for detecting changes in urine sodium excretion. Urine and 
plasma samples were fractionated and a natriuretic substance 
separated which could have physiological relevance since it 
was found only in extracts from sodium-loaded patients. 
Evidence suggests that this substance affects sodium reab­
sorption in the distal tubule at a site beyond that for 
potassium secretion.
Studies of plasma renin "activity" revealed that, nor­
mally, renin substrate concentration is rate limiting.
However, under steady state conditions, no relationship was 
found between substrate concentration and plasma renin 
activity. Therefore from a physiologic standpoint, renin 
secretion appears to compensate for changes in substrate con­
centration to maintain an appropriate rate of angiotensin 
generation. Heparin was shown to be a specific competitive 
inhibitor of the reaction between renin and renin substrate.
In patients with essential hypertension, a constant
fractional increment in renal venous renin, relative to
arterial renin was observed over a. wide range of peripheral
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renin levels. These data indicate that the clearance of 
renin is a constant fraction of peripheral renin and that 
plasma renin activity reflects renin secretion.
Studies in normal subjects revealed that renin and 
aldosterone respond to, and appear to affect, urine sodium 
excretion, even at high sodium intakes. Also, during 11 
days of sodium deprivation, as expected, renin and aldo­
sterone secretions increased. But aldosterone increased 
proportionally more than renin. The discrepancy could be 
explained by accompanying potassium retention. This study 
highlights the importance of both trophic stimuli for aldo- 
sterone,— angiotensin II and potassium.
The importance of another coordinate in the renin-aldo­
sterone system was revealed when potassium administration to 
man and rats suppressed renin secretion and potassium 
deprivation increased it.
Notwithstanding these interrelationships, sodium and 
potassium homeostasis cannot be explained solely in terms of 
the two renal actions of aldosterone to promote sodium reab­
sorption and potassium secretion since the simultaneous effect 
on both ions would lead to inappropriate variations in one 
when intake of the other changed. A balanced control system 
can be proposed if the concurrent effect of both sodium and 
potassium on glomerular filtration rate and proximal tubular 
sodium reabsorption, and consequently distal sodium supply, 
are taken into account. Changes in distal sodium supply
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can affect urine sodium excretion, but when aldosterone 
is high, more sodium is reabsorbed distally. This results 
in increased potassium secretion and reduction in sodium 
excretion. Thus, urine sodium excretion is inversely related 
to aldosterone activity and directly related to distal 
sodium supply, whereas potassium excretion is directly 
related to both aldosterone and distal sodium supply.
Hence, changes in distal sodium supply counterbalance the 
dual and opposing actions of aldosterone, allowing one 
ion to be held constant in the face of large excess or 
paucity of the other.
Control of. blood pressure by the renin-angiotensin- 
aldosterone system proceeds simultaneously. Studies in­
dicate that a positive sodium balance increases pressor 
responsiveness to angiotensin II both hydraulically and 
by increasing vascular receptor affinity for it.
Studies in rats of the role of renin and angiotensin 
in renovascular hypertension, revealed that hypertension 
is maintained in one model (two kidneys, one renal artery 
clamped) by vasoconstriction due to increased angiotensin
II. However, in another model (uninephrectomized, remaining 
renal artery clamped) blood pressure is not sustained by 
excess angiotensin. Improved understanding of the mechanisms 
of hypertension in these models led to a new analysis of 
the human counterpart. Three criteria were developed which, 
in combination, have been successful in identifying curable
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unilateral renovascular hypertension: (1) elevated peripheral
plasma renin in relation to sodium excretion, i.e., demonstrat­
ion that excess renin secretion sustains the hypertension,
(2) complete contralateral suppression of renin secretion,
i.e. an indicator that the contralateral kidney is unaffected 
and (3) renal ischemia of the suspect kidney. This last 
parameter can be quantitated simply by comparing the relationship 
of renal renin to peripheral renin with data derived from 
patients with essential hypertension.
It is proposed that the renin-angiotensin-aldosterone 
system comprises two interacting negative feed-back loops.
In one, sodium''and potassium balance are maintained by 
aldosterone coordinated with changes in distal tubular sodium 
supply. In the other, blood pressure is supported by 
aldosterone coordinated with angiotensin. When the effective 
blood volume is compromised, angiotensin II vasoconstriction 
acts to support blood pressure until aldosterone induced 
sodium retention restores blood volume and turns off renin 
release,
— 2 2 4—
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